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The neurotransmitter dopamine is involved in various physiological central 
nervous system (cns) functions as well as the pathogenesis of several neuropsy-
chiatric disorders, including Parkinson’s disease, schizophrenia, drug addiction 
and hyperprolactinemia. Pharmacological methods to alter dopamine neuro-
transmission currently have only limited efficacy in alleviating the symptoms 
of these disorders, but adverse side effects can be debilitating. Thus, improve-
ment of dopaminergic pharmacotherapy remains a high priority. This thesis 
describes several early phase drug development trials with novel compounds 
that aim to improve dopaminergic pharmacotherapy by various strategies. 
This introductory chapter provides an overview of dopamine neurotransmis-
sion and the various disorders associated with dopaminergic systems. Also, 
several pharmacological strategies for improvement of dopaminergic pharma-
cotherapy as well as the specific aims of the following chapters of this thesis are 
outlined.
dopamine neurotransmission
Dopamine is a monoamine neurotransmitter, which is produced by neurons 
in the midbrain and hypothalamus. The synthesis of dopamine starts with the 
uptake of tyrosine from blood by amino acid transporters1. Once inside the neu-
ron, tyrosine is converted to L-dopa by the cytosolic enzyme tyrosine hydroxy-
lase (th), which is the rate-limiting enzyme in dopamine synthesis1. In turn, 
L-dopa is converted to dopamine by the cytosolic enzyme aromatic L-amino 
acid decarboxylase (aaad)1. Subsequently, dopamine is transported from the 
cytoplasm into storage vesicles. Upon arrival of an action potential, the stor-
age vesicles discharge their dopamine contents into the synaptic cleft by means 
of exocytosis1. Dopamine traverses the synaptic cleft and binds to receptors on 
the postsynaptic neuron. Five different types of dopamine receptors have been 
characterized, termed the d1, d2, d3, d4 and d5 receptor, all of which are g pro-
tein-coupled receptors. d1-like receptors (which include the d1 and d5 receptor 
subtypes) are stimulatory Gs-coupled receptors and d2-like receptors (which 
include d2, d3 and d4 receptor subtypes) are inhibitory Gi-coupled receptors2
,3. 
Two major isoforms of the d2 receptor exist due to alternative splicing, termed 
d2-short (or d2s) and d2-long (or d2l) receptors2
,3. The d2l receptor appears to 
be expressed mostly on postsynaptic membranes, while the d2s receptor appears 
to be expressed mostly on presynaptic membranes and to be involved in auto-
receptor function2,4. Neurotransmitter action is terminated by the reuptake of 
dopamine by dopamine transporters (dat) that actively pump extracellular do-
pamine from the synapse back into the nerve terminal5.
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The perikarya of most dopaminergic neurons are located in the substantia nigra 
and ventral tegmental area of the mesencephalon and in the periventricular and 
arcuate nuclei of the hypothalamus. The dopaminergic neurons project to vari-
ous brain structures through several anatomically organized pathways6-9 (see 
Table 1 and Figure 1), including:
• The nigrostriatal pathway originates in the substantia nigra and projects  
to the striatum and acts to modulate the output activity of the striatum.  
This pathway is involved in various motor and cognitive functions10-12.
• The mesocortical pathway originates in the ventral tegmental area and 
projects to the prefrontal, insular, motor and sensory cortices. This pathway  
is involved in encoding and use of working memory information by 
prefrontal cortex circuits13,14.
• The mesolimbic pathway originates in the ventral tegmental area 
and projects to the limbic cortices, hippocampus, nucleus accumbens 
and amygdala. This pathway is involved in reward and reinforcement 
mechanisms and appears to encode prediction of reward and facilitate 
learning of reward associations2,3,15,16.
• The tuberoinfundibular pathway originates in the periventricular and 
arcuate nuclei of the hypothalamus and projects to the external zone of  
the median eminence, and is involved in hypothalamic inhibitory control  
of prolactin secretion17,18.
• Dopaminergic neurons in the area postrema and nucleus tractus solitarius 
are involved in the control of emesis7,19.
Dopamine neurotransmission is under stimulatory and inhibitory control of 
various other neurotransmitters. Furthermore, the presence of various feedback 
mechanisms, modulatory influence of interneurons and interactions between 
neurotransmitters ultimately result in very complex neurocircuits. In general, 
dopamine neurotransmission is stimulated by glutamate20 and inhibited by 
γ-aminobutyric acid (gaba)21 (see Figure 2), with further modulatory roles of 
serotonin22, acetylcholine23, tachykinin neuropeptides24, as well as several 
others16,25.
disorders associated with dopamine 
neurotransmission
Abnormalities in dopamine neurotransmission contribute to the pathogen-
esis of several neuropsychiatric disorders, including Parkinson’s disease, schizo-
phrenia, drug addiction and hyperprolactinemia. Accordingly, a large number 
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table 1	 Dopamine neuron systems
Dopaminergic pathway Site of origin Site of termination Functions




Mesocortical Ventral tegmental area Prefrontal, insular, motor 
and sensory cortices
Cognitive processes, 
motivation, encoding and 
use of working memory 
information
Mesolimbic Ventral tegmental area Limbic cortices, 
hippocampus, nucleus 
accumbens and amygdala
Reward and reinforcement 
mechanisms.
Motivational, emotional, 
contextual and affective 
influence on behavioral 
processes
Tuberoinfundibular Periventricular nucleus 
Arcuate nucleus
Median eminence Inhibition of prolactin 
secretion
Incerto-hypothalamic Zona incerta, posterior 
hypothalamus
Hypothalamus, septum Autonomic and 
neuroendocrine responses
Periventricular Periaqueductal and 
periventricular grey, dorsal 
motor nucleus of the vagus 








Diencephalospinal Dorsal and posterior 
hypothalamus
Intermedio-lateral cell 
columns of spinal cord
Sensorimotor integration 
and nociception
Olfactory bulb Periglomerular cells Glomeruli (mitral cells) Processing of odorant 
sensory information
Retina Interplexiform cells Inner and outer plexiform 
layers of retina
Light adaptation
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figure 1  Major dopaminergic pathways
figure 2		 Simplified basic dopaminergic regulatory scheme of forebrain structures and basal 
ganglia. The ventral tegmental area projects to the prefrontal, insular, motor and sensory cortices 
(mesocortical pathway) and to the limbic cortices, hippocampus, amygdala and ventral striatum, 
including the nucleus accumbens (mesolimbic pathway). The substantia nigra projects to the dorsal 
striatum, including nucleus caudatus and putamen (nigrostriatal pathway). Dopamine binds to D1-
like receptors, which stimulate second messenger systems, or D2-like receptors, which inhibit second 
messenger systems. Dopamine neurotransmission itself is stimulated by glutamate and inhibited 
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of well-established direct dopaminergic treatments are available, that either 
support the actions of dopamine (precursors and agonists) or inhibit dopami-
nergic activity (full or partial antagonists), depending on the disease. However, 
these drugs currently have only limited efficacy in alleviating the symptoms of 
these disorders, but adverse side effects can be debilitating. Thus, there is still a 
considerable need for new drugs with improved therapeutic windows or more 
selective modes of action.
Parkinson’s disease
The pathological hallmark of Parkinson’s disease is a selective loss of dopami-
nergic neurons from the pars compacta of the substantia nigra, which leads to 
symptoms such as limb resting tremor, bradykinesia, rigidity, postural instabil-
ity and gait disorder26-29. Restoration of dopamine levels is the primary aim of 
pharmacotherapy. The dopamine precursor L-dopa (levodopa) is currently the 
most effective and preferred treatment30. Aromatic L-amino acid decarboxylase 
(aaad) inhibitors, such as carbidopa, are usually added to inhibit peripheral me-
tabolism of levodopa30-32. Also, dopamine receptor agonists such as pergolide, 
bromocriptine, apomorphine, pramipexole and ropirinol, are often used30-32. 
However, not all features of Parkinson’s disease are adequately alleviated by le-
vodopa or dopamine agonists and patterns of response can change over time30. 
Motor complications are frequent and disabling, and include dyskinesia and 
motor fluctuations (wearing off, on-off phenomena)30,31.
Schizophrenia
The involvement of dopamine in the pathophysiology of schizophrenia was 
originally suggested by the observation that dopamine-enhancing drugs can 
have psychotogenic effects and also by the correlation between d2 receptor 
blocking potency of antipsychotic drugs and their dosage for clinical antipsy-
chotic effect33-38. It has been suggested that mesocortical dopaminergic pro-
jections to the prefrontal cortex might be hypoactive (resulting in hypostimu-
lation of d1 receptors and emergence of negative symptoms and cognitive im-
pairments), while subcortical mesolimbic dopaminergic projections might be 
hyperactive (resulting in hyperstimulation of d2 receptors and emergence of 
positive symptoms)35,36,39,40. A recent hypothesis proposes that the locus of do-
pamine dysregulation is primarily at the presynaptic level41. Pharmacological 
treatment options include first generation antipsychotic drugs (also known 
as classic or typical antipsychotics) such as chlorpromazine and haloperidol. 
Side effects related to dopamine blockade in the extrapyramidal system in-
clude dystonia, akathisia, bradykinesia, tremor and tardive dyskinesia42,43. 
In addition, hyperprolactinemia can result from dopamine blockade in the 
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tuberoinfundibular dopaminergic pathway44,45. Other side effects include 
prolonged qt interval and torsade de pointes arrhythmia, related to off-target 
effects on cardiac potassium channels46, and neuroleptic malignant syndrome. 
Second-generation antipsychotic drugs (also known as atypical antipsychotics), 
such as clozapine, risperidone, quetiapine, olanzapine, ziprasidone, aripipra-
zole and amisulpride, generally have a lower risk of extrapyramidal symptoms 
and tardive dyskinesia47-49 and may also be effective against negative symp-
toms, but can cause metabolic syndrome50. Meta-analyses and large clinical 
trials have demonstrated either roughly similar clinical efficacy or moderate 
superiority of second-generation drugs compared with first-generation antipsy-
chotic drugs51-58. Clozapine has superior clinical efficacy in treatment-resistant 
schizophrenia59, and carries a lower risk of extrapyramidal symptoms or hyper-
prolactinemia, but also has an increased incidence of agranulocytosis, requir-
ing frequent monitoring of leukocyte counts. The exact mechanism of action of 
antipsychotic drugs is unknown, but all clinically effective antipsychotic drugs 
have been shown to attenuate dopamine d2 receptor function33
,38,60,61.
Substance abuse and drug addiction
A large body of evidence indicates that the mesolimbic dopaminergic pathway 
is one of the major neuronal circuits involved in the acute rewarding effects of 
drugs of abuse62-66. Although addictive drugs interact with many different neu-
rotransmitter systems, most addictive drugs ultimately cause an acute increase 
in synaptic dopamine in the nucleus accumbens and mesolimbic dopaminer-
gic system67-69, as demonstrated by microdialysis studies in rats70 and positron 
emission tomography (pet) studies in humans71-75. Alcohol, nicotine, opiates, 
cocaine, amphetamine (and derivates such as methamphetamine, methylphe-
nidate and mdma, also known as ecstacy), benzodiazepines and barbiturates all 
increase dopamine transmission in the mesolimbic pathway by various mecha-
nisms76-78. However, although addictive drugs initially lead to dopamine re-
lease in the nucleus accumbens (i.e. signaling reward), with repeated adminis-
tration and as habits develop, increases of dopamine become associated with 
conditioned responses linked with administering the drugs, rather than the 
pharmacological effects of the drug per se15,79. In addicted subjects, the drug-
induced dopamine release in the striatal regions becomes significantly reduced, 
while conditioned cues associated with drug use increase dopamine levels15,79. 
Despite the major role of dopamine neurotransmission in drug addiction, no 
dopaminergic agents have yet been demonstrated to be uniformly effective for 
substance abuse, which may be (at least partly) due to lack of selectivity for the 
mesolimbic pathway80. Thus, current pharmacotherapeutic strategies primar-
ily aim to desensitize or partially antagonize the reward system by interacting 
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with other neurotransmitter systems. Current treatments for alcohol abuse in-
clude the opioid-antagonists naltrexone and nalmefene, the glutamate recep-
tor modulator acamprosate, and sensitizers to the adverse effects of ethanol like 
disulfiram and calcium carbimide77,80,81. Current treatments for nicotine abuse 
include cholinergic drugs like the partial nicotinic acetylcholine receptor ago-
nist varenicline and nicotine-replacement therapy, or monoaminergic therapy 
such as the dopamine- and norepinephrine-reuptake inhibitor bupropion, the 
tricyclic antidepressant nortriptyline and the a2 adrenergic agonist clonidine77. 
Therapies for heroin addiction include the opioid agonists methadone and levo-
a-acetylmethadol, the partial agonist buprenorphine combined with naloxone, 
and the opioid antagonist naltrexone77,80. No effective pharmacotherapeutic 
options for addiction to cocaine, cannabis, methamphetamine or other stimu-
lants exist77,80.
Hyperprolactinemia
Dopamine neurotransmission is also involved in the pathophysiology of hyper-
prolactinemia. Hyperprolactinemia can result from a large variety of disorders, 
including prolactin-secreting pituitary tumors (prolactinomas), lesions to the 
hypothalamus and pituitary gland that interfere with neuroendocrine control 
mechanisms, as well as diseases that can lead to decreased clearance of prolac-
tin, such as liver cirrhosis and chronic renal failure82,83. Hyperprolactinemia 
can also be caused by use of certain drugs. The most common drugs that cause 
hyperprolactinemia are drugs that inhibit dopamine neurotransmission, such 
as dopamine d2 receptor antagonists (e.g. antipsychotic drugs and domperi-
done)44,45,84. Pharmacological treatment of prolactinomas include dopamine 
receptor agonists, such as bromocriptine, cabergoline and quinagolide, whereas 
management of drug-induced hyperprolactinemia includes dose reduction of 
the causative drug or switching to a different drug with lower potential for pro-
lactin elevation, if this can be achieved safely83,85,86.
Emesis
Finally, dopaminergic neurons in the area postrema and nucleus tractus soli-
tarius are involved in the control of emesis7,19. Neurocircuitry in the area pos-
trema and nucleus tractus solitarius involves many neurotransmitters87, but do-
pamine, serotonin and the tachykinin neuropeptide substance P are thought to 
play the largest roles88. Accordingly, several dopamine d2 receptor antagonists 
(including metoclopramide, domperidone and olanzapine), serotonin 5-ht3 re-
ceptor antagonists, as well as the tachykinin nk1 receptor antagonist aprepitant, 
have demonstrated antiemetic efficacy87,89,90.
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strategies for improvement of 
dopaminergic pharmacotherapy
In this thesis, several pharmacological strategies are presented that aim to im-
prove dopaminergic pharmacotherapy by allowing more subtle manipulations 
of dopaminergic systems. Several early phase clinical trials are described that 
are part of larger drug development programs which explore various stategies, 
including improvement of receptor kinetics and receptor selectivity, as well as 
targeting dopaminergic control mechanisms as a means to indirectly modulate 
dopamine neurotransmission.
Improvement of receptor kinetics
It has been proposed that competitive receptor antagonists that dissociate 
quickly from the receptor (i.e. a fast koff constant) are more accommodating to 
physiological fluctuations of endogenous ligand concentrations (i.e. dopamine) 
than drugs with a slow koff91. Fast dissociation might therefore allow for a drug 
effect to occur with an appropriate functioning of physiological systems and a 
substantially lower risk for side effects associated with persistent strong activ-
ity at the receptor91. This pharmacological concept was originally proposed to 
explain the differential effects of typical and atypical antipsychotic drugs91-93, 
but was later criticized because several exceptions were identified94. Although 
the fast dissociation hypothesis may thus not fully qualify as a general model for 
atypical antipsychotic drug action, it does provide a theoretical way to achieve 
reduction of side effects and may thus serve as a strategy for novel drug develop-
ment. Using receptor dissociation rates as a means to screen novel compounds 
for antipsychotic drug candidates, the novel fast dissociating dopamine d2 re-
ceptor antagonist jnj-37822681 was developed95. In chapter 2, the pharma-
cokinetics and central nervous system (cns) effects of jnj-37822681 in healthy 
volunteers are described. In chapter 3, the binding characteristics of jnj-
37822681 in vivo are investigated using positron emission tomography (pet) 
and the radioligand [11C]raclopride to evaluate if jnj-37822681, despite its high 
dissociation rate, is able to achieve significant levels of dopamine d2 receptor 
occupancy.
Improvement of receptor selectivity
Increased receptor selectivity may minimize side effects related to drug action 
at receptor sites other than the primary target. Despite the major role of dopa-
mine neurotransmission in the acute rewarding effects of addictive drugs, no 
dopaminergic agents have been demonstrated to be uniformly effective for 
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drug addiction, which may be (at least partly) due to lack of pharmacological and 
functional selectivity for the mesolimbic pathway, as well as poor tolerability80. 
It has been suggested that selective dopamine d3 receptor antagonism may be an 
effective strategy in pharmacotherapy of addiction96-98. Preclinical models have 
shown that selective dopamine d3 receptor antagonists do not affect the primary 
reinforcing effects of drugs of abuse, but can influence the motivation to self-
administer drugs under certain schedules of reinforcement99. In addition, selec-
tive dopamine d3 receptor antagonists appear to disrupt the responsiveness to 
drug-associated stimuli that play a key role in reinstatement of drug-seeking be-
havior triggered either by re-exposure to the drug itself, re-exposure to environ-
mental cues that had been previously associated with drug-taking behavior, or 
stress99. Thus, selective dopamine d3 receptor antagonists might be efficacious 
in decreasing craving and preventing relapse99,100. gsk598809 is a novel selec-
tive dopamine d3 receptor antagonist101. chapter 4 describes the pharmaco-
kinetics and central nervous system effects of gsk598809. In addition, possible 
interactions between gsk598809 and alcohol were evaluated. Evaluation of in-
teractions with alcohol is important for candidate drugs for pharmacotherapy 
of addiction, because the target population of patients will have substance de-
pendence as primary disorder, and are thus likely to co-administer prescription 
drugs together with alcohol and other drugs of abuse.
Modulation of the tachykinergic control of dopamine 
neurotransmission
An alternative to direct pharmacological modulation of dopamine neurotrans-
mission is modulation of the control mechanisms of dopamine neurotrans-
mission. Among the many control mechanisms, the peptide neuromodulators 
have been proposed as suitable targets for novel drug candidates, perhaps even 
advantageous over antagonists to classic monamine neurotransmitters102, for 
several reasons. First, the effects of peptide neurotransmitters are milder than 
those of monoamines102,103. Second, much evidence indicates that neuropep-
tides are preferentially released after stressful and noxious stimuli, challenges 
or pathological conditions102-104. Thus, antagonists may only act on pathologi-
cal systems with increased peptide release and have limited effects under normal 
conditions102,103. These characteristics together might result in clinical efficacy 
with less pronounced side effects102.
Tachykinins (also known as neurokinins) are a group of related peptide 
neurotransmitters that includes substance P, neurokinin A and neurokinin 
B24,105. Tachykinins control and activate dopaminergic neurons in all major 
dopaminergic pathways, including substantia nigra, ventral tegmental area and 
chapter i – introduction
– 17 –
hypothalamus24,106-108. Tachykinins interact with three types of receptors, the 
neurokinin 1 (nk1), neurokinin 2 (nk2) and neurokinin 3 (nk3) receptor, all of 
which are g protein-coupled receptors24,105. The three tachykinin receptors are 
recognized with moderate selectivity by the endogenous tachykinins. Substance 
P shows the highest affinity for the nk1 receptor, neurokinin A exhibits the 
highest affinity for the nk2 receptor and neurokinin B has the highest affinity 
for the nk3 receptor105. Several clinical trials have evaluated tachykinin receptor 
antagonists for possible antipsychotic activity109-111. Results of an exploratory 
clinical trial with the nk1 receptor antagonist aprepitant in schizophrenia 
patients demonstrated no significant antipsychotic efficacy110. In addition, 
despite an early positive clinical trial with osanetant112, most clinical trials 
with the nk3 receptor antagonists osanetant, talnetant and azd2624 did 
not demonstrate convincing antipsychotic efficacy, although suboptimal 
pharmacokinetic characteristics of osanetant and talnetant may partly account 
for their poor efficacy113,114.
Recently, interest in tachykinins has focused on a potential role in the 
treatment of drug addiction and substance abuse disorders115,116. Substance P 
may play a role in addiction-related behavior by acting directly on nk1 receptors 
in brain areas associated with drug reward, such as the nucleus accumbens 
and ventral pallidum, and on dopaminergic neurons in the ventral tegmental 
area, but also by influencing other neurotransmitters such as serotonin, 
acetylcholine and noradrenalin117. Therefore, it has been suggested that nk1 
receptor antagonists may modulate stress- and reward-related processes 
and may contribute in altering drug reward115. chapter 5 describes the 
pharmacokinetics and central nervous system effects of the nk1 receptor 
antagonist aprepitant. Also, possible interactions between aprepitant and 
alcohol were evaluated. To confirm and to extend the findings obtained with 
aprepitant, the hypothesis that tachykinin receptor antagonists may alter drug 
reward was investigated further. chapter 6 describes the pharmacokinetics 
and central nervous system effects of gsk1144814, which has antagonist action at 
both nk1 and nk3 receptors, in a subgroup of alcohol-intoxicated volunteers, to 
evaluate if dual tachykinin receptor antagonism can modulate the cns effects of 
alcohol.
Modulation of the gabaergic control of dopamine neurotransmission
gaba is one of the major inhibitors of dopamine neurotransmission (see 
Figure 2). Accordingly, drugs that modulate gaba neurotransmission may 
indirectly influence dopamine neurotransmission. Indeed, the gabab recep-
tor agonist baclofen has demonstrated promising results in the treatment of 
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alcohol addiction, probably by inhibiting activity of the mesolimbic dopami-
nergic pathway through activation of gabab receptors in the ventral tegmental 
area118,119. Modulation of the gabaergic control of dopamine neurotransmis-
sion has also been suggested to underlie the therapeutic potential of benzodiaz-
epines in the treatment of schizophrenia120. Benzodiazepines were proposed to 
exert antipsychotic effects because of their agonist effects on gabaergic inhibi-
tion of dopamine neurotransmission120. However, although the sedative and 
anxiolytic effects of benzodiazepines can be useful in the clinical management 
of acutely agitated patients, no significant effects on more specific psychotic 
manifestations of schizophrenia have been demonstrated121.
Benzodiazepines are nonselective allosteric modulators of a1, a2, a3 and a5 
subunit-containing gabaa receptors122. Recently, studies in animal models 
have suggested that gabaa receptor subtypes are associated with different as-
pects of gabaergic drug action, like sedation (a1 subtype), anxiolysis (a2 and a3 
subtypes) and memory impairment (a5 subtype)122
,123. Although gaba gener-
ally causes a reduction of dopaminergic neuronal activity21, benzodiazepines 
have been shown to increase dopamine levels in the mesolimbic pathway76. This 
increase probably results from serial inhibition of coupled gabaergic interneu-
rons in the mesolimbic pathway, which leads to disinhibition of dopaminergic 
neurons, which outweighs the direct inhibitory influence of benzodiazepines 
on those dopaminergic neurons123-125. The disinhibition of dopaminergic 
neurons and the resulting increase in dopamine levels appears to be mediated 
by the a1 receptor subtype124
,125. It has been suggested that selective agonists 
at a3 receptor subtypes without efficacy at a1 receptor subtypes, may attenuate 
dopamine neurotransmission in the mesolimbic pathway, without counterac-
tive disinhibition from gabaergic interneurons123. Accordingly, gabaa recep-
tor subunit-selective agonists may differ significantly from nonselective benzo-
diazepines in their effects on dopaminergic pathways, and may have therapeutic 
potential for (some aspects of) schizophrenia123.
A targeted selection of the proper subtype-selective gabaa agonist would re-
quire a good understanding of the exact role of the various receptor subtypes in 
the regulation of different dopaminergic activities. To explore the exact role of 
the various receptor subtypes in the regulation of dopamine neurotransmission, 
chapter 7 describes the effects of two novel positive modulators of a2 and a3 
subunit-containing gabaa receptors, azd7325 and azd6280126, and the nonse-
lective benzodiazepine lorazepam on circulating prolactin levels as a marker for 
activity of the tuberoinfundibular pathway, which is the most readily accessible 
dopaminergic pathway for evaluation in vivo.
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conclusion and aim of thesis
The neurotransmitter dopamine is involved in the pathogenesis of several neu-
ropsychiatric disorders. Despite the large number of registered dopamine re-
ceptor agonists and antagonists, pharmacological methods to alter dopamine 
neurotransmission currently have only limited efficacy in alleviating the symp-
toms of these disorders, while adverse side effects can be debilitating. This the-
sis describes early phase drug development studies that are part of larger drug 
development programs which explore various stategies for improvement of do-
paminergic pharmacotherapy. These strategies include improvement of recep-
tor kinetics (chapter 2 and 3) and receptor selectivity (chapter 4), as well 
as modulation of dopamine control mechanisms (chapter 5, 6 and 7). This 
thesis aims to evaluate pharmacokinetics and dose-effect relationships of sev-
eral drug candidates on various neurophysiological parameters in healthy vol-
unteers in order to show penetration through the blood-brain barrier, target 
engagement in vivo and differentiation of pharmacodynamic effects on several 
functional cns domains.
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abstract
Using the rate of dissociation from the d2 receptor as a means to screen novel 
compounds for antipsychotic drug candidates, the centrally acting and fast-
dissociating selective dopamine d2 receptor antagonist jnj-37822681 was de-
veloped. In a blinded, placebo-controlled, randomized first-in-human study, 
jnj-37822681 was administered orally to 27 healthy male volunteers at doses 
of 0.5, 2, 5, 10, 15 and 20 mg. Safety, pharmacokinetics and central nervous sys-
tem effects were evaluated by measuring prolactin levels, eye movements, 
adaptive tracking, visual analogue scales, body sway, finger tapping and elec-
troencephalography. jnj-37822681 was well tolerated and somnolence was the 
most frequently reported adverse effect. Peak plasma concentrations increased 
more than proportional to dose, but increases in auc were dose-proportional. 
Prolactin elevations started at doses of 5 mg, while small decreases in adap-
tive tracking were demonstrated at 10 mg doses. At higher doses, jnj-37822681 
caused a small decrease in saccadic peak velocity, smooth pursuit, alertness, fin-
ger tapping and eeg activity, and an increase in body sway. This effect profile 
is likely the result of the selectivity of jnj-37822681 for the d2 receptor, lead-
ing to strong d2 receptor-mediated elevations in serum prolactin, but fewer 
effects on more complex cns functions, which are likely to involve multiple 
neurotransmitters.
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introduction
Current treatment options for schizophrenia and psychosis include a variety 
of drugs, all of which act by attenuating dopamine d2 receptor function1
-3. 
However, these drugs vary considerably in clinical effect and side effect profile. 
Typical antipsychotic drugs are effective against positive symptoms but also 
have a high incidence of extrapyramidal side effects, whereas atypical antipsy-
chotic drugs have far fewer extrapyramidal side effects and may also be effective 
against negative signs4. Several different pharmacological concepts have been 
proposed to account for the distinct effect profile of atypical antipsychotic drugs 
compared with typical antipsychotic drugs. These include, among others, a high 
ratio of serotonin 5-ht2a receptor to dopamine d2 receptor antagonism5, pref-
erential mesolimbic dopamine d2/d3 receptor binding6 and rapid dissociation 
from the dopamine d2 receptor7
-9. The latter hypothesis proposes that fast dis-
sociation rates of an antipsychotic drug from the dopamine d2 receptor may pro-
vide sufficient receptor occupancy for an antipsychotic effect to occur, yet allow 
accommodation to physiological dopamine release with a substantially lower 
risk for extrapyramidal symptoms, hyperprolactinaemia or secondary negative 
signs8-12. However, this hypothesis has been criticized on several grounds. It has 
been argued that this hypothesis can only apply to drugs such as clozapine and 
quetiapine, which have low affinity for the dopamine d2 receptor, and may not 
be generalized as a model for atypical antipsychotic drug action13. Also, this hy-
pothesis may not fully explain the improved neurocognitive effects of atypical 
drugs, nor why clozapine is more effective in treatment-resistant schizophre-
nia4,13-16. However, these limitations do not necessarily preclude usefulness of 
this hypothesis as the basis for a drug development strategy by selecting novel 
candidate drugs on their respective dissociation rates. Moreover, development 
of a novel compound with selectivity for the dopamine d2 receptor and a fast rate 
of dissociation can provide an opportunity to study this hypothesis in a prospec-
tive clinical setting.
Using receptor dissociation rates as a means to screen novel compounds for 
antipsychotic drug candidates, the centrally acting dopamine d2 receptor an-
tagonist jnj-37822681 (see Figure 1) was developed17. jnj-37822681 is a novel 
chemical entity that combines specificity for the dopamine d2 receptor and 
a fast rate of dissociation. In vitro receptor binding studies demonstrated that 
jnj-37822681 displays moderate affinity for the dopamine d2l receptor (ki = 
158 nM) and low affinity for dopamine d1 (ki › 3000 nM) and d3 receptors (ki = 
1159 nM), serotonin 5-ht2a (ki = 2896 nM) and 5-ht2c (ki ›4000 nM) receptors, 
histamine H1 receptors (ki = 4931 nM) and adrenergic a1a receptors (ki ›5000 
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nM). jnj-37822681 also binds to the σ1 receptor (ki = 8.9 nM)17. When tested in 
parallel, the time for 50% dissociation of [3H]jnj-37822681 from the dopamine 
d2l receptor was 6.5 seconds at room temperature and 3.7 seconds at 37°C (koff 
= 0.108 and 0.191 s-1, respectively), which was similar to the dissociation rate of 
[3H]clozapine (14.5 seconds at room temperature and 5.8 seconds at 37°C) and 
significantly faster than those of [3H]haloperidol, [3H]risperidone and [3H]
paliperidone17. In animal models, jnj-37822681 antagonizes the behavior in-
duced by various stimulants in the following potency order: apomorphine-
induced stereotypy (ed50 = 0.194 mg/kg), d-amphetamine-induced stereotypy 
(ed50 = 0.294 mg/kg), d-amphetamine hyperlocomotion (ed50 = 1.02 mg/kg), 
β-phenylethylamine-induced stereotypy (ed50 = 1.17 mg/kg) and phencyclidine-
induced hyperlocomotion (ed50 = 4.7 mg/kg)17. Using the crossed-leg position 
test in rats, the ed50 for inducing catalepsy was higher, at 8.7 mg/kg. These data 
suggest that jnj-37822681 is a potent, specific and fast dissociating dopamine 
d2 antagonist with a relatively low potential for extrapyramidal effects within 
the projected therapeutic dose range. Furthermore, specificity for the dopamine 
d2 receptor by jnj-37822681 may also minimize potential for side effects related 
to interactions with other receptors, such histamine H1, adrenergic a1 and sero-
tonin 5-ht2c, which are thought to contribute to major side effects associated 
with second generation antipsychotics18.
figure 1 Chemical structure of jnj-37822681
The present study was performed to obtain a pharmacokinetic profile of single 
oral doses of jnj-37822681 in healthy volunteers, using a blinded, randomized, 
placebo-controlled study design. In addition, central nervous system (cns) ef-
fects were evaluated using a battery of quantitative tests, sensitive to the central 
effects of various drugs, including antipsychotic drugs (dopamine d2 receptor 












Twenty-four healthy male volunteers, between 18 and 55 years of age and with 
a body mass index between 18 and 30 kg/m2, were planned to participate in an 
alternating panel, blinded, placebo-controlled, randomized, variable dose 
study of six volunteers per dosing group. The study was approved by the medi-
cal ethics review board of the Leiden University Medical Center. Prior to medical 
screening, all volunteers gave written informed consent. All volunteers under-
went training sessions for the pharmacodynamic tests in order to make them ac-
quainted with the procedures and to reduce possible learning effects.
Treatments
Volunteers were randomly assigned to a treatment sequence consisting of 
three study periods with administration of single ascending oral doses of jnj-
37822681 and one interspersed study period with administration of placebo. 
Volunteers were randomly divided over two alternating panels. Twelve volun-
teers were assigned to the first panel and received 0.5 mg, 5 mg, 15 and 20 mg of 
jnj-37822681 or matching placebos. Twelve other volunteers were assigned to 
the second panel and received 2 mg, 10 mg, 15 mg and 20 mg of jnj-37822681 or 
matching placebos. All periods were separated by a washout time of two weeks. 
Dose escalation steps were guided by the observed safety, tolerability and the 
pharmacokinetic and pharmacodynamic data of the previous dose levels. jnj-
37822681 was administered in a liquid (1 mg/mL; only for the 0.5 mg dose) or 
solid (capsules of 1 and 10 mg) dosage formulation after a 10 hour fasting period.
Safety monitoring
Evaluation of adverse events, 12-lead electrocardiograms (ecg), blood pressure, 
heart rate, body temperature measurements, urinalysis and blood sampling 
for haematology and chemistry was performed at regular time points after each 
dose administration. Blood pressure was measured using automated oscillo-
metric monitors. ecgs were obtained with Cardiofax V equipped with ecaps12 
analysis program (Nihon-Kohden, Tokyo, Japan). In addition, continuous ecg 
monitoring was performed from 30 minutes prior to dosing until 12 hours after 
dose administration using one-lead telemetric ecg. Volunteers were evaluated 
for akathisia and extrapyramidal symptoms, using the Barnes akathisia rating 
scale23 and Simpson-Angus scale24.
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Pharmacokinetics
Venous blood samples for jnj-37822681 plasma concentration analysis were col-
lected prior to dose administration and at 15 and 30 minutes and 1, 11⁄™, 2, 3, 4, 6, 
8, 12, 16, 24, 36, 48 and 72 hours after dose administration. The concentration of 
jnj-37822681 in plasma samples was determined using liquid chromatography-
mass spectrometry with a lower limit of quantification of 0.2 ng/mL.
Pharmacodynamic testing
Pharmacodynamic measurements were performed as described previous-
ly20,25, prior to dose administration and at fixed time intervals around 1, 11⁄™, 
2, 3, 4, 6, 8 and 12 hours after dose administration. Volunteers were tested indi-
vidually in a quiet room with ambient illumination. quantitative tests, sensi-
tive to single oral doses of antipsychotic drugs19 such as haloperidol20,21 and 
risperidone22 in healthy volunteers, included measurements of smooth pur-
suit and saccadic eye movements, adaptive tracking, body sway, finger tapping, 
visual analogue scales, electroencephalography and serum prolactin levels.
Analysis of eye movements
To evaluate oculomotor performance and sedation, smooth pursuit and sac-
cadic eye movements were recorded as described previously26-29, using a 
microcomputer-based system for data recording and analysis (Cambridge 
Electronic Design Ltd., Cambridge, uk), Nihon-Kohden equipment for stimu-
lus display, signal collection and amplification (Nihon-Kohden, Tokyo, Japan), 
and disposable surface electrodes (Medicotest N-oo-S, Olstykke, Denmark). 
For smooth pursuit eye movements, a target light source moves sinusoidally 
over 20° eyeball rotation at frequencies ranging from 0.3 to 1.1 Hz. The time 
in which the eyes were in smooth pursuit was calculated for each frequency 
and expressed as the percentage of stimulus duration. The average percent-
age of smooth pursuit for all frequencies was used as parameter. For saccadic 
eye movements, the target light source jumps from side to side. Peak velocity 
(degrees per second), reaction time and inaccuracy (%) was calculated of all arti-
fact-free saccades.
Adaptive tracking
To evaluate visuo-motor coordination, the adaptive tracking task was per-
formed as described previously28-32, using customized equipment and software 
developed by K.W. Hobbs (Hertfordshire, uk). Adaptive tracking is a pursuit 
tracking task in which a circle moves randomly over a computer screen and the 
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volunteer must try to keep a dot inside the moving circle using a joystick. If this 
effort is successful, the speed of the moving circle is increased and if the effort is 
unsuccessful, the speed is reduced. Performance was scored over a fixed period of 
three minutes.
Body sway
Postural stability in the sagittal plane was measured with an apparatus similar 
to the Wright ataxiameter33, using a string attached to the waist of the subject. 
Movements over a period of two minutes, while standing still with eyes closed, 
were integrated and expressed as mm sway.
Finger tapping
The finger tapping test was adapted from the Halstead-Reitan test battery34 to 
evaluate motor activation and fluency. The volunteer is instructed to rest the 
wrist of the dominant hand on a table and to tap as quickly as possible with the 
index finger onto the space bar of a key board. The mean tapping rate is used for 
statistical analysis.
Visual analogue scales
Subjective effects were quantified using a Dutch translation of the visual ana-
logue scales (vas), originally described by Norris35, to derive three composite 
factors corresponding to alertness, mood (contentedness) and calmness, as de-
scribed by Bond & Lader36. Additional psychedelic effects were monitored using 
an adapted version of the visual analogue scales as described by Bowdle37.
Electroencephalography
Electroencephalography (eeg) recordings were obtained at leads Fz-Cz and Pz-
Oz, according to the international 10/20 system, using disposable silver-silver 
chloride electrodes (Medicotest N-oo-S, Olstykke, Denmark). Signals were 
amplified by use of a Grass 15lt series amplifier systems with a time constant 
of 0.3 seconds and a low pass filter at 100 Hz. Data collection and analyses were 
performed using customized ced and Spike2 for Windows software (Cambridge 
Electronics Design, Cambridge, uk). For each lead, fast Fourier transform analy-
sis was performed to obtain the sum of amplitudes in the δ (0.5-3.5 Hz), θ (3.5-
7.5 Hz), a (7.5-11.5 Hz) and β (11.5-30 Hz) frequency ranges. Measurements were 
performed with eyes closed in sessions of 1 minute, consisting of 8 consecutive 
blocks of 8 seconds. Data blocks containing artifacts were identified by visual in-
spection and excluded from analysis.
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Serum prolactin levels
Blood samples for measurement of prolactin levels were collected in plain 
tubes and serum was separated by centrifugation (2000 g at 4°C for 10 minutes). 
Prolactin levels were determined using an electrochemiluminescence immu-
noassay (eclia) on a Modular Analytics E170 (Elecsys module) immunoassay 
analyzer.
Statistical analysis
Pharmacokinetic parameters of jnj-37822681 were determined based on the in-
dividual plasma concentration-time data, using WinNonlin software version 5.0 
(Pharsight, Mountain View, California, usa), and included peak plasma concen-
tration (Cmax), time to reach peak plasma concentration (tmax), area under the 
plasma concentration-time curve extrapolated to infinity (auc∞) and terminal 
half-life (t1⁄™).
Pharmacodynamic parameters were compared using a mixed model 
analysis of variance (using sas proc mixed) with treatment, period, time and 
treatment by time as fixed factors, and with subject, subject by treatment and 
subject by time as random factors, and with the average pre-value (average over 
all measurements prior to dosing) as covariate. Body sway, peeg and prolactin 
data were log-transformed prior to analysis to correct for the expected log-
normal distribution of the data. Contrasts relative to placebo treatment were 
calculated in original measurement unit with 95% confidence intervals and 
the associated p-value, except for the log-transformed parameters, which were 
calculated as a percentage relative to placebo. Following the observation that 
pharmacodynamic effects were maximal between 1 and 3 hours after dosing, 
data analysis was repeated for all measurements up to 5 hours. Using a restricted 
time range for analysis has the benefit that medication-related effects are 
detected more easily. All calculations were performed using sas for Windows 
version 9.1.2 (sas Institute Inc., Cary, North Carolina, usa).
results
Subjects
Participants had a mean age of 26.6 years (range 18-53), weight of 74.6 kg (range 
57-93) and body mass index of 22.9 kg/m2 (range 20-30). After inclusion, three 
volunteers were discontinued later (one volunteer because of acute appendicitis 
and two volunteers for personal reasons) and were replaced. Therefore, data was 
obtained from 27 volunteers in total. However, pharmacodynamic data from 
one volunteer was excluded from analysis, prior to data review, after additional 
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information about an undeclared psychiatric history had surfaced after study 
completion, which violated the in- and exclusion criteria of the study. In total, 14 
volunteers were able to complete all four study periods. The remaining 13 volun-
teers missed one or more study periods for reasons unrelated to treatment with 
jnj-37822681. A total of 18 volunteers received placebo, 9 volunteers received 
0.5 mg, 7 volunteers received 2 mg, 9 volunteers received 5 mg, 8 volunteers re-
ceived 10 mg, 16 volunteers received 15 mg and 16 volunteers received 20 mg of 
jnj-37822681.
Clinical observations
Twenty-four volunteers (89%) reported at least one adverse event (see Table 1). 
One volunteer was hospitalized for acute appendicitis three days after having 
received 5 mg of jnj-37822681. The most frequently reported adverse effect 
was somnolence (21 volunteers, 78%). Other common events were headache (9 
volunteers, 33%), dizziness (4 volunteers, 15%) and fatigue (4 volunteers, 15%). 
Adverse effects were mild and occasionally moderate and all disappeared spon-
taneously within a few hours. Transient mild restlessness (akathisia) was report-
ed by one volunteer after 20 mg and by another volunteer after 15 and 20 mg of 
jnj-37822681. The volunteer with an undeclared psychiatric history reported 
mild restlessness after administration of placebo. All events, except the event 
following placebo administration, were associated with very small increases on 
the Barnes akathisia rating scale, started within one hour after dosing and re-
solved within 3 hours after dosing. Mild musculoskeletal stiffness was reported 
by one volunteer after 10 mg and by another volunteer after 15 mg, without con-
comitant changes on the Simpson-Angus scale. There were no clinically relevant 
changes in heart rate, blood pressure, body temperature, haematology, biochem-
istry, urinalysis or any of the ecg intervals.
Pharmacokinetic and pharmacodynamic parameters
Pharmacokinetic parameters are summarized in Table 2. At the lowest dose of 
0.5 mg, derived pharmacokinetic parameters could not be estimated reliably, 
because most values were below the lower limit of quantification. jnj-37822681 
was rapidly absorbed followed by a mean terminal half-life of approximate-
ly 38 hours after 2 mg and 24 to 27 hours after doses between 5 and 20 mg (see 
Figure 2). With increasing doses, absorption gradually increased, with tmax 
changing from 3.47 hours after 0.5 mg to 1.35 hours after 20 mg. Peak plasma 
concentration (Cmax) increased more than dose-proportional within the dose 
range of 0.5 to 20 mg, whereas increases in the extent of exposure (auc∞) were 
dose-proportional.
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Pharmacodynamic parameters are summarized in Table 3. In line with the phar-
macokinetic profile of jnj-37822681, pharmacodynamic effects were maximal 
between 1 and 3 hours after dosing and disappeared within 8 hours. Statistically 
significant elevations of serum prolactin levels were found at doses of 5 mg and 
higher (see Figure 3), increasing up to 758% in estimated mean at 20 mg over the 
first five hours. At doses of 10 mg, jnj-37822681 significantly decreased adaptive 
tracking. At doses of 15 and 20 mg, jnj-37822681 significantly decreased saccad-
ic peak velocity, smooth pursuit eye movements, finger tapping rate, eeg a and 
β activity, and increased body sway. No consistent and statistically significant 
changes were found on any of the visual analogue scales, except a small decrease 
of vas alertness following 20 mg (difference -2.7 mm; 95% confidence interval 
-4.4/-1.0; p = 0.0034).
table 1 Summary of common adverse events, with an incidence higher than 5%. Incidence is 
based on the number of subjects (with percentages between brackets), not the number of events. 
Adverse event Placebo 0.5 mg 2 mg 5 mg 10 mg 15 mg 20 mg
Somnolence 1 (6) 1 (11) 1 (14) 5 (56) 2 (25) 11 (69) 14 (88)
Headache 1 (6) 1 (11) 1 (14) 2 (22) 0 4 (25) 2 (13)
Dizziness 0 0 0 0 0 1 (6) 3 (19)
Akathisia 1 (6) 0 0 0 0 1 (6) 2 (13)
Paraesthesia 0 0 1 (14) 1 (11) 0 1 (6) 0
(Vasovagal) syncope 1 (6) 0 0 0 1 (13) 0 1 (6)
Fatigue 0 0 1 (14) 3 (33) 0 0 0
Nausea 1 (6) 0 0 0 1 (13) 1 (6) 1 (6)
Nasopharyngitis 0 0 0 2 (22) 1 (13) 0 0
Musculoskeletal stiffness 0 0 0 0 1 (13) 1 (6) 0
table 2 Pharmacokinetic parameters of jnj-37822681. All data are presented as means (with 
standard deviation). Pharmacokinetic parameters of the 0.5 mg dose could not be estimated reliably. 
Parameter 2 mg 5 mg 10 mg 15 mg 20 mg
Cmax (ng/mL) 2.84 (0.91) 10.5 (5.51) 31.5 (5.14) 47.6 (13.9) 73.3 (26.4)
tmax (h) 2.76 (1.11) 2.46 (0.99) 1.44 (0.18) 1.47 (0.53) 1.35 (0.6)
auc∞ (ng.h/mL) 57.5 (15.9) 123 (40) 303 (32.7) 432 (81.4) 598 (141)
Terminal half life (h) 37.9 (14.4) 26.7 (4.8) 27.3 (5.7) 24.4 (3.7) 26.3 (5.9)
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figure 2 Time course of plasma concentration of jnj-37822681 following administration of 2 
mg (closed triangles), 5 mg (open triangles), 10 mg (closed circles), 15 mg (open circles) and 20 mg (closed 
diamonds). Means are presented with standard deviations as error bars.
 
figure 3 Serum prolactin levels following administration of placebo (closed squares), 0.5 mg 
(open squares), 2 mg (closed triangles), 5 mg (open triangles), 10 mg (closed circles), 15 mg (open circles) 
and 20 mg (closed diamonds) of jnj-37822681. Means are presented with standard deviations as error 
bars.
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table 3 Pharmacodynamic parameters of jnj-37822681. Treatment differences in least square 
means are shown from 0 to 5 hours relative to baseline. Statistically significant results are indicated 
in bold. Results of the 0.5 mg and 2 mg doses are not shown because these doses did not show any 
statistically significant difference compared with placebo on the pharmacodynamic parameters. 
 

























































































































































The present study evaluated pharmacokinetics and central nervous system (cns) 
effects of single oral doses of jnj-37822681 in healthy volunteers. The main ef-
fect of jnj-37822681 was dose-related elevation of serum prolactin, which nor-
malized within 8 hours, while other subjective, neuropsychological and neuro-
physiological effects were generally small. The time course of cns effects cor-
responded well with the pharmacokinetics of jnj-37822681 with a tmax of ap-
proximately 1-3 hours.
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The elevation of serum prolactin levels is most likely the result of blockade of do-
pamine d2 receptors in the pituitary gland by jnj-37822681. Prolactin release by 
the lactotroph cells in the anterior pituitary gland is under inhibitory control by 
dopamine, released from hypothalamic tracts, which binds to the lactotrophic 
dopamine d2 receptors38
,39. Pharmacologic blockade of the d2 receptors on the 
lactotrophs removes the inhibitory control of dopamine, resulting in hyper-
prolactinaemia40. All antipsychotics (d2 antagonists) cause increases in plas-
ma prolactin, although the extent and duration can vary41-43. As a result, only 
some agents cause clinically relevant hyperprolactinaemia (prolactin-elevating 
agents), whereas others do not (prolactin-‘sparing’ agents)44. The highest rates 
of hyperprolactinaemia are observed with the atypical antipsychotic drugs ris-
peridone and amisulpride45. It has been suggested that prolactin-sparing anti-
psychotics lack clinically relevant hyperprolactinaemia, because they are associ-
ated with a short-lasting transient prolactin increase immediately after dosing, 
without accumulation over time, as the prolactin level has returned to baseline 
prior to the next dose42,43. Also, it has been proposed that fast dissociation may 
explain this effect, because this may lead to rapidly declining rates of pituitary 
d2 receptor occupancy over time42. Indeed, the fast dissociating antipsychotic 
drugs clozapine and quetiapine are not associated with clinically relevant hy-
perprolactinaemia45-48. The currently measured prolactin levels after adminis-
tration of jnj-37822681 are higher than those after single oral doses of 2 mg of 
risperidone22, 3 mg of haloperidol20, 50 mg of clozapine49 or 150 mg of quetiap-
ine50 in healthy volunteers. However, as demonstrated in Figure 3, serum pro-
lactin has largely returned to baseline levels within 8 hours after administration 
of jnj-37822681, which may prevent accumulation during chronic treatment. 
Future clinical trials with repeated dosing regimes are needed to determine 
whether jnj-37822681 produces sustained and clinically relevant hyperprolac-
tinaemia with therapeutic use.
The decreases in smooth pursuit performance and saccadic peak velocity and 
the results of body sway after administration of jnj-37822681 are indicative of 
decreased attention and slight sedation19,28,29. Similar effects have been dem-
onstrated following single dose administration of 2 mg of risperidone22 and 3 
mg of haloperidol in healthy volunteers20. In fact, sedation is a common effect 
of most registered antipsychotic drugs and occurs particularly with drugs that 
show significant histamine H1 receptor antagonism51. jnj-37822681 exhibits 
low affinity in vitro for this receptor (ki = 4931 nM). Reduced attention after ad-
ministration of jnj-37822681 therefore seems to be related to dopamine d2 re-
ceptor antagonism per se. However, the somnolence reported by the volunteers 
was generally very mild, without subjective distress, and disappeared sponta-
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neously within a few hours. The results of adaptive tracking and finger tapping 
are indicative of slightly impaired (visuo-)motor performance19. These effects 
have also been previously demonstrated after single oral doses of risperidone22 
and haloperidol in healthy volunteers20. At the highest doses, a few volunteers 
reported transient mild restlessness (akathisia) with an accompanying small in-
crease in scores on the Barnes akathisia rating scale. However, these effects were 
very mild and resolved spontaneously and rapidly, without need for anticholin-
ergic (or other) treatment. No other motor symptoms were observed.
The observed psychomotor effects of jnj-37822681 are relatively small 
in comparison with the elevations in serum prolactin. These findings could 
theoretically be related to insufficient penetration through the blood-brain 
barrier. If a compound does not easily cross the blood-brain barrier, the 
concentration in the pituitary gland (which is situated outside the blood-brain 
barrier) may rise much higher than the concentration within the brain52,53. 
However, preclinical studies in rodents have demonstrated much higher 
levels in brain tissue compared to plasma, resulting in brain-to-plasma ratios 
of 10 to 16, indicating good blood-brain barrier penetration (unpublished 
results). Also, in a separate positron emission tomography (pet) study using 
[11C]raclopride in healthy volunteers, it was demonstrated that jnj-37822681 
produces striatal dopamine d2 receptor occupancy up to 60-74% after oral doses 
of 20 mg54. Therefore, the small central effects of jnj-37822681 seem unlikely 
to result from lack of penetration through the blood-brain barrier. A more likely 
explanation of these findings may be the selectivity of jnj-37822681 for the 
dopamine d2 receptor. Prolactin release is controlled primarily by dopamine 
acting on dopamine d2 receptors, whereas the other pharmacodynamic tests 
measure more complex cns functions, which are likely to involve multiple 
neurotransmitter receptor systems. Accordingly, specific dopamine d2 
antagonism by jnj-37822681 significantly affects prolactin release, while other 
pharmacodynamic tests show only small effects.
Hyperprolactinaemia-inducing dose equivalencies of a wide range of regis-
tered antipsychotic drugs are correlated with affinity for d2 receptors, and also 
with the lowest therapeutic maintenance dose, indicating a close d2 mediated 
relationship between prolactin response and therapeutic efficacy19. Therefore, 
it has been suggested that the effects of novel antipsychotic compounds may be 
compared with established antipsychotic agents by using the prolactin response 
to estimate dose equivalencies and to estimate a likely therapeutic starting dose, 
provided that penetration through the blood-brain barrier is sufficient19. By 
plotting the dose of haloperidol that produces a prolactin reponse equivalent 
to 5 mg of jnj-37822681 onto the curve describing the relationship between 
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the dose equivalency and the lowest therapeutic maintenance dose (Figure 2 
in De Visser et al19), an estimated dose of 5-10 mg of jnj-37822681 is predicted 
as the lowest therapeutic maintenance dose (ignoring any possible accumula-
tion after multiple dosing). Preliminary results of a recently completed multi-
center, double blind, placebo-controlled trial with jnj-37822681 (10 mg, 20 mg 
or 30 mg bid) in patients with schizophrenia indicate antipsychotic efficacy of 
all doses superior to placebo with low frequency of extrapyramidal symptoms55. 
Confirmation of these findings may support the ‘fast dissociation’ hypothesis 
as a means to achieve an atypical antipsychotic effect profile. Despite the short-
comings of the ‘fast dissociation’ hypothesis as a general model for atypical drug 
action, screening of novel candidate drugs on their respective dopamine d2 re-
ceptor dissociation rates may be a useful strategy for novel antipsychotic drug 
development.
In conclusion, the present study demonstrates the prolactin response and 
small cns effects of single oral doses of jnj-37822681, attributable to its selective 
dopamine d2 receptor antagonism. During the further process of development 
of jnj-37822681, studies using multiple dosing regimes in patients with 
schizophrenia or psychosis are needed to evaluate antipsychotic efficacy, but 
also to evaluate specifically the potential for inducing akathisia, sedation or 
sustained hyperprolactinaemia.
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abstract
jnj-37822681 is a novel, fast-dissociating dopamine d2 receptor antagonist, 
currently in development as an antipsychotic drug candidate. A previous first-
in-human study demonstrated mild central nervous system effects of jnj-
37822681 in healthy male volunteers. Significant but transient serum prolactin 
elevations were demonstrated, whereas other neurophysiological effects were 
relatively small. To investigate striatal dopamine d2 receptor occupancy by 
variable single doses of jnj-37822681, an open-label [11C]raclopride positron 
emission tomography study was performed in twelve healthy male volunteers, 
using the simplified reference tissue model with cerebellum as reference tissue. 
Oral administration of jnj-37822681 resulted in dose-dependent dopamine 
d2 receptor occupancy. Receptor occupancy increased from 9-19% at 2 mg doses 
to 60-74% at 20 mg doses of jnj-37822681. Therefore, single oral doses of jnj-
37822681 can produce occupancy levels that are generally associated with clini-
cal efficacy for registered antipsychotic drugs.
chapter 3 – receptor occupancy by jnj-37822681  
– 45 –
introduction
The theory that rapid dissociation rates of an antipsychotic drug from the 
dopamine d2 receptor is a principal pharmacological characteristic that 
determines the distinct effect profile of atypical antipsychotic drugs, has been 
proposed specifically to explain the lower incidence of extrapyramidal side 
effects, hyperprolactinaemia or secondary negative signs compared with typical 
antipsychotic drugs1-6. However, this theory may not fully explain the efficacy 
of clozapine in treatment-resistant schizophrenia7,8. In addition, it has been 
argued that this hypothesis does not apply to all atypical antipsychotic drugs 
but only to drugs such as clozapine and quetiapine, which have low affinity for 
the dopamine d2 receptor7
,9-11. Nevertheless, despite the limitations of the ‘fast 
dissociation hypothesis’ as a general model for atypical drug action, screening of 
novel compounds by their respective dissociation rates may be a useful means to 
select novel antipsychotic drug candidates with an improved side effect profile. 
Moreover, development of a novel compound with selectivity for the dopamine 
d2 receptor and a fast rate of dissociation can provide an opportunity to study 
the ‘fast dissociation hypothesis’ in a prospective clinical setting.
Recently, the novel chemical entity jnj-37822681 was developed, which com-
bines selectivity for the dopamine d2 receptor with a fast rate of dissociation12. 
jnj-37822681 has moderate affinity for the dopamine d2l receptor and low af-
finity for dopamine d1 and d3 receptors, serotonin 5-ht2a and 5-ht2c recep-
tors, histamine H1 receptors and adrenergic a1a receptors12. jnj-37822681 also 
binds to the σ1 receptor. When tested in parallel, the time for 50% dissociation 
of [3H]jnj-37822681 from the dopamine d2l receptor was similar to that of 
[3H]clozapine and significantly faster than that of [3H]haloperidol, [3H]risperi-
done and [3H]paliperidone12. In animal models, jnj-37822681 antagonized 
apomorphine-induced behavior in rats with a low potential for catalepsy12. In 
a separate study, pharmacokinetics and central nervous system (cns) effects of 
jnj-37822681 were evaluated in healthy volunteers13. The main pharmacody-
namic effect was a dose-related elevation of serum prolactin starting at doses of 
5 mg, whereas other subjective and neurophysiological effects were small and 
only observed at higher doses. Somnolence was the most frequent reported ad-
verse event. No significant extrapyramidal effects were noted, although tran-
sient mild restlessness (akathisia) was reported occasionally after higher doses. 
The purpose of the present study was to characterize the relationship between 
plasma concentration following single oral doses of jnj-37822681 and striatal 
dopamine d2 receptor occupancy in vivo.




An open-label study was performed to obtain 16 positron emission tomography 
(pet) scans using [11C]raclopride, after administration of various dosages of jnj-
37822681 in healthy male volunteers, in order to characterize the saturation 
curve of jnj-37822681 within tolerable dose levels. To enable calculation of do-
pamine d2 receptor occupancy, baseline pet scans without prior administration 
of jnj-37822681 were also performed in each volunteer. The study was approved 
by the medical ethics review committee of the vu University Medical Center in 
Amsterdam. Prior to medical screening, all volunteers gave written informed 
consent. Medical screening included medical history, physical examination, 
urinalysis, routine haematology and chemistry, 12-lead electrocardiography and 
an mri scan to exclude cerebral pathology. Up to three [11C]raclopride pet scans 
were performed per individual volunteer: one baseline scan and up to two scans 
following a single oral dose of jnj-37822681. The postdose scans were initiated 
2 hours (±30 minutes) after dosing. This time point was chosen to coincide with 
the expected tmax of the plasma concentrations of jnj-37822681 (which varied 
between approximately 4 hours after 0.5 mg to 1.5 hours after 20 mg) and the 
presence of central nervous system effects (which were maximal between 1 and 
3 hours after dosing)13. The first two volunteers were scanned following admin-
istration of 10 mg of jnj-37822681. This 10 mg dose was expected to result in a 
dopamine d2 receptor occupancy of about 75%, based on previous pet studies of 
jnj-37822681 in Cynomolgus monkeys and pharmacokinetic data from healthy 
volunteers13. Subsequent doses were chosen based on the outcomes of the previ-
ous pet scans. The maximum dose was set to 20 mg jnj-37822681, because safety 
data above 20 mg were not available at the time of study execution. Moreover, 
preclinical studies suggested that this dose would result in significant occu-
pancy of striatal dopamine d2 receptors and allow for reasonable estimation of 
the dose-occupancy relationship. Blood samples for pharmacokinetic analyses 
of jnj-37822681 were taken before dosing and prior to, at the midpoint of and 
immediately after each scan. Plasma concentrations of jnj-37822681 were deter-
mined using liquid chromatography-mass spectrometry. At several time points, 
development of akathisia or other extrapyramidal symptoms was evaluated us-
ing the Barnes akathisia rating scale and the Simpson-Angus scale14,15. In addi-
tion, blood pressure and heart rate measurements, 12-lead electrocardiograms, 
urinalysis, alcohol breath test and routine blood chemistry and haematology 
were performed on the days before and after administration of jnj-37822681. 
Administration of first and second doses of jnj-37822681 was always separated 
by a washout time of at least 7 days.
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Magnetic resonance imaging (mri)
T1-weighted gradient echo pulse mri scans were obtained using a Philips 3 Tesla 
Achieva scanner (Philips Healthcare Nederland, Eindhoven, The Netherlands). 
These scans were used to exclude cerebral pathology and to define regions of in-
terest (roi).
Positron emission tomography (pet)
pet scans were performed on an ecat exact hr+ scanner (Siemens/cti, 
Knoxville, Tennessee, usa), equipped with a neuro-insert to reduce the contri-
bution of scattered photons. This scanner enables the acquisition of 63 transax-
ial planes over a 15.5 cm axial field of view16. First, using three retractable rotat-
ing line sources, a 10 minute transmission scan was performed in 2D acquisition 
mode. This scan was used to correct the subsequent emission scan for photon 
attenuation. Next, a dynamic emission scan in 3D acquisition mode was per-
formed. Data acquisition comprised of 21 frames (6 · 5, 3 · 10, 4 · 60, 2 · 150, 2 · 
300 and 4 · 600 seconds) with a total duration of 60 minutes. At the start of this 
scan, 196 ± 13 mbq [11C]raclopride with specific activity (sa) in the range of 32-
111 gbq/µmol and a total volume of 12 mL was administered intravenously using 
an infusion pump (medrad, Beek, The Netherlands) at a rate of 0.8 mL/sec, fol-
lowed by a flush of 42 mL saline at 2.0 mL/sec. The total injected amount of raclo-
pride did not differ significantly between baseline and postdose pet scans (1.33 ± 
0.52 µg and 1.09 ± 0.98 µg respectively, p = 0.38) and all amounts were less than 1% 
of a clinically active raclopride dose (range 0.48-4.43 µg). The scanning protocol 
was identical for baseline and postdose scans. [11C]raclopride was produced in 
the government licensed gmp facility of the department of Nuclear Medicine & 
pet Research (no. 108897F) according to current gmp guidelines (EudraLex vol-
ume 4) using a previously reported method17.
Image analysis
All pet sinograms were corrected for dead time, scatter, decay, randoms and 
tissue attenuation and reconstructed using filtered back projection with a 0.5 
Hanning filter, resulting in a transaxial spatial resolution of ~ 7 mm full width 
at half maximum in the centre of the field of view. Images were then transferred 
to ultrasparc workstations (Sun Microsystems Inc., Santa Clara, California, 
usa) for further analysis. For each subject, all scans were co-registered to the 
corresponding individual mri. Left and right putamen, together with cerebel-
lum, roi were defined manually on the mri scan and then projected onto the 
co-registered pet scans, guaranteeing identical roi for all successive scans of the 
same subject. Total putamen was obtained as the volume weighted average of 
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left and right putamen. Putamen time-activity curves were analysed using the 
simplified reference tissue model (srtm) with cerebellum as reference tissue18. 
This provides an estimate of the nondisplaceable binding potential bpnd19. For 
each [11C]raclopride scan following administration of jnj-37822681, dopamine 
d2 receptor occupancy in putamen was derived by relating its bpnd (bpnd
drug) to 
the corresponding baseline bpnd (bpndbaseline):
Receptor occupancy (%)    =	     	1	 – 
          bpnddrug                  ]  ·   100 %		 	 	 					[							           bpndbaseline
This approach assumes that affinity is not affected by a pharmacological dose 
of jnj-37822681. For illustrative purposes, the simplified reference tissue mod-
el was also applied at the voxel level using a basis function implementation of 
srtm, generating parametric images of bpnd20. To describe the induced d2 re-
ceptor occupancy as a function of plasma concentration of jnj-37822681, data 
were fitted to the following equation:
Receptor occupancy (%)   =           
 100 ·  Cp 
               Cp + EC50
where Cp stands for the plasma concentration of jnj-37822681 and ec50 for 
the estimated plasma concentration of jnj-37822681 that results in 50% recep-
tor occupancy. Cp was calculated as the mean of plasma concentrations of jnj-
37822681, measured prior to, at midpoint of and immediately after each pet scan.
Data were further analyzed using pve-lab, a software program using a 
probability map of 35 delineated roi that has been validated previously21, in 
order to evaluate receptor occupancy in the caudate nucleus, putamen and 
striatum (left, right and total).
results
Subjects
All participants were healthy males, aged 18 to 34 years, with a body mass index 
ranging from 20 to 29 kg/m2. Four included volunteers dropped out before ad-
ministration of jnj-37822681 and their first planned postdose pet scan for rea-
sons unrelated to the study. Data obtained in these volunteers were not used for 
analysis. Four volunteers completed one baseline [11C]raclopride scan and two 
scans following administration of different doses of jnj-37822681. Eight addi-
tional volunteers underwent one baseline and only one postdose scan. Therefore, 
in total, data were obtained in 12 volunteers, consisting of 12 baseline scans and 16 
postdose scans with six different doses of jnj-37822681 ranging from 2 to 20 mg.
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Clinical observations
All reported adverse events were mild in severity. The most commonly reported 
adverse event was somnolence, occurring three times after 15 mg and three times 
after 20 mg of jnj-37822681. A mild restless feeling after administration of 20 
mg was reported by one volunteer. There were no consistent and clinically rel-
evant abnormalities in blood pressure, heart rate, 12-lead electrocardiogram, 
blood chemistry and haematology. In addition, no consistent and clinically 
relevant changes were observed on the Barnes akathisia rating scale and the 
Simpson-Angus scale.
Plasma concentration of jnj-37822681
Plasma concentrations of jnj-37822681, measured prior to, at midpoint of and 
immediately after each pet scan, are shown in Table 1.
table 1 Plasma concentration of jnj-37822681 in all individual subjects. The mean plasma 
concentration of jnj-37822681 was determined from plasma samples taken immediately before, at 
midpoint, and immediately after pet scanning.	
	
Dose (mg) Subject number Plasma jnj-37822681 (ng/mL)
Prior to pet scan At midpoint of  
pet scan
After pet scan Mean
2 1006 1.92 1.63 1.59 1.71
2 1102 1.41 1.71 2.93 2.02
2 1105 1.96 1.84 1.65 1.82
5 1002 10.9 7.34 6.06 8.10
5 1007 8.05 5.92 5.29 6.42
7 1107 11.9 8.82 11.2 10.6
10 1001 19.4 16.8 15.0 17.1
10 1002 19.8 14.0 11.6 15.1
15 1003 25.8 20.6 22.3 22.9
15 1005 32.5 27.1 21.7 27.1
15 1106 33.1 18.8 16.4 22.8
20 1003 10.6 13.1 17.6 13.8
20 1004 49.5 37.9 36.4 41.3
20 1005 74.5 52.7 39.2 55.5
20 1007 30.7 24.0 20.5 25.1
20 1101 57.7 49.8 42.6 50.0
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Binding potential and D2 receptor occupancy
bpnd values and d2 receptor occupancies in the manually defined left and right 
putamen are shown in Table 2. Average baseline bpnd was 2.85 ± 0.21 (range 2.38 
to 3.06). A decrease in bpnd and corresponding increase in receptor occupancy 
was seen with increasing doses of jnj-37822681. Examples of reconstructed 
parametric bpnd images are shown in Figure 1. Receptor occupancy increased 
from 9-19% after an oral dose of 2 mg to 60-74% after an oral dose of 20 mg of jnj-
37822681, as illustrated in Figure 2. Receptor occupancy as a function of plasma 
concentration of jnj-37822681 provided an estimated ec50 of 14.5 ng/mL (coeffi-
cient of variation 5.4%). The associated hyperbolic function is shown in Figure 3.
Calculated d2 receptor occupancies in the caudate nucleus, putamen and 
striatum using pve-lab, are shown in Table 3. In general, occupancy levels by jnj-
37822681 in caudate nucleus and putamen were similar.
figure 1 Transaxial (left), coronal (middle) and sagittal (right) parametric bpnd images of sub-
ject 1007, co-registered to corresponding mri data. Top row represents baseline images, obtained prior 
to administration of medication. Middle row represents images following administration of 5 mg of 
jnj-37822681, resulting in striatal D2 receptor occupancy of 30%. Bottom row represents images follow-
ing administration of 20 mg of jnj-37822681, resulting in striatal D2 receptor occupancy of 65%.
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figure 2 Dopamine D2 receptor occupancy as function of administered dose of jnj-37822681 for 
manually defined putamen (volume weighted average of left and right putamen).
figure 3 Dopamine D2 receptor occupancy as function of mean plasma concentration of jnj-
37822681 for manually defined putamen (volume weighted average of left and right putamen). The 
fitted curve indicates that receptor occupancy between 65 and 80% is achieved by plasma concentrations 
between 27 and 58 ng/mL.
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table 2 Binding potential (bpnd) and dopamine D2 receptor occupancy levels in all subjects for 







2 1006 2.38 2.17 9
2 1102 3.06 2.48 19
2 1105 3.01 2.56 15
5 1002 3.01 1.90 37
5 1007 2.69 1.87 30
7 1107 2.85 1.61 44
10 1001 3.01 1.41 53
10 1002 3.01 1.52 50
15 1003 2.90 1.20 59
15 1005 3.06 1.09 64
15 1106 2.74 1.21 56
20 1003 2.90 1.15 60
20 1004 2.80 0.77 73
20 1005 3.06 0.78 74
20 1007 2.69 0.93 65
20 1101 2.64 0.76 71
table 3 Dopamine D2 receptor occupancy in all subjects for PVE-lab defined caudate nucleus, 
putamen and striatum (left and right).
Dose (mg) Subject
number
Caudate nucleus Putamen Whole striatum
2 1006 13,6 11,9 12,8
2 1102 12,1 15,5 14,3
2 1105 22,3 19,3 20,2
5 1002 32,5 34,1 33,2
5 1007 41,3 29,9 34,3
7 1107 47,6 44,3 45,5
10 1001 57,5 48,7 51,8
10 1002 50,0 49,3 49,5
15 1003 60,8 59,2 59,7
15 1005 63,4 63,5 63,4
15 1106 62,1 55,9 57,7
20 1003 62,3 59,0 60,2
20 1004 76,8 74,5 75,4
20 1005 75,8 73,5 74,4
20 1007 73,3 65,2 67,9
20 1101 71,4 70,7 71,1
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discussion
The present study was performed to characterize striatal dopamine d2 receptor 
occupancy over a range of oral dosages of jnj-37822681. Dosages from 2 to 20 mg 
resulted in receptor occupancy levels ranging from 9 to 74%, with a hyperbolic 
function providing a good description of the saturation curve (see Figure 3).
pet studies following single dose administration of novel compounds in 
healthy volunteers are widely used in early phase drug development to evaluate 
binding characteristics in vivo and to guide dose selection for future clinical 
trials. However, the predictive value of single dose pet studies for dose selection 
in clinical trials is somewhat limited because single dose estimates may differ 
from steady state estimates after multiple dosing. For example, single dose 
pet studies with ziprasidone22,23 have predicted higher dopamine d2 receptor 
occupancy than multiple dose studies23,24. On the other hand, pet studies in 
healthy volunteers after single doses of olanzapine25 and risperidone26, even in 
spite of very small sample sizes and limited dose ranges, have provided rather 
accurate predictions of receptor occupancy in schizophrenic patients following 
subchronic treatment27-31. Preliminary results of a separate pet study with 
jnj-37822681 demonstrate that, although refinement after multiple dose 
administration enhances predictive value to some extent, measurements of 
d2 receptor occupancy following single doses appear to provide reasonable 
estimates for guidance and interpretation of clinical studies32,33.
Several pet studies using [11C]raclopride have consistently demonstrated 
that, following haloperidol treatment, a striatal dopamine d2 receptor occu-
pancy higher than 65% is associated with clinical response, whereas occupancy 
above 80% is associated with extrapyramidal side effects34-39. Similar occupancy 
levels have been found with other typical agents such as chlorpromazine40, per-
phenazine40 and loxapine41 and with atypical agents such as risperidone29-31 
and olanzapine28,29,42. Accordingly, it has been suggested that 65-80% recep-
tor occupancy is optimal for most registered antipsychotic agents in terms of 
antipsychotic effect and adverse (i.e. extrapyramidal) events in clinical prac-
tice37,39,43. The present data indicate that 65 to 80% receptor occupancy is associ-
ated with plasma concentrations of 27 to 58 ng/mL of jnj-37822681 (see Figure 
3). However, target levels of 65 to 80% striatal dopamine d2 receptor occupancy 
do not always represent absolute thresholds for antipsychotic activity and ex-
ceptions have been identified. First, pet studies with long-acting depot injec-
tions of haloperidol decanoate44 and risperidone45 in schizophrenic patients 
have demonstrated dopamine d2 receptor occupancy levels below 60% without 
clinical relapse, suggesting that sustained dopamine d2 receptor occupancy be-
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tween 65 and 80% (although associated with acute clinical response) may not be 
necessary to maintain clinical effect. It is possible that lower levels of dopamine 
d2 receptor occupancy offer some protection against psychotic relapses, or that 
long-term adaptive changes contribute to the stable clinical situation in chroni-
cally well-treated schizophrenic patients. Second, the partial d2 receptor agonist 
aripiprazole is associated with occupancy levels over 80% at therapeutic doses, 
while the risk for extrapyramidal symptoms seems to increase only at occupancy 
levels of 90% or higher46,47. This apparent discrepancy with dopamine d2 recep-
tor antagonists, however, could reflect the distinct pharmacological character-
istics of aripiprazole. Third, pet studies have demonstrated lower occupancy 
levels with clozapine29,35,40 and quetiapine48 at clinically effective doses. It has 
been suggested that the occupancy levels of clozapine and quetiapine may have 
been underestimated because these drugs, compared with other antipsychotics, 
can rather easily be displaced from the d2 receptor by endogenous dopamine re-
lease5. Further studies with shorter time intervals between dosing of quetiapine 
and pet scanning showed higher occupancy levels, reflecting a rapid reduction 
in occupancy after transiently high levels49,50.
Despite a fast koff, jnj-37822681 is able to achieve relatively high dopamine 
d2 receptor occupancy levels. If fast dissociation is the reason why clozapine 
and quetiapine are therapeutically active at relatively low striatal occupancy 
levels, this could also be the case for jnj-37822681. Preliminary results of 
a recently completed multicenter, double blind, placebo-controlled trial 
with twice daily dosing of 10, 20 and 30 mg of jnj-37822681 in patients with 
schizophrenia indicate clinical efficacy superior to placebo with low frequency 
of extrapyramidal symptoms with all three dosing regimes51. The present study 
demonstrates that doses of 10 mg of jnj-37822681 are associated with merely 
50-53% receptor occupancy two hours after dose administration. It would be of 
interest to further study the time course of d2 receptor occupancy, in order to 
assess whether jnj-37822681, similar to quetiapine, produces only transiently 
high levels of receptor occupancy with a rapid reduction over time.
Central neurophysiological and neuropsychological effects of single doses 
up to 20 mg of jnj-37822681 are generally quite small with the exception 
of increases in serum prolactin13. Small decreases in adaptive tracking were 
observed after doses of 10 mg, whereas small reductions in saccadic peak velocity, 
smooth pursuit eye movements, alertness, finger tapping and a and β activity 
on the eeg and an increase in body sway were observed at higher doses. The 
present data demonstrate that 20 mg doses of jnj-37822681 can induce receptor 
occupancy levels that are generally associated with clinical response (i.e. 65 
to 80%) for registered antipsychotic drugs. Therefore, the mild cns effects of 
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jnj-37822681, compared with the increase in serum prolactin, do not seem to 
result from lack of d2 receptor occupancy. A more likely explanation of these 
findings may be the selectivity of jnj-37822681 for the dopamine d2 receptor. 
Prolactin release is controlled primarily by dopamine acting on dopamine d2 
receptors, whereas the other pharmacodynamic tests measure more complex 
cns functions, which are likely to involve multiple neurotransmitter receptor 
systems. Accordingly, specific dopamine d2 antagonism by jnj-37822681 
significantly increases prolactin release, while only moderately affecting the 
other pharmacodynamic tests.
Within the present small group of healthy volunteers, none of the investigat-
ed dosages of jnj-37822681 was associated with receptor occupancy levels above 
80%. Accordingly, akathisia and other extrapyramidal side effects were absent. 
However, in a previous study with similar doses in healthy volunteers, transient 
mild restlessness was reported occasionally following the highest dosages13. Es-
pecially at the higher doses, peak plasma concentrations are reached somewhat 
earlier than two hours after dosing13. Striatal dopamine d2 receptor occupancy 
could therefore have increased transiently above 80%, with an associated higher 
risk for peak dose-related extrapyramidal symptoms. To further characterize 
the relationship between dopamine d2 receptor occupancy by jnj-37822681 and 
the emergence of extrapyramidal side effects, pet studies at higher dosages of 
jnj-37822681 would be needed. The present study was limited to a maximum 
dose level of 20 mg jnj-37822681, because no safety data above 20 mg were avail-
able at the time of study execution.
Several imaging studies have demonstrated a non-uniform blockade of 
striatal d2/d3 receptors, with higher occupancy levels in the head of the caudate 
nucleus than in the putamen, by amisulpride52, risperidone52, clozapine53 and 
aripiprazole46, although this finding was not replicated for risperidone54. To 
explore this issue, pve-lab21 was used in the present study to evaluate occupancy 
levels by jnj-37822681 in caudate nucleus and putamen. No clear differences 
in occupancy levels were found, but sample sizes in the different dosing groups 
may have been too small.
Postulated clinical importance of dopamine d2 receptor antagonism in ex-
trastriatal limbic and neocortical regions has been a matter of some controversy. 
Preferential extrastriatal dopamine d2 receptor binding was first demonstrat-
ed with clozapine55 and later with olanzapine56 using single photon emission 
computed tomography (spect) and [123I]epidepride, although pet studies with 
[11C]raclopride and [11C]flb457 did not confirm preferential extrastriatal bind-
ing by clozapine57,58. However, all these studies have been criticized on method-
ological grounds59-61. Subsequently, other pet studies using [76Br]flb457 or 
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[18F]fallypride have demonstrated preferential extrastriatal binding by clozap-
ine53,62,63, quetiapine62,64 and ziprasidone23, but not haloperidol63,65. Contra-
dictory results have been obtained with risperidone and olanzapine, as spect 
using [123I]epidepride and pet using [76Br]flb457 demonstrated preferential 
extrastriatal binding63,66, whereas pet using [18F]fallypride or [11C]flb457 and 
[11C]raclopride in the same subjects, did not54,65,67. A recent meta-analysis of 
spect and pet in vivo receptor imaging data68 demonstrated that both typical 
and atypical antipsychotic drugs produce high d2 receptor occupancy in tempo-
ral cortex, whereas only the typical antipsychotic drugs produced high d2 recep-
tor occupancy in the striatum. The present study using [11C]raclopride does not 
allow for accurate estimation of limbic and neocortical binding characteristics 
of jnj-37822681. Future pet studies with high affinity ligands, such as [11C]
flb457 and [18F]fallypride, are needed to quantify extrastriatal binding by jnj-
37822681. Such studies would also enable evaluation of pituitary dopamine d2 
receptor occupancy, as demonstrated in recent pet studies69,70.
In conclusion, the present results provide guidance for dose selection in 
future clinical trials using jnj-37822681 in patients with an acute exacerbation 
of schizophrenia. Preliminary results of the recently completed multicenter, 
double blind, placebo-controlled trial with jnj-37822681 in patients with 
schizophrenia indicate clinical efficacy superior to placebo with low frequency 
of extrapyramidal symptoms51. Confirmation of these findings may support 
the usefulness of dissociation rates as a strategy for novel antipsychotic drug 
development.
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abstract
gsk598809 is a novel selective dopamine d3 receptor antagonist, currently in 
development for treatment of substance abuse and addiction. In a blinded, 
randomized, placebo-controlled study, effects of single oral doses of 175 mg 
gsk598809 were evaluated in healthy volunteers. Pharmacokinetics, central 
nervous system (cns) effects and potential for interactions with alcohol were 
evaluated, using an alcohol infusion paradigm and analysis of eye movements, 
adaptive tracking, visual analogue scales, body sway, serum prolactin and verbal 
visual learning test. Adverse effects of gsk598809 included headache, dizziness 
and somnolence. Plasma concentration of gsk598809 was maximal 2-3 hours 
postdose and decreased with a half life of roughly 20 hours. cns effects were lim-
ited to prolactin elevation and decreased adaptive tracking. Co-administration 
of gsk598809 and alcohol did not affect alcohol pharmacokinetics, but caused 
a 9% decrease of Cmax and a 15% increase of auc of gsk598809. cns effects of 
co-administration were mainly additive, except a small supra-additive increase 
in saccadic reaction time and decrease in delayed word recall. In conclusion, 
gsk598809 causes elevation of serum prolactin and a small decrease in adap-
tive tracking performance. After co-administration with alcohol, effects of 
gsk598809 are mainly additive and the combination is well tolerated in healthy 
volunteers.
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introduction
A large body of evidence indicates that the mesolimbic dopaminergic pathway, 
which includes dopaminergic neurons in the ventral tegmental area project-
ing to the nucleus accumbens and other limbic forebrain structures, is one of 
the major neuronal circuits involved in the acute rewarding effects of drugs of 
abuse1-5. Although addictive drugs interact with many different neurotrans-
mitter systems, most drugs ultimately cause an acute increase in synaptic dopa-
mine in the nucleus accumbens and the mesolimbic dopaminergic system6-8, as 
demonstrated by microdialysis studies in rats9 and positron emission tomogra-
phy (pet) studies in humans10-14. Several important observations have suggest-
ed that dopamine d3 receptors may play a significant role in the effects of drugs 
of abuse and the pathophysiology of drug addiction15,16. First, dopamine d3 re-
ceptors are located primarily in mesolimbic regions such as nucleus accumbens 
and ventral striatum17-21. Second, studies in animal models have demonstrated 
that dopamine d3 receptor activation may be involved in the reinforcing effects 
and self-administration of cocaine22. Third, long term drug exposure appears to 
cause upregulation of dopamine d3 receptors as demonstrated in postmortem 
studies of cocaine overdose fatalities23,24. Accordingly, it has been suggested 
that dopamine d3 antagonism may be an effective strategy in pharmacotherapy 
of addiction15,25,26.
gsk598809 is a novel, potent and selective dopamine d3 receptor antago-
nist27, which is being developed as a novel treatment for substance dependence 
disorders. Functional assays showed that gsk598809 has greater than 100-fold 
selectivity for dopamine d3 receptors over dopamine d2, histamine H1, musca-
rinic M1, M2, M3, M4, serotonin 5-ht1a, 5-ht1b and 5-ht1d receptors (data on 
file). Conditioned place preference (cpp) experiments in animal models indicat-
ed that gsk598809 significantly reduced nicotine- and cocaine-seeking behavior 
in a dose-dependent manner (data on file). In addition, gsk598809 significantly 
prevented relapse to nicotine-seeking behavior, although no effect was observed 
on reducing alcohol consumption in rats (data on file).
The present study was performed to evaluate the pharmacokinetics and cen-
tral nervous system (cns) effects of single oral doses of gsk598809 in healthy 
volunteers. Special emphasis was given to evaluating possible interactions 
with alcohol, because the target population of patients will have alcohol depen-
dence as primary disorder, or may abuse alcohol as comorbidity next to another 
substance abuse disorder. Pharmacokinetic interactions between alcohol and 
gsk598809 are theoretically possible, because a metabolite of gsk598809 shows 
in vitro to have a potential for inhibiting cyp2e, which is one of the main en-
zymes involved in alcohol metabolism28. Also, pharmacodynamic interactions 
neuropharmacology of novel dopamine modulators
– 64 –
are theoretically possible as both compounds are centrally active and influence 
the dopamine system. However, apart from these theoretical possibilities, there 
are no reasons to assume a priori that any specific pharmacodynamic interac-
tion will occur between gsk598809 and alcohol. Currently, no validated human 
pharmacodynamic markers for dopamine d3 antagonism are available. For ex-
ploratory purposes, we used a battery of quantitative central nervous system 
tests, sensitive to various compounds, including alcohol29 and antipsychotic 
drugs (dopamine d2 receptor antagonists)30, was used to evaluate pharmacody-
namic effects. An oral dose of 175 mg gsk598809 was chosen because positron 
emission tomography using [11C]-(+)-phno in healthy volunteers has demon-
strated that this dose can induce high occupancy (near 100%) of dopamine d3 
receptors in the substantia nigra27. Also, previous studies in healthy volunteers 
demonstrated that this dose is generally well tolerated (data on file).
methods
Study design
Twenty healthy volunteers, between 18 and 65 years of age and with a body mass 
index (bmi) between 18 and 30 kg/m2, were planned to participate in a blind-
ed, randomized, placebo-controlled, double-dummy, four-period cross-over 
study. The study was approved by the medical ethics review board of the Leiden 
University Medical Center and registered at the nih database of clinical trials 
(website http://clinicaltrials.gov) with identifier nct00887367 and gsk id num-
ber 106591. Prior to medical screening, all volunteers gave written informed con-
sent. All volunteers underwent training sessions for the pharmacodynamic tests 
in order to minimize possible learning effects.
Volunteers were assigned to a randomized treatment sequence (see Figure 
1), consisting of one period of oral administration of 175 mg of gsk598809 
combined with intravenous alcohol infusion (alcohol clamping, see below 
for further details), one period of oral administration of 175 mg of gsk598809 
combined with intravenous placebo infusion, one period of oral placebo 
administration combined with intravenous alcohol infusion, and one period 
with oral placebo administration combined with intravenous placebo infusion. 
This study design enables analysis of the following comparisons (see Figure 1):
• Administration of 175 mg gsk598809 (n = 20) versus placebo (n = 20)
• Intravenous alcohol infusion (n = 20) versus placebo (n = 20)
• Co-administration of 175 mg gsk598809 and intravenous alcohol infusion  
(n = 20) versus placebo (n = 20)
• Co-administration of 175 mg gsk598809 and intravenous alcohol infusion  
(n = 20) versus intravenous alcohol infusion alone (n = 20)
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figure 1 Study design.
gsk598809 or matching placebo was administered orally 30 minutes after 
the start of the ethanol (or placebo) infusion. The alcohol (or placebo) infusion 
continued for 5 hours in total to cover the main part of the plasma concentra-
tion curve of gsk598809. Each study period consisted of five study days. The 
randomized treatment was administered in the morning of the first study day, 
followed by pharmacokinetic and pharmacodynamic measurements at regular 
time points. All periods were separated by a wash-out time of at least five days.
Occasional (non-daily) smokers were eligible to participate in the study. 
Subjects were excluded from participation if they smoked on a daily basis. 
Also, subjects were excluded if they had an average daily intake of greater than 
2 units (in case of females) or 3 units (in case of males) or an average weekly 
alcohol intake of greater than 14 units (in case of females) or 21 units (in case of 
males). One unit is equivalent to a half-pint (220 mL) of beer or 1 (25 mL) measure 
of spirits or 1 glass (125 mL) of wine. Subjects were instructed to abstain from 
smoking and alcoholic drinks on the day preceding all study periods and all 
subsequent study days. In addition, use of illicit drugs was not permitted. In all 
study periods, breath alcohol measurements were performed to ascertain non-
use of alcohol. Also, urine drug screening for cocaine, amphetamines, opiates 
(morphine), benzodiazepines, barbiturates and thc (Innovacon, Inc., San 
Diego, California, usa) was performed to ascertain non-use of illicit drugs.
Alcohol clamping
The method for attaining constant alcohol levels has been described in detail 
elsewhere29,31. In brief, alcohol (ethanol 10% w/v solution in 5% glucose) was in-
fused intravenously over a period of five hours, guided by breath alcohol mea-
surements to maintain a pseudo-steady state alcohol serum level of 0.6 g/L. This 
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system effects without causing too many inadvertent effects and is considered 
safe, since it is only just above the legal driving limit in the Netherlands (i.e. 0.5 
g/L). Alcohol infusion started 30 minutes prior to administration of gsk598809. 
The infusion rate for the first ten minutes was determined using demographic 
data of the volunteer (weight, height, age and gender). Infusion rates were sub-
sequently adjusted, guided by breath alcohol measurements at baseline and 
at every five minutes for the first 30 minutes after the start of the infusion, ev-
ery 10 minutes for the next 30 minutes and then every half hour until the end, 
using two calibrated Alco-Sensor iv Intoximeters (Honac, Apeldoorn, the 
Netherlands), which were alternated to avoid fatigue of the sensors. To prevent 
local pain at the beginning of the alcohol infusion, an additional diluting glu-
cose 5% infusion at 100 mL/h was given to all participants during the first 10 min-
utes after the start of the alcohol infusion over the same infusion line. Alcohol 
clamping was performed in a randomized, double-blind, placebo-controlled 
fashion by an infusion assistant, who was not a member of the study team. A 
sham procedure, consisting of saline infusion in a manner similar to the alco-
hol infusion, including repeated breath alcohol measurements and subsequent 
infusion rate adjustments, was used to maintain blinding of the subject and 
the rest of the team. The mock infusion rate adjustments were provided by the 
clamping program.
Safety monitoring
Evaluation of adverse events, 12-lead electrocardiograms (ecg), blood pressure, 
heart rate, alcohol breath test, urinalysis and blood sampling for haematology 
and chemistry was performed at regular time points after each dose administra-
tion. Automated oscillometric blood pressures were measured using a Nihon-
Kohden bsm-1101k monitor or a Colin Pressmate bp 8800. ecgs were obtained 
with Cardiofax V equipped with ecaps12 analysis program (Nihon-Kohden, 
Tokyo, Japan). In addition, telemetry monitoring was started at the beginning 
of alcohol infusion and was continued for six hours. Volunteers were evaluated 
for akathisia and extrapyramidal symptoms, using the Barnes Akathisia Rating 
Scale32, Simpson-Angus Scale33 and Abnormal Involuntary Movement Scale34.
Pharmacokinetics
Venous blood samples for gsk598809 concentration analysis were collected pri-
or to dose administration and at 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 
and 72 hours after dose administration. Concentration of gsk598809 in plasma 
samples was determined using protein precipitation followed by hplc/ms anal-
ysis with a lower limit of quantification (llq) of 0.5 ng/mL. Pharmacokinetic 
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parameters of gsk598809 include the maximum observed plasma concentra-
tion (Cmax), time to reach maximum plasma concentration (tmax), area under 
the plasma concentration-time curve extrapolated to infinity (auc∞) and termi-
nal phase half life (t1⁄™).
Venous blood samples for pharmacokinetic analysis of serum alcohol were 
taken prior to start of infusion and at 15, 30, 45, 60, 90, 150, 210, 270 and 390 min-
utes after start of alcohol infusion. Serum alcohol levels were measured with an 
enzymatic assay (Roche Diagnostics, Mannheim, Germany) using a Hitachi 911 
(Boehringer Mannheim, Mannheim, Germany). In this enzymatic assay, alcohol 
and nicotinamide adenine dinucleotide (nad+) are converted to acetaldehyde 
and nadh by alcohol dehydrogenase (adh). The nadh formed during the reac-
tion, measured photometrically as a rate of change in absorbance, is directly pro-
portional to the alcohol concentration.
Pharmacodynamic testing
All pharmacodynamic measurements were performed as described previous-
ly35,36. Volunteers were tested individually in a quiet room with ambient illu-
mination. quantitative tests, sensitive to the effects of alcohol29 and single oral 
doses of antipsychotic drugs (dopamine d2 receptor antagonists)30 such as halo-
peridol36,37 and risperidone38 in healthy volunteers, included measurements of 
smooth pursuit and saccadic eye movements, adaptive tracking, body sway, vi-
sual analogue scales, the visual verbal learning test (vvlt) and serum prolactin 
levels. Previous studies using the alcohol clamping paradigm and this pharma-
codynamic test battery29 demonstrated that smooth pursuit eye movements and 
body sway were the most sensitive pharmacodynamic parameters for the effects 
of alcohol. In order to obtain accurate time profiles of the effects of alcohol and 
gsk598809, smooth pursuit eye movements and body sway were recorded at a 
high frequency. The other pharmacodynamic tests could not be performed as 
frequently due to limitations in time and logistics.
Analysis of eye movements
To evaluate oculomotor performance and sedation, smooth pursuit and sac-
cadic eye movements were recorded as described previously39-42, using a micro-
computer-based system for data recording and analysis (Cambridge Electronic 
Design Ltd., Cambridge, uk), Nihon-Kohden equipment for stimulus display, 
signal collection and amplification (Nihon-Kohden, Tokyo, Japan), and dispos-
able surface electrodes (Medicotest N-oo-S, Olstykke, Denmark). For smooth 
pursuit eye movements, a target light source moves sinusoidally over 20° eyeball 
rotation at frequencies ranging from 0.3 to 1.1 Hz. The time in which the eyes 
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were in smooth pursuit was calculated for each frequency and expressed as the 
percentage of stimulus duration. The average percentage of smooth pursuit for 
all frequencies was used as parameter. Smooth pursuit eye movements were re-
corded prior to dose administration and at 10, 20, 30, 60, 90, 120, 150, 180, 210, 
240, 270, 300, 330, 360, 390, 420 and 450 minutes after dose administration. For 
saccadic eye movements, the target light source jumps from side to side. Peak 
velocity (degrees per second), reaction time and inaccuracy (%) was calculated of 
all artifact-free saccades. Saccadic eye movements were recorded prior to dose 
administration and at 30, 90, 150, 210, 270, 330, 390 and 450 minutes after dose 
administration.
Adaptive tracking
To evaluate visuo-motor coordination, the adaptive tracking task was per-
formed as described previously41-45, using customized equipment and software 
developed by K.W. Hobbs (Hertfordshire, uk). Adaptive tracking is a pursuit 
tracking task in which a circle moves randomly over a computer screen and the 
volunteer must try to keep a dot inside the moving circle using a joystick. If this 
effort is successful, the speed of the moving circle is increased and if the effort 
is unsuccessful, the speed is reduced. The adaptive tracking task was performed 
prior to dose administration and at 30, 90, 150, 210, 270, 330, 390 and 450 min-
utes after dose administration and performance was scored over a fixed period of 
three minutes. Average performance and standard deviation of scores were used 
for analysis.
Body sway
Postural stability in the sagittal plane was measured with an apparatus similar 
to the Wright ataxiameter46, using a string attached to the waist of the volun-
teer. Measurements were performed prior to dose administration and at 10, 20, 
30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420 and 450 minutes af-
ter dose administration. Movements over a period of two minutes, while stand-
ing still with eyes closed, were integrated and expressed as mm sway.
Visual analogue scales
Subjective effects were quantified prior to dose administration and at 30, 
90, 150, 210, 270, 330, 390 and 450 minutes after dose administration using a 
Dutch translation of the visual analogue scales (vas), originally described by 
Norris47, to derive three composite factors corresponding to alertness, mood 
(contentedness) and calmness, as described by Bond & Lader48. In addition, a 
visual analogue scale was used to quantify the subjective effects of alcohol.
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Visual verbal learning test
The visual verbal learning test (vvlt)49 is an adapted version of the auditory 
verbal learning test50 and was performed 150 minutes after dose administra-
tion. Three trials of 30 words are presented on a computer screen in the same se-
quence. The volunteer is requested to reproduce as many words as possible at the 
ending of each trial (immediate recall) and after 30 minutes (delayed recall). The 
number of correctly reproduced words is analyzed for each trial. Also, a recogni-
tion test is performed, consisting of 15 previously presented words and 15 new 
words, in which the volunteer has to indicate recognition of the word (delayed 
recognition) as quickly as possible. Response time and the number of correctly 
recognized words are analyzed.
Serum prolactin levels
Blood samples for measurement of prolactin levels were collected at baseline 
and at 60, 90, 120, 210, 390, 720 and 1320 minutes after study drug administra-
tion and serum was separated by centrifugation (2000 g at 4°C for 10 minutes). 
Prolactin levels were determined using an electrochemiluminescence immu-
noassay (eclia) on a Modular Analytics E170 (Elecsys module) immunoassay 
analyzer.
Statistical analysis
Analysis of variance models were performed on the pharmacokinetic param-
eters, including the factors treatment and period as fixed effects and subject 
as random effect. auc and Cmax pharmacokinetic parameters were log-trans-
formed prior to analysis. Comparisons were expressed as ratios of the pharma-
cokinetic parameters after gsk598809 combined with ethanol relative to those 
after alcohol alone or relative to those after gsk598809 alone.
Pharmacodynamic data were compared using a mixed model analysis of 
variance with treatment, gender, period, time, and treatment by time as fixed 
factors, and with subject, subject by treatment and subject by time as random 
factors. vvlt data were compared using a mixed model analysis of variance with 
treatment, gender and period as fixed factors, and with subject as random factor. 
The parameters body sway, prolactin, saccadic eye movements and the delayed 
word variables were log-transformed prior to analysis to correct for the expected 
log-normal distribution of the data. The following contrasts were calculated (see 
Figure 1): alcohol versus placebo, gsk598809 versus placebo, co-administration 
of gsk598809 and alcohol versus placebo, co-administration of gsk598809 and 
alcohol versus alcohol alone. Supra-additive effects (defined as effects, resulting 
from co-administration of two independent agents, being greater than the sum 
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of effects of each individual agent) were evaluated by analyzing the contrast of 
the effects of co-administration of gsk598809 and alcohol with subtraction 
of the effects of gsk598809 alone versus the effects of alcohol alone with 
subtraction of the effects of placebo:
After identifying gender effects on prolactin levels, analysis of prolactin data 
was repeated using a mixed model analysis of variance with treatment, gender, 
period, time, treatment by gender, treatment by time, gender by time and treat-
ment by gender by time as fixed factors, and with subject, subject by treatment 
and subject by time as random factors. Contrasts were calculated in original 
measurement unit with 95% confidence intervals and the associated p-value, 
except for the log-transformed parameters, which were calculated as a percent-
age relative to placebo or alcohol. All calculations were performed using sas for 
Windows version 9.1.3 (sas Institute Inc., Cary, North Carolina, usa).
results
Subjects
Twenty volunteers (10 males and 10 females) were included in the study. 
Volunteers had a mean age of 32.8 years (range 18-55), weight of 73.5 kg (range 
54-108) and body mass index (bmi) of 23.6 kg/m2 (range 18.5-29.8). One female 
volunteer tested positive for benzodiazepines on the drug screen in study period 
2 and thereby violated the exclusion criteria. She was subsequently withdrawn 
from the study and not replaced. This volunteer was administered alcohol infu-
sion and placebo capsules in the first study period.
Clinical observations
All adverse events were transient and mild or moderate in severity and no seri-
ous adverse events occurred during the study. Overall, the most frequent ad-
verse effect were headache, somnolence, feeling drunk, dizziness, fatigue, pain 
at infusion site, nausea and vomiting (see Table 1). Somnolence and fatigue were 
reported more frequently after gsk598809 administration combined with al-
cohol (n = 18), compared to alcohol alone (n = 8), gsk598809 alone (n = 4) or pla-
cebo (n = 4). There were no consistent and clinically relevant changes on the 
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Movement Scale. Mild short-lasting akathisia was reported spontaneously 
once after administration of gsk598809 combined with alcohol and once after 
gsk598809 alone, but these events were not verified objectively by the Barnes 
Akathisia Rating Scale, when this was performed as scheduled. There were no 
consistent and clinically relevant changes in vital signs, blood chemistry and 
haematology or any of the ecg intervals.
Pharmacokinetics of alcohol
Following intravenous infusion, serum alcohol concentration increased rapid-
ly and remained constant at the target level all over the time of infusion, after 
which serum concentrations declined (see Figure 2).
Pharmacokinetics of gsk598809
Pharmacokinetic parameters are presented in Table 2. Oral administration of 
gsk598809 resulted in peak levels after roughly 2 to 3 hours (see Figure 3) with 
an apparent bi-exponential decline and a half life of roughly 20 hours.
table 1 Summary of common adverse events, reported by two subjects or more. Incidence is 










Headache 6 (32%) 9 (45%) 5 (26%) 7 (37%)
Somnolence 1 (5%) 4 (20%) 3 (16%) 11 (58%)
Dizziness 1 (5%) 6 (30%) 6 (32%) 5 (26%)
Akathisia 0 0 1 (5%) 1 (5%)
Feeling drunk 0 7 (35%) 0 6 (32%)
Fatigue 3 (16%) 4 (20%) 1 (5%) 7 (37%)
Infusion site pain 0 3 (15%) 0 2 (11%)
Catheter site related reaction 0 1 (5%) 1 (5%) 0
Nausea 0 1 (5%) 3 (16%) 3 (16%)
Vomiting 0 1 (5%) 4 (21%) 0
Dry mouth 0 0 0 2 (11%)
Upper respiratory tract infection 0 2 (10%) 0 0
Dysmenorrhoea 1 (5%) 0 0 1 (5%)
Oropharyngeal discomfort 1 (5%) 0 0 1 (5%)
Skin reaction 1 (5%) 1 (5%) 0 0
) ]
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figure 2 Serum alcohol levels after intravenous alcohol infusion starting at t = -0.5 hours and 
continuing until t = 4.5 hours, in combination with oral administration (at t = 0 hours) of gsk598809 




figure 3 Plasma concentrations of gsk598809 after oral administration (at t = 0 hours), in 
combination with intravenous alcohol infusion (open circles) or placebo infusion (closed circles) 
starting at t = -0.5 hours and continuing until t = 4.5 hours. Means are presented with standard 
deviations as error bars.
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Pharmacokinetics of gsk598809 combined with alcohol
No relevant effect of gsk598809 on ethanol pharmacokinetic parameters was 
observed. Regarding the effects of alcohol on gsk598809 pharmacokinetic pa-
rameters, an average 15% increase in auc∞ of gsk598809 (ratio of ls geometric 
means 1.15; 90% confidence interval 1.02/1.30) and an average 9% decrease in 
Cmax of gsk598809 (ratio of ls geometric means 0.91; 90% confidence interval 
0.83/1.00) was observed after administration of gsk598809 combined with alco-
hol compared to gsk598809 alone. Other parameters were roughly similar com-
pared to gsk598809 alone (see Table 2).
Pharmacodynamics of alcohol
Following alcohol infusion, a statistically significant decrease in adaptive track-
ing and smooth pursuit eye movements and increase in body sway were ob-
served compared to placebo, but there were no effects on saccadic peak velocity, 
inaccuracy or reaction time (see Table 3 and Figures 4 to 7). Clear increases in 
the feeling of being drunk were noted. In addition, there was some decrease in 
alertness on the vas Bond & Lader scales, compared with placebo (see Table 4 and 
Figure 8). Alcohol did not demonstrate any clear effect on vvlt performance (see 
Table 5).
Pharmacodynamics of gsk598809
Following administration of gsk598809, transient increases in serum prolac-
tin were observed (see Figure 9). Peak prolactin levels, which increased much 
more in females than in males (p ‹ 0.0001), were reached roughly 3 hours after 
study drug administration and normalized within 12 hours. Administration 
of gsk598809 also caused a decrease in adaptive tracking performance, which 
was maximal between 2 and 6 hours after dose administration (see Table 3 and 
Figure 6). No statistically significant effects were observed on any of the other 
pharmacodynamic parameters (see Tables 3 to 5 and Figures 4, 5, 7 and 8).
Pharmacodynamics of gsk598809 combined with alcohol
Co-administration of gsk598809 and alcohol resulted in additive effects on 
several pharmacodynamic parameters, compared to either treatment alone (see 
Tables 3 to 5 and Figures 4 to 8). While the effects of administration of gsk598809 
alone or alcohol alone on saccadic eye movements did not reach statistical signifi-
cance, co-administration of gsk598809 and alcohol resulted in a significant im-
pairment. No significant supra-additive effects were found on any of the phar-
macodynamic parameters, except a small increase in saccadic reaction time (see 
Table 3) and a small decrease in delayed word recall on the vvlt (see Table 5).
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table 2 Pharmacokinetic parameters of gsk598809 with and without co-administration 
of alcohol. Data are presented as geometric means (with coefficient of variation), except tmax which 
is presented as median (with range). Note: n = 19 for all calculated values, except t1⁄™ and auc∞	of 
gsk598809 alone (n = 11) and combined with alcohol (n = 15), because these parameters could not be 
calculated reliably in 8 subjects and 4 subjects, respectively.
Parameter gsk598809 gsk598809 + alcohol
Cmax (ng/mL) 1320 (39) 1190 (39)
tmax (h) 2.07 (2.0-6.05) 3.03 (2.00-7.87)
auc0-t (ng.h/mL) 14000 (28) 15700 (27)
auc∞ (ng.h/mL) 14000 (32) 16600 (23)
Terminal half life (h) 19.3 (33) 21.6 (27)
table 3 Neurophysiological effects of administration of alcohol alone, gsk598809 alone and 
co-administration of gsk598809 and alcohol. Treatment differences in least square means are shown 
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table 4 Visual analogue scales (vas) results after administration of alcohol alone, gsk598809 
alone and co-administration of gsk598809 and alcohol. Treatment differences in least square means 



































































































table 5 Visual verbal learning test (vvlt) results after administration of alcohol alone, 
gsk598809 alone and co-administration of gsk598809 and alcohol. Treatment differences in least 
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figure 4 Time course of smooth pursuit eye movements following administration of 
gsk598809 capsules combined with alcohol infusion (open circles), gsk598809 capsules combined 
with placebo infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) 
and placebo capsules combined with placebo infusion (closed triangles). Least square means are 
presented with 95% confidence intervals as error bars.
figure 5. Time course of saccadic peak velocity following administration of gsk598809 capsules 
combined with alcohol infusion (open circles), gsk598809 capsules combined with placebo infusion 
(closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules 
combined with placebo infusion (closed triangles). Least square means are presented with 95% 
confidence intervals as error bars.
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figure 6 Time course of adaptive tracking performance following administration of gsk598809 
capsules combined with alcohol infusion (open circles), gsk598809 capsules combined with placebo 
infusion (closed circles), placebo capsules combined with alcohol infusion (open triangles) and placebo 
capsules combined with placebo infusion (closed triangles). Least square means are presented with 95% 
confidence intervals as error bars.
figure 7 Time course of body sway following administration of gsk598809 capsules combined 
with alcohol infusion (open circles), gsk598809 capsules combined with placebo infusion (closed 
circles), placebo capsules combined with alcohol infusion (open triangles) and placebo capsules 
combined with placebo infusion (closed triangles). Least square means are presented with 95% 
confidence intervals as error bars.
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figure 8 Time course of alertness (visual analogue scales of Bond & Lader) following 
administration of gsk598809 capsules combined with alcohol infusion (open circles), gsk598809 
capsules combined with placebo infusion (closed circles), placebo capsules combined with alcohol 
infusion (open triangles) and placebo capsules combined with placebo infusion (closed triangles). Least 
square means are presented with 95% confidence intervals as error bars.
figure 9 Time course of serum prolactin in female (left panel) and male subjects (right panel), 
following administration of	gsk598809	capsules combined with alcohol infusion (open circles), 
gsk598809 capsules combined with placebo infusion (closed circles), placebo capsules combined 
with alcohol infusion (open triangles) and placebo capsules combined with placebo infusion (closed 
triangles). Means are presented with standard deviations as error bars.
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discussion
The present study was performed to evaluate the pharmacokinetics and central 
nervous system (cns) effects of single oral doses of 175 mg of the novel dopamine 
d3 receptor antagonist gsk598809 in healthy volunteers and possible interac-
tions with alcohol. Within the present group of healthy volunteers, single doses 
of gsk598809 were generally well tolerated. The most frequent adverse effects 
were mild headache, dizziness, somnolence, nausea and vomiting. gsk598809 
did not induce any significant extrapyramidal symptoms. Mild short-lasting 
akathisia was reported spontaneously once after administration of gsk598809, 
although this was not verified objectively by the Barnes Akathisia Rating Scale, 
when this was performed according to protocol. Plasma concentration of 
gsk598809 increased rapidly after oral administration (tmax of roughly 2 to 3 
hours) and subsequently decreased in an apparent bi-exponential manner (ter-
minal half life of roughly 20 hours). No effect of gsk598809 on the pharmaco-
kinetics of alcohol was observed, but alcohol decreased Cmax and increased the 
auc of gsk598809 to a limited extent, which is not considered to be of any clini-
cal significance.
The cns effects of gsk598809 alone were limited to an elevation of serum 
prolactin and a small decrease in adaptive tracking performance, with a time 
course that corresponds well with the observed pharmacokinetics. This study 
represents the first use of this pharmacodynamic test battery to evaluate the 
effects of a selective dopamine d3 antagonist in healthy volunteers. As a result, 
no data of other dopamine d3 receptor antagonists are available for comparison 
with the effects of gsk598809. Antipsychotic drugs (dopamine d2 receptor 
antagonists) have been evaluated extensively with this pharmacodynamic test 
battery30,36-38, but differences in tissue expression of d2 and d3 receptors and 
differences in receptor affinity profiles of the various drugs significantly limit 
the comparison of their effects to those of gsk598809.
Prolactin secretion by the lactotroph cells of the pituitary gland is under in-
hibitory control by dopamine, released predominantly from tuberoinfundibu-
lar dopaminergic neurons, acting on lactotrophic dopamine d2 receptors51
,52. 
Pharmacological blockade of dopamine d2 receptors removes this inhibitory 
influence and subsequently increases prolactin levels. However, the role of dopa-
mine d3 receptor antagonism in the control of prolactin secretion is unknown. 
An autoradiographic study has demonstrated presence of d3 receptors in the 
pituitary gland18, but the density was quite low and any possible role for dopa-
mine d3 receptors in the pituitary gland in endocrine function remains unclear. 
Alternatively, dopamine d3 antagonism may cause prolactin elevation by acting 
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at the level of the hypothalamus. The periventricular and arcuate nuclei of the 
hypothalamus constitute the origin of the tuberoinfundibular dopaminergic 
pathway, which projects to the median eminence, where dopamine is released 
into the hypophyseal portal vessels51,53,54. Hypothalamic expression of dopa-
mine d3 receptors has not yet been examined in full detail, but one study found 
no detectable levels in the arcuate nucleus, whereas the periventricular nucleus 
was not investigated17. Therefore, any possible effect of dopamine d3 antago-
nism on the hypothalamus, leading to prolactin elevation, also remains unclear. 
Another theoretical possibility is that gsk598809 could be acting on extra-dopa-
minergic mechanisms of prolactin control. However, a more likely explanation 
is that, despite a greater than 100-fold selectivity for d3 receptors over d2 recep-
tors, gsk598809 at doses of 175 mg might cause enough d2 receptor antagonism 
to modestly increase prolactin secretion.
The increases in serum prolactin following gsk598809 administration were 
much larger in female volunteers than in male volunteers (see Figure 9). Similar 
gender differences in prolactin levels have been previously demonstrated after 
administration of typical antipsychotic drugs55-59 and atypical antipsychotic 
drugs60-62, which have been attributed to an enhanced responsiveness of 
lactotrophs to prolactin-releasing stimuli by females, compared to males, due to 
the effects of estrogens51,63-65.
The other pharmacodynamic tests used in this study measure complex cns 
functions. The neurophysiological and neurochemical mechanisms underly-
ing these cns functions have not yet been fully characterized, but are likely to 
involve multiple neurotransmitter receptor systems. The decrease in adaptive 
tracking performance after administration of gsk598809 indicates slight im-
pairment in visuo-motor performance. Similar impairments in adaptive track-
ing performance have also been observed after administration of single doses 
of antipsychotic drugs (dopamine d2 antagonists) such as haloperidol36 and 
risperidone38 in healthy volunteers. However, unlike haloperidol and risperi-
done, gsk598809 did not affect smooth pursuit and saccadic eye movements, 
memory performance or any of the visual analogue scales. This clearly demon-
strates the pharmacological distinctions between gsk598809 and antipsychot-
ic drugs, but it is not necessarily an argument for d3 receptor selectivity, since 
most antipsychotic drugs affect other neurotransmitter systems in addition to 
d2 receptors. Recently, however, we examined the novel selective dopamine d2 
receptor antagonist jnj-37822681 in healthy volunteers using similar pharma-
codynamic tests66. Single oral doses of 15 mg jnj-37822681 caused a reduction 
in adaptive tracking performance of about 2%, comparable to 175 mg doses of 
gsk598809. Also, this dose of jnj-37822681 caused about 60% d2 receptor oc-
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cupancy67 and produced prolactin elevations of more than 700%66, much larger 
than the 117% increase found with gsk598809 in this study. jnj-37822681 also 
impaired saccadic and smooth pursuit eye movements66, which were unaffected 
by gsk598809. Although these indirect comparisons have their limitations, they 
provide at least some support for the in vivo selectivity of gsk598809 for dopa-
mine d3 receptors.
In addition to obtaining a dopamine d3 receptor-mediated profile of cns ef-
fects, our study was specifically designed to evaluate potential pharmacokinetic 
and pharmacodynamic interactions between gsk598809 and alcohol. An in-
travenous alcohol clamping paradigm was used to achieve pseudo-steady state 
levels of alcohol, which produced clear and expected cns effects, similar to pre-
viously reported results of this alcohol clamping paradigm29,31. Co-administra-
tion of gsk598809 with intravenous alcohol levels at pseudo-steady state was 
generally well tolerated. However, somnolence and fatigue were reported more 
frequently, compared with the other treatments. Mild akathisia was reported 
spontaneously once, which was not verified objectively by the Barnes Akathi-
sia Rating Scale, similar to the event after administration of gsk598809 alone. 
Co-administration of gsk598809 and alcohol generally produced additive cns 
effects, without clear signs of supra-additive amplification of the effects of each 
treatment alone. Both gsk598809 and alcohol caused slight impairments of sac-
cadic eye movements that failed to reach statistical significance by themselves, 
but the combination clearly differed from placebo. There was a small supra-ad-
ditive increase in saccadic reaction time (see Table 3) and there were also some in-
dications that memory might be affected more by the combination than by each 
drug individually. These findings suggest that caution may be needed in the use 
of gsk598809 in individuals who consume alcohol moderately or excessively, al-
though the effects will probably be dominated by alcohol.
In conclusion, the present study demonstrates elevation of serum prolactin 
and a small decrease in adaptive tracking performance after administration of 
the novel selective dopamine d3 receptor antagonist gsk598809 within a small 
group of healthy volunteers. An interaction with intravenous alcohol infusion 
at pseudo-steady state was demonstrated, resulting in a decreased Cmax 
and increased auc of gsk598809 and mainly additive effects on several cns 
parameters. Although somnolence and fatigue were reported more frequently, 
the combination was generally well tolerated by healthy volunteers.
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abstract
Recent interest in nk1 receptor antagonists has focused on a potential role in 
the treatment of drug addiction and substance abuse. In the present study, the 
potential for interactions between the nk1 receptor antagonist aprepitant 
and alcohol, given as an infusion at a target level of 0.65 g/L, was evaluated. 
Amitriptyline was included as positive control to provide an impression of the 
profile of central nervous system (cns) effects. In a double-blind, randomized, 
placebo- and amitriptyline-controlled study, the pharmacokinetics and cns 
effects of aprepitant and alcohol were investigated in 16 healthy volunteers. 
Cognitive and psychomotor function tests included the visual verbal learning 
test (vvlt), Bond and Lader visual analogue scales (vas), digit symbol substitu-
tion test (dsst), visual pattern recognition, binary choice reaction time, critical 
flicker fusion (cff), body sway, finger tapping and adaptive tracking. Alcohol 
impaired finger tapping and body sway. Amitriptyline impaired dsst perfor-
mance, vas alertness, cff, body sway, finger tapping and adaptive tracking. No 
impairments were found after administration of aprepitant. Co-administration 
of aprepitant with alcohol was generally well tolerated and did not cause sig-
nificant additive cns effects, compared with alcohol alone. Therefore, our study 
found no indications for clinically relevant interactions between aprepitant and 
alcohol.
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introduction
The peptide neurotransmitter substance P and its preferred receptor, the neuro-
kinin 1 (nk1) receptor have been the focus of several different drug development 
programs. Recently, interest in nk1 receptor antagonists has focused on a po-
tential role in the treatment of drug addiction and substance abuse disorders1. 
Substance P may play a role in addiction-related behavior by acting directly on 
nk1 receptors in brain areas associated with drug reward, such as the nucleus 
accumbens and ventral pallidum, and on dopaminergic neurons in the ventral 
tegmental area, but also by influencing other neurotransmitters such as sero-
tonin, acetylcholine and noradrenalin2. Studies in animals have demonstrated 
that pharmacological blockade of nk1 receptors dose-dependently suppresses 
alcohol intake3 and stress-induced reinstatement of alcohol seeking behavior4. 
Also, the rewarding effects of opiates (but not cocaine) are absent in nk1 receptor 
knockout mice5,6 and in mice with bilateral ablation of nk1 receptor-expressing 
neurons in the amygdala7. A recent case-control association study identified 
two haplotypes and a single nucleotide polymorphism (snp) in the nk1 receptor 
gene (nk1r) that were significantly associated with the development of alcohol 
dependence8. Furthermore, a recent clinical trial with the nk1 receptor antago-
nist ly686017 in detoxified alcoholic inpatients demonstrated suppression of 
spontaneous alcohol cravings and improved overall well-being9.
The present study was performed to evaluate possible interactions between the 
nk1 receptor antagonist aprepitant and alcohol. Pharmacokinetic interactions 
are not expected because aprepitant is metabolized primarily by cyp3a410, where-
as alcohol is metabolized by a pathway that involves alcohol dehydrogenase, cat-
alase and cyp2e11. However, pharmacodynamic interactions are theoretically 
possible as both compounds are centrally active and may influence several neu-
rotransmitters, including dopamine2,12. A battery of quantitative tests, sensitive 
to the central effects of various compounds, including alcohol13, was used to eval-
uate pharmacodynamic central nervous system (cns) effects. Similar to the phase 
iii trials with aprepitant for the indication of major depressive disorder14, an oral 
dose of 160 mg of aprepitant had been chosen for this study, because this dose was 
generally well tolerated in the depression program and was expected to result in 
high occupancy of central nk1 receptors. Positron emission tomography (pet) us-
ing [18F]spa-rq in healthy volunteers has demonstrated that daily doses of 100 mg 
aprepitant or higher achieve high levels (›90%) of nk1 receptor occupancy in the 
striatum15. The effects of co-administration of aprepitant and alcohol were pri-
marily compared with those of alcohol alone and aprepitant alone. At the time of 
study execution, no other studies evaluating nk1 receptor antagonists with this 
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pharmacodynamic test battery were avaliable. As a consequence, no a priori esti-
mation of effect size of aprepitant with or without alcohol could be made. To set a 
clinical benchmark for the effect size of cns effects of co-administration of aprepi-
tant and alcohol, we included amitriptyline as a comparator drug. Amitriptyline 
shows a wide range of significant cns effects in healthy volunteers, which have 
been well characterized previously using this pharmacodynamic test battery16.
methods
Study design
Sixteen healthy male or female volunteers, between 18 and 55 years of age were 
planned to participate in a double-blind, randomized, placebo- and active com-
parator-controlled, triple-dummy, four treatment, two-period crossover study 
to investigate the psychomotor and cognitive effects of aprepitant and ethanol 
in healthy volunteers. The study was approved by the medical ethics committee 
of the Leiden University Medical Center. Prior to medical screening, all volun-
teers gave written informed consent. Medical screening included a medical his-
tory, physical examination, urinalysis, routine haematology and chemistry and 
12-lead electrocardiography (ecg). All volunteers underwent training sessions 
for the pharmacodynamic tests in order to minimize possible learning effects.
This study was designed primarily to compare the effects of co-administra-
tion of aprepitant and alcohol with those of alcohol alone and aprepitant alone. 
To optimize the likelihood of detecting possible pharmacodynamic effects, 
aprepitant was administered daily for 7 days, after which plasma concentrations 
of aprepitant can be expected to be maximal (Merck & Co., data on file). As stated, 
amitriptyline was included in this study as an pharmacodynamic comparator, 
which is expected to exert its maximum tolerable effects after a single dose.
The study consisted of study periods of 10 days (see Figure 1). On day 1, all 
volunteers were administered 50 mg amitriptyline (or placebo capsules) and a 
placebo-ethanol infusion (consisting of a 5% glucose solution). On day 2 and 3, all 
volunteers were administered placebo capsules to allow a complete washout of 
amitriptyline. On days 4 to 10, all volunteers took 160 mg aprepitant once daily 
as nanoparticle capsules (or placebo capsules). On day 10, all volunteers received 
an active alcohol infusion (5% alcohol in a 5% glucose solution, see below for 
details). Psychomotor and cognitive testing was performed on day 1, 9 and 10 
(see Figure 2). This study design minimizes carry-over effects of amitriptyline 
administration at day 1 on the pharmacodynamic measurements on days 9 and 
10, as the half life of amitriptyline is roughly 20 hours17. On days 2, 4, 6 and 8, 
the volunteers reported to the clinic for administration of study medication. On 
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days 3, 5 and 7, the volunteers administered study medication at home, which 
was confirmed by telephone. Each volunteer participated in two study periods in 
a randomized, blinded crossover fashion (see Figure 1). Both study periods were 
separated by a washout period of at least 14 days.
 
figure 1 Study design. Active treatments are indicated in bold.
figure 2 Schedule of pharmacokinetic and pharmacodynamic tests performed on days 1, 9 and 
10 of both study periods. a Pharmacokinetic (pk) sampling includes blood sampling for aprepitant con-
centration analysis on study days 9 and 10, and breath sampling for alcohol concentration analysis on 
study day 1 and 10. b Psychomotor tests include the adaptive tracking test, critical flicker fusion, finger 
tapping, and body sway. c Amitriptyline (or placebo) on study day 1, aprepitant (or placebo) on study day 
9 and 10. d Alcohol infusion on study day 10 and placebo infusion on day 1
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This rather complex study design enables, after combining both study periods, 
analysis of the following comparisons:
• On day 1, single doses of amitriptyline (or placebo) are administered, followed 
by pharmacokinetic and pharmacodynamic measurements. These data 
enable analysis of the effects of single oral doses of amitriptyline (n = 16) 
compared with placebo (n = 16).
• On days 4-9, single daily doses of aprepitant (or placebo) are administered. 
On day 9, pharmacokinetic and pharmacodynamic measurements are 
performed. These data enable analysis of the effects of aprepitant (n = 16) 
compared with placebo (n = 16). 
• On day 1, a placebo-ethanol infusion (consisting of a 5% glucose solution) 
and placebo capsules (or amitriptyline) are administered, followed by 
pharmacokinetic and pharmacodynamic measurements. On day 10, an 
alcohol infusion and placebo capsules (or aprepitant) are administered, 
followed by pharmacokinetic and pharmacodynamic measurements. These 
data enable analysis of the effects of alcohol infusion (n = 16) compared with 
placebo infusion (n = 16), although it is recognized that the estimated effects 
are confounded with day.
• On day 10, an alcohol infusion and aprepitant (or placebo capsules) are admin-
istered, followed by pharmacokinetic and pharmacodynamic measurements. 
These data enable analysis of co-administration of aprepitant and alcohol  
(n = 16), compared with co-administration of placebo and alcohol (n = 16).
Alcohol infusion paradigm
The procedure for attaining pseudo-steady state alcohol levels was based on the 
method of Hartmann et al18 and performed as described earlier19-21. In brief, al-
cohol (ethanol 5% w/v solution in 5% glucose) was administered intravenously 
to achieve a target blood alcohol concentration of 0.65 g/L, beginning 21⁄™ hours 
after administration of aprepitant (or placebo) and ending 61⁄™ hours after study 
drug administration in order to coincide with the expected maximal plasma 
concentration of aprepitant (tmax of the marketed 80 mg and 125 mg capsules is 
roughly 4 hours)22. Breath alcohol concentrations were determined at 0, 60, 90, 
150, 180, 210 and 300 minutes after start of the alcohol infusion using a calibrated 
hand-held Alco-Sensor iv Intoximeter (Honac, Apeldoorn, the Netherlands), 
which has a limit of quantification (loq) of 0.01 g/L. Alcohol infusion was per-
formed at a constant rate for the first hour, followed by a slower constant rate 
over the next 3 hours to maintain the target level.
Rates of infusion were set individually, based on measured alcohol kinetics 
in each volunteer during a separate alcohol infusion, after inclusion in the study 
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but prior to the first study period. During this pre-study infusion, 50 gram of 
alcohol was administered intravenously over 1 hour (500 mL of 100 g/L ethanol 
solution in 5% glucose). Serum alcohol and breath alcohol concentrations were 
determined prior to infusion and at 30, 55, 75, 90, 120, 180, 240, 300 and 360 min-
utes after start of the alcohol infusion. Individual pharmacokinetic para meters 
were calculated by fitting the serum alcohol concentrations to a two-compart-
ment open model with Michaelis-Menten kinetics, derived from previous stud-
ies18-20. Population parameters were used as priors in a Bayesian nonlinear re-
gression analysis to generate pharmacokinetic parameters of individual infu-
sion regimes. The regime that approaches and stays at 0.65 g/L was applied on 
subsequent alcohol infusions. Pseudo-steady state alcohol levels were attained 
after approximately 90 minutes. To avoid an overshoot in the alcohol levels, the 
infusion of alcohol was terminated whenever the level of 1.00 g/L was reached. 
Pharmacokinetic modeling and simulation was performed using nonmem 
(software version V, University of California, San Francisco, usa).
Aprepitant pharmacokinetics
Venous blood samples for aprepitant concentration analysis were collected prior 
to study drug administration on days 1, 9 and 10 and at 1⁄™, 11⁄™, 31⁄™, 4, 5, 51⁄™, 6 
and 71⁄™ hours after study drug administration of aprepitant (or placebo) on days 
9 and 10 (see Figure 2). The concentration of aprepitant in plasma samples was 
determined using hplc-ms/ms with a lower limit of quantification (llq) of 10 
ng/mL, using a previously reported method23,24.
Safety monitoring
Evaluation of adverse events, 12-lead electrocardiograms (ecg), blood pressure, 
heart rate, body temperature, urinalysis and blood sampling for haematology 
and chemistry was performed at regular time points during the study.
Pharmacodynamic testing
Volunteers were tested on days 1, 9 and 10 of each study period individually in 
a quiet room with ambient illumination. Cognitive function tests included the 
visual verbal learning test (vvlt) and Bond and Lader visual analogue scales 
(vas), which were performed roughly 21⁄™ hours after study drug administra-
tion (see Figure 2), and the digit symbol substitution test (dsst), visual pattern 
recognition with immediate and delayed recall and binary choice reaction time, 
which were performed roughly 4 hours after study drug administration (see 
Figure 2). Psychomotor function tests were performed prior to dose administra-
tion and at 11⁄™, 3, 41⁄™, 6, 71⁄™ and 9 hours after drug administration (see Figure 
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2) and included critical flicker fusion (cff), body sway, finger tapping and adap-
tive tracking. The primary endpoint of this study was the digit symbol substi-
tution test (dsst). The visual verbal learning test (vvlt), Bond and Lader visual 
analogue scales (vas), pattern recognition, binary choice reaction time, critical 
flicker fusion (cff), finger tapping, adaptive tracking, and body sway were sec-
ondary endpoints. Change from baseline critical flicker fusion (cff), finger tap-
ping, adaptive tracking and body sway were exploratory endpoints.
Digit-symbol substitution test
During the digit-symbol substitution test (dsst)25, the volunteer is asked to as-
sign symbols to random digits using a substitution key that is presented on the 
worksheet. Each digit-symbol association constitutes one response and volun-
teers are instructed to complete as many responses as possible within 90 seconds. 
The number of correct substitutions is analyzed.
Visual verbal learning test
During the visual verbal learning test (vvlt)26, three trials of 30 words are pre-
sented on a computer screen in the same sequence. The volunteer is requested to 
reproduce as many words as possible at the ending of each trial (immediate re-
call) and after 30 minutes (delayed recall). The number of correctly reproduced 
words is analyzed for each trial. Also, a recognition test is performed, consist-
ing of 15 previously presented words and 15 new words, in which the volunteer 
has to indicate recognition of the word (delayed recognition) as quickly as pos-
sible. Response time (msec) and the number of correctly recognized words are 
analyzed.
Visual pattern recognition
A trial of 14 abstract visual patterns is presented on a computer screen for a du-
ration of 3 seconds per pattern. A recognition test is performed, consisting of 
the same 14 previously presented patterns along with new patterns, in which 
the volunteer has to indicate recognition of the pattern as quickly as possible 
at the ending of the trial (immediate recall) and after 30 minutes (delayed re-
call). Response time (msec) and the number of correctly recognized patterns are 
analyzed.
Binary choice reaction time
Choice reaction time27 is measured by displaying either a red or green block on 
either the left side or right side of a computer screen in random order. The volun-
teer reacts by pushing a button on either side of the keyboard, corresponding to 
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the position of the colored block on the screen. Sixty stimuli are presented and 
response time (msec) and the number of correct responses are analyzed.
Visual analogue scales
Subjective effects were quantified using a Dutch translation of the visual ana-
logue scales (vas), originally described by Norris28, to derive three composite 
factors corresponding to alertness, mood (contentedness) and calmness, as de-
scribed by Bond & Lader29.
Critical flicker fusion
An intermittent light source is used with an increasing and decreasing fre-
quency. The frequency at which the flickering light is perceived as a steady light 
source is termed the critical flicker fusion (cff) threshold, which is a measure for 
cns activation30. Volunteers are requested to respond by pressing a button at the 
moment they see fusion of flickering (when frequency is increased) or when the 
light starts to flicker (when frequency is decreased). Average response (threshold 
frequency in Hz) during four sequences is calculated.
Body sway
Postural stability in the sagittal plane was measured with an apparatus similar 
to the Wright ataxiameter31, using a string attached to the waist of the volunteer. 
Movements over a period of two minutes, while standing still with eyes closed, 
were integrated and expressed as mm sway.
Finger tapping
The finger tapping test was adapted from the Halstead-Reitan test battery32 to 
evaluate motor activation and fluency. The volunteer is instructed to rest the 
wrist of the dominant hand on a table and to tap as quickly as possible with the 
index finger onto the space bar of a key board. The mean tapping rate is used for 
statistical analysis.
Adaptive tracking
To evaluate visuo-motor coordination, the adaptive tracking task was performed 
as described previously33, using customized equipment and software developed 
by K.W. Hobbs (Hertfordshire, uk). Adaptive tracking is a pursuit tracking task 
in which a circle moves randomly over a computer screen and the volunteer must 
try to keep a dot inside the moving circle using a joystick. If this effort is success-
ful, the speed of the moving circle is increased and if the effort is unsuccessful, 
the speed is reduced. Performance was scored over a fixed period of 10 minutes.
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Statistical analysis
Evaluation of the numbers of correct substitutions from the digit symbol sub-
stitution test (dsst) was performed using an analysis of variance (anova) model 
appropriate for a two-period crossover design, with factors for sequence, sub-
ject-within-sequence, period, treatment and within subject error. A two-sided 
90% confidence interval (equivalent to a one-sided 95% confidence interval) for 
the true mean treatment difference was computed from the anova using the 
mean squared error and referencing a t-distribution. Data from day 1 were used 
for comparison of amitriptyline and placebo. Data from day 9 were used for com-
parison of aprepitant and placebo. Data from day 10 were used for comparison 
of alcohol and co-administration of aprepitant and alcohol. An anova with fac-
tors for subjects and treatment was used to compare alcohol (data from day 10) 
and placebo for alcohol (data from day 1), although the estimated alcohol effect 
was confounded with day. vvlt results, visual pattern recognition with imme-
diate and delayed recall, binary choice reaction time and visual analogue scales 
were each analyzed with the same methods used for the dsst. It was determined 
post-hoc that due to observed statistically significant differences between treat-
ment groups at baseline, critical flicker fusion (cff), finger tapping, adaptive 
tracking and body sway should be baseline adjusted. The change from baseline 
values were also analyzed with the same methods used for the dsst, with the ad-
dition of factors for hour and the interaction of treatment-by-hour to the anova 
model. The measurements performed 11⁄™ hours after study drug administration 
were not included in the change from baseline analyses, because this time point 
was prior to alcohol infusion. For body sway data, the fold change from baseline 
was calculated, because the data were distributed as log-normal. All tests were 
performed at a significance level of 0.05 (two-tailed). No corrections for multiple 
comparisons were made.
In addition, to get an impression of possible effects of alcohol infusion on the 
pharmacokinetics of aprepitant after multiple doses, the repeated measured 
aprepitant plasma concentrations after co-administration of alcohol and aprepi-
tant on day 10, were compared to those after administration of aprepitant alone 
on day 9, using a mixed model analysis of variance with treatment, time and 
treatment by time as fixed factors and subject, subject by treatment and subject 
by time as random factors. Because the alcohol infusion started 21⁄™ hours after 
administration of aprepitant (or placebo), only the blood samples taken after t = 
21⁄™ hours were included in the analysis. Furthermore, because on days 9 and 10, 
aprepitant had already been administered for 6 and 7 days, respectively, the pre-
values (i.e. the plasma concentration measurements before aprepitant adminis-
tration on days 9 and 10, respectively) were included in the model as a covariate. 
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It is recognized that, in this analysis, treatments are sequential and not random-
ized. Data were natural log-transformed prior to analysis and the log scale esti-
mates of the treatment difference (plasma concentration of aprepitant with or 
without alcohol) and 95% confidence interval for the treatment difference were 
exponentiated to obtain the geometric mean ratio and 95% confidence interval.
results
Subjects
A total of 17 healthy volunteers (9 males and 8 females) were included and ran-
domized. Participants had a mean age of 27 years (range 18-53), weight of 77.1 kg 
(range 52.6-95) and body mass index of 24.9 kg/m2 (range 19.8-30.2). One volun-
teer was withdrawn after completing the first study period, because of phlebitis 
on both arms on day 11. This volunteer was randomized to receive treatments B 
and C and was replaced by a new volunteer who completed both study periods. 
Safety data from all 17 volunteers is reported below. Statistical analysis was sub-
sequently performed on all pharmacokinetic and pharmacodynamic data sets of 
all volunteers who completed both study periods (i.e. n = 16).
Clinical observations
Adverse events were generally mild and occasionally moderate in severity. No 
serious adverse events occurred during the study. The most frequently reported 
adverse events after administration of aprepitant were tiredness or somnolence 
(7), headache (2) and dizziness (2). The most frequently reported adverse events 
after administration of amitriptyline were tiredness or somnolence (15) and diz-
ziness (2). The most frequently reported adverse events after alcohol infusion 
were feeling drunk (13), tiredness or somnolence (6), altered taste (2) and local in-
fusion reactions (which generally consisted of pain at the infusion site) (9). The 
combination of aprepitant with alcohol infusion did not affect the frequency 
or intensity of feeling drunk and local infusion reactions. The most frequently 
reported adverse events after co-administration of aprepitant and alcohol were 
feeling drunk (13), local infusion reactions (10), tiredness or somnolence (9), 
headache (3), nausea (2), altered taste (2) and dry mouth (2). There were no clini-
cally relevant changes in heart rate, blood pressure, haematology, biochemistry, 
urinalysis or ecg.
Pharmacokinetics of alcohol
Following intravenous infusion, breath alcohol levels increased rapidly and re-
mained fairly constant at the target level all over the time of infusion (see Figure 3).
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figure 3 Breath alcohol levels after intravenous alcohol infusion starting at t = 21⁄™ hours and 
continuing until t = 61⁄™ hours on day 10, in combination with oral administration (at t = 0 hours) of 
aprepitant (open circles) or placebo (closed circles). Means are presented with standard deviations as 
error bars.
figure 4 Plasma levels of aprepitant after oral administration at t = 0 hours, either alone on day 9 
(closed circles) or in combination with alcohol infusion on day 10 (open circles), starting at t = 21⁄™ hours 
and ending at t = 61⁄™ hours. Means are presented with standard deviations as error bars.
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Pharmacokinetics of aprepitant
As expected, plasma concentrations of aprepitant during study days 9 and 10 
were generally quite stable, showing only a small increase at 3.5 to 4 hours after 
dose administration (see Figure 4), consistent with its tmax.
Pharmacokinetics of co-administration of alcohol and aprepitant
Plasma concentrations of aprepitant (see Figure 4) were higher when adminis-
tered alone on day 9, compared with co-administration of alcohol on day 10 (es-
timate of difference in mean time-profile in percents was 11.3%; 95% confidence 
interval 3.9/18.2%; p = 0.0065).
Pharmacodynamics of alcohol
No statistically significant differences in the results of dsst, binary choice reac-
tion time or any of the visual analogue scales were observed, as demonstrated in 
Table 1. Despite a small decrease in immediate recall after the first and third trial 
(p = 0.049 and p = 0.026, respectively) and shorter reaction time (for incorrect an-
swers) for word recognition (p = 0.012), no consistent effects of alcohol on vvlt 
performance was observed. Also, despite a shorter reaction time (for incorrect 
answers) for immediate recognition (p = 0.042), no consistent effects of alcohol 
administration on visual pattern recognition were observed.
As demonstrated in Table 2, body sway and finger tapping were significantly 
impaired (p = 0.029 or lower), whereas critical flicker fusion did not demonstrate 
any clear effect of alcohol administration compared to placebo. Adaptive 
tracking performance was significantly decreased at 7.5 hours postdose (p = 
0.012), while decreases at 4.5 hours and 6 hours approached (but failed to reach) 
significance level.
Pharmacodynamics of amitriptyline
As demonstrated in Table 1, amitriptyline significantly decreased dsst perfor-
mance compared to placebo (p = 0.008). Despite a small decrease in immediate 
recall (numbers correct) after the third trial (p = 0.014), no consistent effects of 
amitriptyline on vvlt performance were observed. Visual pattern recognition 
and binary choice reaction time remained unaffected. vas alertness was signifi-
cantly decreased (p = 0.005), but no differences were found in any of the other vi-
sual analogue scales.
As demonstrated in Table 2, critical flicker fusion, body sway, finger tapping 
and adaptive tracking were significantly reduced after administration of 
amitriptyline compared to placebo (p = 0.044 and lower).
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table 1 Results of cognitive tests (n = 16). All results are expressed as differences in treatment 
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table 2 Results of psychomotor tests (n = 16) using change from baseline analysis. All results are 
expressed as differences in treatment means (with 90% confidence intervals and p-values), except body 
sway data which are expressed as geometric mean ratios (with 90% confidence intervals and p-values). 
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Pharmacodynamics of aprepitant
As demonstrated in Table 1, the cns effects of aprepitant were limited. There was 
no impairment of dsst performance, vvlt performance, binary choice reaction 
time or any of the visual analogue scales, compared with placebo.
As demonstrated in Table 2, no clear effects on critical flicker fusion, body 
sway, finger tapping and adaptive tracking were demonstrated after administra-
tion of aprepitant compared to placebo.
Pharmacodynamics of co-administration of aprepitant and alcohol
No statistically significant effects were observed in the results of dsst, binary 
choice reaction time or any of the visual analogue scales after co-administra-
tion of alcohol and aprepitant compared to administration of alcohol alone, as 
demonstrated in Table 1. Despite a longer reaction time (for incorrect answers) 
for immediate recognition after co-administration of alcohol and aprepitant 
compared to administration of alcohol alone (p = 0.043), no consistent effects of 
co-administration of aprepitant and alcohol on visual pattern recognition was 
observed.
As demonstrated in Table 2, no clear effects on critical flicker fusion, body 
sway, finger tapping and adaptive tracking were demonstrated after co-
administration of alcohol and aprepitant compared with alcohol alone.
discussion
This study had been performed primarily to evaluate central nervous system 
(cns) effects of single oral doses of the now marketed nk1 receptor antagonist 
aprepitant and possible interactions with alcohol in healthy volunteers, using 
an intravenous alcohol infusion paradigm to achieve pseudo-steady state lev-
els of alcohol. Aprepitant was generally well tolerated in this study and adverse 
events were similar to those reported previously in healthy volunteers22 and pa-
tients with major depressive disorder14, although diarrhea was not reported in 
our group of volunteers. Co-administration of aprepitant with intravenous al-
cohol infusion at pseudo-steady state was also generally well tolerated. Adverse 
events were comparable with those after administration of alcohol alone.
Following administration of aprepitant alone, no significant impairments 
were observed with either the cognitive or the psychomotor tests. This study 
represents the first use of this pharmacodynamic test battery to evaluate the 
effects of a selective nk1 antagonist in healthy volunteers. As a result, no data of 
other selective nk1 receptor antagonists are available for comparison with the 
effects of aprepitant. Recently, the nk3 receptor antagonist talnetant has been 
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evaluated with this pharmacodynamic test battery in healthy volunteers34. 
Single oral doses of 200 mg talnetant decreased vas calmness and alpha power 
eeg and improved adaptive tracking performance. However, differences in 
tissue expression of nk1 and nk3 receptors and differences in receptor affinity 
profiles of aprepitant and talnetant significantly limit the comparison of their 
effects. Another recent study using a similar pharmacodynamic test battery 
evaluated possible interactions of alcohol and gsk1144814, a dual antagonist 
at both nk1 and nk3 receptors35. Co-administration of gsk1144814 and alcohol 
resulted in small additional impairments in saccadic reaction time and peak 
velocity, adaptive tracking performance, alertness, sleepiness, word recognition 
score and recognition reaction time at some point, compared with the effects 
of alcohol alone. The effects of gsk1144814 alone (without co-administration 
of alcohol) were not investigated, but the interaction with alcohol suggests 
that gsk1144814 either has small pharmacodynamic effects of its own or that 
gsk1144814 slightly modifies the effects of alcohol. However, the limited effect 
size of the interaction suggests that the pharmacodynamic effects of gsk1144814 
are also limited. Therefore, antagonists at central nk1 receptors seem to affect 
cns performance of healthy volunteers to a rather limited extent.
Positron emission tomography (pet) using [18F]spa-rq in healthy volunteers 
has demonstrated that daily doses of 100 mg aprepitant or higher can achieve 
high levels (›90%) of nk1 receptor occupancy in the striatum15, which provides 
support for sufficient cns penetration and nk1 receptor occupancy by aprepi-
tant at the dose employed in this study. Therefore, the limited effect size and 
scope of the cns effects of aprepitant in this study do not seem to result from lack 
of central nk1 receptor occupancy. It has been suggested that antagonism of neu-
ropeptide receptors may show less dramatic effects than antagonism of classic 
neurotransmitter receptors, because the neuromodulatory nature of substance 
P and other neuropeptides seems to result in milder effects than drugs that in-
terfere directly with the levels of monoamines and amino acid transmitters36. In 
addition, much evidence indicates that neuropeptides are released after stress-
ful and noxious stimuli36-38. Accordingly, it has been suggested that neuropep-
tides exert their main action after various types of challenges or pathological 
conditions36,38. Neuropeptide receptor antagonists might therefore have signif-
icant effects in pathological conditions with increased peptide release, whereas 
effects in normal healthy volunteers are limited36,38.
In addition to obtaining a nk1 receptor mediated profile of cns effects, our 
study was specifically designed to evaluate potential interactions between apre-
pitant and alcohol. Pharmacokinetic interactions between aprepitant and alco-
hol were not expected, given their separate pathways of metabolism. Aprepi-
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tant is metabolized primarily by cyp3a410, whereas alcohol is metabolized by a 
pathway that involves alcohol dehydrogenase, catalase and cyp2e11, although 
alcohol has been suggested as a potential inducer of cyp3a4 activity39. Plasma 
concentrations of aprepitant (see Figure 4) were statistically significantly higher 
when administered alone on day 9, compared with co-administration of alcohol 
on day 10, but the difference was quite small, with a cumulative mean difference 
in plasma concentrations of 11.3% (95% confidence interval: 3.9-18.2%), which 
might be considered not clinically meaningful. However, this study was not spe-
cifically designed to evaluate the induction of aprepitant metabolism by alcohol 
and there is a limitation with the statistical analysis, because treatments are se-
quential and not randomized.
Pharmacodynamic interactions between aprepitant and alcohol are theoreti-
cally possible as both compounds are centrally active and may influence several 
neurotransmitters, including dopamine, at various sites in the brain2,12. The in-
travenous alcohol infusion produced clear and expected cns effects, similar to 
previously reported results of this alcohol infusion paradigm13,19,20. Contrary 
to those investigations, our study did not find a clear decrease in vas alertness, 
but the visual analogue scales were performed shortly after the start of the al-
cohol infusion at which time blood alcohol concentration probably had not yet 
reached significant levels. Co-administration of aprepitant and alcohol did not 
result in significant additive effects, compared to the effects of alcohol alone, on 
any of the pharmacodynamic parameters, and is therefore not very likely to re-
sult in a clinically relevant interaction. To get a further impression of the effect 
size of pharmacodynamic effects, amitriptyline was included in this study as a 
pharmacodynamic comparator. Amitriptyline is one of the first ‘reference’ tricy-
clic antidepressant drugs40 and its cns effects have long been known in the lit-
erature16. Amitriptyline demonstrated significant and expected impairments in 
almost all pharmacodynamic parameters, in contrast with the limited effects of 
aprepitant. These findings generally confirmed the large functional cns effects 
of a single dose of 50 mg amitriptyline, which were generally larger than those of 
alcohol levels above the legal driving limit in most Western countries.
In conclusion, our study demonstrates no significant cns impairments after 
administration of aprepitant in healthy volunteers. Furthermore, co-adminis-
tration of aprepitant with intravenous alcohol levels at pseudo-steady state was 
generally well tolerated and did not result in significant additive cns effects, 
compared to the effects of alcohol alone. Therefore, our study found no indica-
tions for clinically relevant additive effects when alcohol is co-administered 
with aprepitant.
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abstract
aims: Antagonism of both nk1 and nk3 receptors may be an effective strategy in 
pharmacotherapy of schizophrenia, drug addiction or depression. gsk1144814 
is a novel selective dual nk1/nk3 receptor antagonist. The potential influence of 
gsk1144814 on the effects of alcohol was investigated.
methods: In a blinded, randomized, placebo-controlled, two-period cross-
over study, the pharmacokinetics and central nervous system (cns) effects of 
single oral doses of 200 mg gsk1144814 were evaluated in 20 healthy volunteers, 
using a controlled alcohol infusion paradigm to maintain stable alcohol levels 
with subsequent analysis of eye movements, adaptive tracking, body sway, visu-
al analogue scales, Epworth sleepiness scale and the verbal visual learning test.
results: Frequent adverse effects were mild somnolence, fatigue and head-
ache. Plasma concentration of gsk1144814 in the presence of alcohol was maxi-
mal 1.5 hours after dose administration. gsk1144814 did not affect alcohol phar-
macokinetics. Co-administration of gsk1144814 and alcohol impaired saccadic 
reaction time and peak velocity, adaptive tracking, alertness, sleepiness, word 
recognition and recognition reaction time compared with administration of al-
cohol alone, but the size of the interaction was small.
conclusions: Administration of gsk1144814 in the presence of alcohol is gen-
erally well tolerated and not likely to produce clinically relevant additional im-
pairments after alcohol consumption.
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introduction
Antagonists at the neurokinin-1 (nk1) and neurokinin-3 (nk3) receptors have 
been evaluated in several clinical trials for possible antidepressant and anti-
psychotic activity, respectively1-3. Clinical trials with the nk1 receptor antago-
nists casopitant, aprepitant and L-759274 have demonstrated antidepressant 
efficacy4-6, although these findings were not replicated for the latter two com-
pounds7,8. An early clinical trial with the nk3 receptor antagonist osanetant 
has demonstrated antipsychotic efficacy in schizophrenic patients9, but fur-
ther clinical development of this compound has been discontinued because of 
poor pharmacokinetic characteristics3,10. Development of another nk3 receptor 
antagonist, talnetant, also has been discontinued, due to rather low penetra-
tion of the blood-brain barrier3,10. Recently, interest in nk1 and nk3 receptor 
antagonists has focused on a potential role in the treatment of drug addiction 
and substance abuse disorders. Involvement of neurokinin receptors in the eti-
ology of substance abuse disorders has been suggested by recent studies, which 
identified haplotypes and single nucleotide polymorphisms (snp) in the nk1r 
gene11 and tacr3 gene12, encoding the nk1 and nk3 receptor respectively, that 
were significantly associated with the development of alcohol dependence. 
Pre-clinical studies in various animal models have demonstrated that pharma-
cological blockade of nk1 receptors dose-dependently suppresses alcohol in-
take13 and stress-induced reinstatement of alcohol seeking behavior14, while 
pharmacological blockade of nk3 receptors attenuates the behavioural effects of 
cocaine15,16 and prevents behavioral sensitization to cocaine17. Furthermore, a 
recent clinical trial with the nk1 receptor antagonist ly686017 in detoxified alco-
holic inpatients has demonstrated suppression of spontaneous alcohol cravings 
and improved overall well-being18. Together, these data suggest that antago-
nism of both nk1 and nk3 receptors may be an effective strategy in pharmaco-
therapy of schizophrenia, drug addiction or depression, especially in patients 
with co-morbid schizophrenia and substance abuse disorder, which is quite 
common19,20 and is associated with poor clinical outcome21,22.
gsk1144814 is a novel selective high affinity ligand for recombinant human 
nk1 and nk3 receptors, that is being developed as a novel treatment for schizo-
phrenia, depression and substance abuse disorders (data on file). Pre-clinical in 
vitro studies demonstrated that gsk1144814 was selective for the human nk1 and 
nk3 receptors, versus 88 other non-tachykinin human receptors, enzymes and 
transporters (data on file). Previous studies of gsk1144814 in healthy volunteers 
demonstrated peak levels within one hour and a terminal elimination half life of 
roughly 15 hours (data on file).
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A potential role for gsk1144814 in pharmacotherapy of drug abuse and addiction 
necessitates evaluation of possible interactions with drugs of abuse, because the 
target population of patients will have alcohol dependence as primary disorder 
or co-morbidity. Pharmacodynamic interactions are theoretically possible as 
both compounds are centrally active and may potentially influence several neu-
rotransmitters, including dopamine, at various sites in the brain23,24. nk1 recep-
tor antagonists with chemical structures similar to gsk1144814, such as casopi-
tant25 and aprepitant26, are metabolized primarily by cyp3a4. In contrast, alco-
hol is metabolized by a pathway that involves alcohol dehydrogenase, catalase 
and cyp2e27. Accordingly, pharmacokinetic interactions between gsk1144814 
and alcohol are not expected. Therefore, in the present study, we investigated 
whether single oral doses of gsk1144814 can modulate the central nervous sys-
tem (cns) effects of alcohol in healthy volunteers. An intravenous alcohol infu-
sion paradigm28 was used to achieve pseudo-steady state alcohol levels, while 
either single oral doses of gsk1144814 or placebo were co-administered. A re-
cent literature review29 identified the most sensitive and useful functional bio-
markers for the acute cns effects of alcohol, which included divided attention, 
focused attention, visuomotor control, visual analogue scales for subjective ef-
fects, reaction time, working memory and inhibition, digit-symbol substitu-
tion, motor control, postural stability and immediate recall (auditory or verbal 
memory). A previous study using the alcohol clamping method30 demonstrated 
significant effects of alcohol on smooth pursuit eye movements, adaptive track-
ing, body sway and visual analogue scales for alertness and the subjective ef-
fects of alcohol, while the peak velocity of saccadic eye movements also seemed 
to decrease somewhat, albeit not statistically significant. These quantitative 
tests were all included in the present study, while the visual verbal learning test 
(vvlt)31 was added to evaluate effects on memory. To our knowledge, no other 
nk1/nk3 receptor antagonists have been evaluated using these tests and we are 
unaware of other cns tests capable of demonstrating effects in healthy volun-
teers after single oral doses. Thus, our study can be regarded as exploratory in 
that regard. However, the quantitative tests used in this study have previously 
been demonstrated to be sensitive to the central effects of various compounds, 
including antipsychotic drugs32, antidepressant drugs33 and the nk3 receptor 
antagonist talnetant34. Finally, also for exploratory purposes, we included an 
adapted version of the Epworth sleepiness scale35,36 in this study to evaluate its 
usefulness for assessing drug-induced sleepiness in early phase clinical trials. An 
oral dose of 200 mg gsk1144814 was chosen based on observed pharmacokinet-
ics in previous studies in healthy volunteers and on auc and noael estimations 
derived from animal models (data on file). This dose is generally well tolerated 
in healthy volunteers and can produce high levels of receptor occupancy (›99% 
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nk1 receptor occupancy in frontal cortex), as demonstrated by positron emis-
sion tomography (pet) using [11C]gr205171 in healthy volunteers (data on file). 
To demonstrate that the effects of alcohol combined with gsk1144814 do not sig-
nificantly differ from the effects of alcohol alone, we applied generally accepted 
statistical criteria for bioequivalence.
methods
Study design
Twenty healthy volunteers, between 18 and 65 years of age and with a body 
mass index between 19 and 30 kg/m2, were planned to participate in a blinded, 
randomized, placebo-controlled, two-period cross-over study. The study was 
approved by the medical ethics review board of the Leiden University Medical 
Center and registered at the nih database of clinical trials (website http://clini-
caltrials.gov) with identifier nct01181908 and gsk id number 113476. Prior 
to medical screening, all volunteers gave written informed consent. Medical 
screening included a medical history, physical examination, urinalysis, rou-
tine hematology and chemistry, 12-lead electrocardiography (ecg) and 24-hour 
Holter-ecg recording. All volunteers underwent training sessions for the phar-
macodynamic tests in order to minimize possible learning effects.
Volunteers were assigned to a randomized treatment sequence, consisting of 
one study period of intravenous alcohol infusion (alcohol clamping, see below 
for further details) combined with oral administration of 200 mg of gsk1144814 
and one study period of intravenous alcohol infusion combined with oral 
placebo administration. gsk1144814 or matching placebo was administered 
orally 30 minutes after the start of the alcohol infusion. The alcohol infusion 
continued until 5 hours after study drug administration, in order to coincide 
with the expected tmax of gsk1144814. Subjects remained in the clinic until 48 
hours after study drug administration. The first study period was preceded 
by a baseline study day in which all study-related activities were performed 
following unblinded intravenous saline infusion without drug administration, 
to familiarize all volunteers with the study-related procedures. All periods were 
separated by a wash-out time of approximately 7 days.
Subjects were excluded if they had an average weekly alcohol intake of great-
er than 14 units (in case of females) or 21 units (in case of males). Subjects with a 
past history of alcohol abuse or dependence were excluded. Subjects were also 
excluded if they had a history of regular use of tobacco- or nicotine-containing 
products within 6 months prior to screening, as indicated by urinary cotinine 
levels. Subjects were instructed to abstain from alcoholic drinks on the day pre-
ceding all study periods and all subsequent study days. In addition, the use of to-
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bacco products or illicit drugs was not permitted. In all study periods, breath al-
cohol measurements and urinary cotinine analysis were performed to ascertain 
non-use of alcohol and tobacco. Also, urine drug screening for cocaine, amphet-
amine, methamphetamine, opiates (morphine), benzodiazepines, barbiturates, 
mdma and thc (Innovacon, Inc., San Diego, California, usa) was performed to 
ascertain non-use of illicit drugs.
Alcohol clamping
The method for attaining constant alcohol levels has been described in detail 
elsewhere28,30. In brief, alcohol (ethanol 10% w/v solution in 5% glucose) was in-
fused intravenously over a period of 51⁄™ hours in total, guided by breath alcohol 
measurements to achieve a pseudo-steady state alcohol serum level of 0.6 g/L. 
This target level was chosen because it produces significant central nervous sys-
tem effects without causing too many inadvertent effects and is considered safe, 
since it is only just above the legal driving limit in the Netherlands (i.e. 0.5 g/L). 
The alcohol infusion started 30 minutes prior to administration of gsk1144814. 
The infusion rate for the first ten minutes was determined using individual 
demographic characteristics (weight, height, age and sex). Infusion rates were 
subsequently adjusted, guided by breath alcohol measurements at baseline and 
at every five minutes for the first 30 minutes after the start of the infusion, ev-
ery 10 minutes for the next 30 minutes and then every half hour until the end, 
using two calibrated Alco-Sensor iv Intoximeters (Honac, Apeldoorn, the 
Netherlands), which were alternated to avoid any fatigue of the apparatus. To 
prevent local pain at the beginning of the alcohol infusion, an additional dilut-
ing glucose 5% infusion at 100 mL/h was administered to all participants during 
the first 10 minutes after the start of the alcohol infusion through the same infu-
sion line. The time profiles of the individually adjusted infusion rates necessary 
to maintain a target alcohol serum level of 0.6 g/L provide an indirect measure of 
individual alcohol pharmacokinetics and were subsequently used for statistical 
comparison between treatments.
Safety monitoring
Evaluation of adverse events, 12-lead electrocardiograms (ecg), blood pres-
sure, heart rate, body temperature, urinalysis and blood sampling for hematol-
ogy and chemistry was performed at regular time points after dose administra-
tion. Automated oscillometric blood pressures were measured using a Nihon-
Kohden bsm-1101k monitor or a Colin Pressmate bp 8800. ecgs were obtained 
with Cardiofax V equipped with ecaps12 analysis program (Nihon-Kohden, 
Tokyo, Japan).
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Pharmacokinetics
Venous blood samples for concentration analysis of gsk1144814 were collected 
prior to dose administration and at 30 minutes and 1, 11⁄™, 2, 21⁄™, 3, 31⁄™, 4, 5, 6, 8, 
12 and 24 hours after dose administration. Plasma concentrations of gsk1144814 
were determined using protein precipitation followed by hplc/ms/ms analysis 
with a lower limit of quantification (llq) of 1.5 ng/mL.
Pharmacodynamic testing
Pharmacodynamic measurements were performed as described previously34,37, 
prior to dose administration and at fixed time intervals at 1, 2, 3, 41⁄™ and 8 hours 
after dose administration. Volunteers were tested individually in a quiet room 
with ambient illumination. quantitative tests included measurements of 
smooth pursuit and saccadic eye movements, adaptive tracking, body sway, vi-
sual analogue scales and an adapted version of the Epworth sleepiness scale. In 
addition, the visual verbal learning test (vvlt) was performed at 2 and 41⁄™ hours 
after dose administration.
Analysis of eye movements
To evaluate oculomotor performance and sedation, smooth pursuit and sac-
cadic eye movements were recorded as described previously38-41, using a com-
puter-based system for signal collection (Cambridge Electronic Design Ltd., 
Cambridge, uk) and amplification (Grass-Telefactor, An Astro-Med, Inc. Product 
Group, Braintree, usa), and disposable surface electrodes (Medicotest N-oo-S, 
Olstykke, Denmark). For smooth pursuit eye movements, a target light source 
moves sinusoidally over 20° eyeball rotation at frequencies ranging from 0.3 to 
1.1 Hz. The time in which the eyes were in smooth pursuit was calculated for each 
frequency and expressed as the percentage of stimulus duration. The average 
percentage of smooth pursuit for all frequencies was used as parameter. For sac-
cadic eye movements, the target light source jumps from side to side. Peak ve-
locity (degrees per second), reaction time and inaccuracy (%) was calculated of all 
artifact-free saccades.
Adaptive tracking
To evaluate visuo-motor coordination, the adaptive tracking task was per-
formed as described previously40-44, using customized equipment and software 
developed by K.W. Hobbs (Hertfordshire, uk). Adaptive tracking is a pursuit 
tracking task in which a circle moves randomly over a computer screen and the 
volunteer must try to keep a dot inside the moving circle using a joystick. If this 
effort is successful, the speed of the moving circle is increased and if the effort is 
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unsuccessful, the speed is reduced. Performance was scored over a fixed period of 
three minutes.
Body sway
Postural stability in the sagittal plane was measured with an apparatus similar 
to the Wright ataxiameter45, using a string attached to the waist of the volunteer. 
Movements over a period of two minutes, while standing still with eyes closed, 
were integrated and expressed as mm sway.
Visual analogue scales
Subjective effects were quantified using a Dutch translation of the visual ana-
logue scales (vas), originally described by Norris46, to derive three composite 
factors corresponding to sedation, mood (contentedness) and calmness, as de-
scribed by Bond & Lader47. In addition, a visual analogue scale was used to quan-
tify the subjective effects of alcohol.
Epworth sleepiness scale
For exploratory purposes, an adapted version of the Epworth sleepiness 
scale35,36 was included in this study. The Epworth sleepiness scale is a self-ad-
ministered scale for assessing subjective daytime sleepiness persisting from 
week to week, independent of changes with the time of day and from day to day. 
Eight specific situations are presented in a questionnaire and subjects are in-
structed to rate the chance they would have dozed when those situations occur 
in daily life in recent time, on a scale from 0 to 3 with increasing chance of doz-
ing. Scores of individual items are summed to produce a total score. In this study, 
the volunteers were instructed to rate the chance of dozing in the recent hour in-
stead of the recent days to weeks, to assess if the Epworth sleepiness scale is sensi-
tive to single dose drug effects over the course of a few hours.
Visual verbal learning test
The visual verbal learning test (vvlt)31 is an adapted version of the auditory ver-
bal learning test48. Three trials of 30 words are presented on a computer screen 
in the same sequence. The volunteer is requested to reproduce as many words as 
possible at the ending of each trial (immediate recall) and after 30 minutes (de-
layed recall). The number of correctly reproduced words is analyzed for each 
trial. Also, a recognition test is performed, consisting of 15 previously present-
ed words and 15 new words, in which the volunteer has to indicate recognition 
of the word (delayed recognition) as quickly as possible. Response time and the 
number of correctly recognized words are analyzed.
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Statistical analysis
Pharmacokinetic parameters of gsk1144814 in the presence of alcohol were 
determined based on the individual plasma concentration-time data, using 
WinNonlin professional edition software version 5.2 (Pharsight Corporation, 
Mountain View, California, usa) and included the maximum observed plasma 
concentration (Cmax), time to reach maximum plasma concentration (tmax) and 
area under the plasma concentration-time curve from time zero extrapolated 
to the last time of quantifiable concentration (auc0-t) and to 24 hours post-dose 
(auc0-24 hours).
Effects of gsk1144814 administration on the pharmacokinetics of alcohol 
were evaluated by comparing the rates of alcohol infusion necessary to maintain 
a pseudo-steady state alcohol serum level of 0.6 g/L, using a mixed model 
analysis of variance with treatment, period, time and treatment by time as fixed 
factors and with subject, subject by treatment and subject by time as random 
factors.
Pharmacodynamic parameters were compared using a mixed model 
analysis of variance with treatment, period, time and treatment by time as fixed 
factors and with subject and subject by period as random factors. Saccadic eye 
movement data (reaction time, peak velocity and inaccuracy) and body sway 
data were log-transformed prior to analysis. vvlt data were compared using a 
mixed model with treatment and period as fixed effects and subject as random 
effect. Treatment differences with corresponding 90% confidence intervals were 
calculated. All calculations were performed using sas for Windows version 9.1.2 
(sas Institute Inc., Cary, North Carolina, usa).
results
Subjects
Twenty healthy male volunteers were included in the study. Participants had a 
mean age of 27.6 years (range 18-62), weight of 75.9 kg (range 60-90) and body 
mass index of 22.8 kg/m2 (range 19.9-27.6). All volunteers completed both study 
periods and a follow-up visit, except one volunteer who completed both study 
periods but was subsequently lost to follow-up. Pharmacokinetic and pharma-
codynamic data from this volunteer were included in the statistical analysis.
Clinical observations
All adverse events were transient and mild or moderate in severity and no seri-
ous adverse events occurred during the study. Overall, the most common ad-
verse events were somnolence and fatigue (see Table 1). Somnolence, headache, 
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infusion reaction (generally consisting of redness of skin and burning feeling at 
infusion site), nausea, phlebitis, diarrhea, dizziness and light headedness were 
reported more frequently after co-administration of alcohol and gsk1144814, 
whereas fatigue and vasovagal reaction were reported more frequently after 
administration of alcohol alone. There were no consistent and clinically rel-
evant changes in vital signs, blood chemistry and hematology or any of the ecg 
intervals.
table 1 Summary of common adverse events, reported by two subjects or more. Incidence is 
based on the number of subjects, not the number of events. 
 




Somnolence 7 (35%) 13 (65%)
Fatigue 6 (30%) 4 (20%)
Headache 5 (25%) 7 (35%)
Feeling drunk 6 (30%) 8 (40%)
Infusion reaction 3 (15%) 5 (25%)
Nausea 2 (10%) 3 (15%)
Phlebitis 1 (5%) 2 (10%)
Diarrhoea 0 2 (10%)
Dizziness 1 (5%) 2 (10%)
Light headedness 1 (5%) 2 (10%)
Vasovagal reaction 2 (10%) 1 (5%)
 
Pharmacokinetics
Following intravenous alcohol infusion, breath alcohol levels increased rapidly 
and remained constant at the target level all over the time of infusion (see Figure 
1). The rate of alcohol infusion necessary to maintain a pseudo-steady state alco-
hol serum level of 0.6 g/L (see Figure 2) was not significantly different between 
administration of gsk1144814 and placebo capsules (p = 0.5105).
Following co-administration of 200 mg tablets of gsk1144814 and 
intravenous alcohol infusion, gsk1144814 was rapidly absorbed (see Figure 
3). Median time to peak concentration (tmax) was 1.5 hours (range 0.97-3.48). 
The geometric mean Cmax was 1500 ng/mL (coefficient of variation 21.6%, 95% 
confidence interval 1360-1660). The geometric mean auc0-t and auc0-24 hours 
were 7680 ng.h/mL (coefficient of variation 29.7%, 95% confidence interval 
6700-8800) and 7630 ng.h/mL (coefficient of variation 30.5%, 95% confidence 
interval 6610-8810), respectively.
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figure 1 Breath alcohol levels after intravenous alcohol infusion starting at t = -0.5 hours and 
continuing until t = 5 hours, in combination with oral administration (at t = 0 hours) of gsk1144814 
(open circles) or placebo (closed circles). Means are presented with standard deviations as error bars.
figure 2 Alcohol infusion rates necessary to maintain a pseudo-steady state alcohol serum 
level of 0.6 g/L, starting at t = -0.5 hours and continuing until t = 5 hours, in combination with oral 
administration (at t = 0 hours) of gsk1144814 (open circles) or placebo (closed circles). Means are 
presented with standard deviations as error bars.
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figure 3 Plasma levels of gsk1144814 after oral administration at t = 0 hours, in combination 
with intravenous alcohol infusion starting at t = -0.5 hours and continuing until t = 5 hours. Means are 
presented with standard deviations as error bars.
figure 4 Adaptive tracking performance after intravenous alcohol infusion combined with 
oral administration (at t = 0 hours) of either gsk1144814 (open circles) or placebo (closed circles). The 
grey curve represents measurements following unblinded intravenous saline infusion (without drug 
administration) during a baseline study day preceding the first study period, which is included in the 
figure for reference. Means are presented with standard deviations as error bars.
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Pharmacodynamics
Neurophysiological parameters are summarized in Table 2 and Figures 4, 5, 6 
and 7. There was a statistically significant increase in saccadic reaction time at 1 
hour and a decrease in saccadic peak velocity at 41⁄™ hours after co-administra-
tion of gsk1144814 and alcohol compared with administration of alcohol alone. 
A clear reduction of overall adaptive tracking performance was observed after 
co-administration of gsk1144814 and alcohol compared with alcohol alone, al-
though the time course of effects was not very consistent. Effects were statistical-
ly significant at 1, 41⁄™ and 8 hours, while effects at 2 and 3 hours were not statis-
tically significant. There were no statistically significant differences in saccadic 
inaccuracy, smooth pursuit eye movements and body sway.
Subjective effects are summarized in Table 3 and Figures 8, 9 and 10. An increase 
in sedation was observed at 3 and 41⁄™ hours after co-administration of gsk1144814 
and alcohol compared with alcohol alone. There were no statistically significant 
differences in contentedness, calmness or the feeling of being drunk. The Epworth 
sleepiness scale demonstrated a clear increase of sleepiness in the first 3 hours after 
co-administration of gsk1144814 and alcohol compared with alcohol alone.
table 2 Neurophysiological parameters. Treatment differences between co-administration 
of alcohol and gsk1144814 compared with co-administration of alcohol and placebo, are expressed 
as differences in treatment means (with 90% confidence intervals and p-values) or as geometric mean 
ratios (with 90% confidence intervals and p-values). Statistically significant results are indicated in 
bold. The alcohol infusion started 30 minutes prior to administration of gsk1144814 (at t = 0) and 
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figure 5 Body sway after intravenous alcohol infusion combined with oral administration (at 
t = 0 hours) of either gsk1144814 (open circles) or placebo (closed circles). The grey curve represents 
measurements following unblinded intravenous saline infusion (without drug administration) during 
a baseline study day preceding the first study period, which is included in the figure for reference. 
Means are presented with standard deviations as error bars.
figure 6 Saccadic peak velocity after intravenous alcohol infusion combined with oral 
administration (at t = 0 hours) of either gsk1144814 (open circles) or placebo (closed circles). The grey 
curve represents measurements following unblinded intravenous saline infusion (without drug 
administration) during a baseline study day preceding the first study period, which is included in the 
figure for reference. Means are presented with standard deviations as error bars.
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figure 7 Smooth pursuit measurements after intravenous alcohol infusion combined with 
oral administration (at t = 0 hours) of either gsk1144814 (open circles) or placebo (closed circles). The 
grey curve represents measurements following unblinded intravenous saline infusion (without drug 
administration) during a baseline study day preceding the first study period, which is included in the 
figure for reference. Means are presented with standard deviations as error bars.
figure 8 Visual analogue scale (vas) sedation scores after intravenous alcohol infusion combined 
with oral administration (at t = 0 hours) of either gsk1144814 (open circles) or placebo (closed circles). 
The grey curve represents scores following unblinded intravenous saline infusion (without drug 
administration) during a baseline study day preceding the first study period, which is included in the 
figure for reference. Means are presented with standard deviations as error bars.
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figure 9 Visual analogue scale (vas) scores for the subjective effects of alcohol after intravenous 
alcohol infusion combined with oral administration (at t = 0 hours) of either gsk1144814 (open circles) 
or placebo (closed circles). The grey curve represents scores following unblinded intravenous saline 
infusion (without drug administration) during a baseline study day preceding the first study period, 
which is included in the figure for reference. Means are presented with standard deviations as error 
bars.
 
figure 10 Epworth sleepiness scale scores after intravenous alcohol infusion combined with 
oral administration (at t = 0 hours) of either gsk1144814 (open circles) or placebo (closed circles). 
The grey curve represents scores following unblinded intravenous saline infusion (without drug 
administration) during a baseline study day preceding the first study period, which is included in the 
figure for reference. Means are presented with standard deviations as error bars.
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table 3	 Subjective effects. Treatment differences between co-administration of alcohol and 
gsk1144814 compared with co-administration of alcohol and placebo, are expressed as differences 
in treatment means (with 90% confidence intervals and p-values). Statistically significant results are 
indicated in bold. The alcohol infusion started 30 minutes prior to administration of gsk1144814 (at t = 




































































































































table 4 Results of the visual verbal learning test (vvlt). Treatment differences between co-
administration of alcohol and gsk1144814 compared with co-administration of alcohol and placebo, are 
expressed as differences in treatment means (with 90% confidence intervals and p-values). Statistically 
significant results are indicated in bold. 
 
Parameter Difference (90% CI) p-value
Immediate recall 1st trial (correct) -0.20 (-1.24/0.84) 0.742
Immediate recall 2nd trial (correct) -0.65 (-1.89/0.59) 0.377
Immediate recall 3rd trial (correct) 0.40 (-1.11/1.91) 0.652
Delayed recall (correct) -0.50 (-2.10/1.10) 0.594
Relative recall (%) -7.96 (-17.85/1.93) 0.180
Word recognition (correct) -2.33 (-4.19/-0.47) 0.043
Recognition time (correct) 68.44 (28.09/108.80) 0.009
 
The results of the visual verbal learning test (vvlt) are summarized in Table 4. 
There were no significant differences in immediate, delayed or relative recall, 
but word recognition score was reduced and recognition reaction time was 
increased after co-administration of gsk1144814 and alcohol compared with 
alcohol alone.
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discussion
A potential role of nk1 and nk3 antagonism in the treatment of substance abuse 
disorders and psychosis necessitates evaluation of possible pharmacokinetic 
and pharmacodynamic interaction with drugs of abuse. The present study was 
performed primarily to evaluate if single oral doses of gsk1144814 can modulate 
the cns effects of alcohol in healthy volunteers, because the target population of 
patients will have alcohol dependence as primary disorder or co-morbidity.
In general, administration of gsk1144814 in the presence of alcohol was well 
tolerated. Median time to peak concentration of gsk1144814 (tmax) in the pres-
ence of alcohol was 1.5 hours while the mean Cmax was 1500 ng/mL, which were 
in line with results from previous studies with gsk1144814 in healthy volunteers. 
Administration of gsk1144814 did not notably affect alcohol pharmacokinetics, 
as the infusion rates necessary to maintain stable alcohol levels were similar be-
tween treatment groups. However, administration of gsk1144814 did affect sev-
eral alcohol-induced pharmacodynamic impairments. Saccadic reaction time, 
saccadic peak velocity and adaptive tracking performance, alertness, sleepiness, 
word recognition score and recognition reaction time were all impaired to a 
small extent at some point following co-administration of gsk1144814 and alco-
hol, compared with administration of alcohol alone. These interactions suggest 
either that gsk1144814 has mild pharmacodynamic effects of its own that are su-
perimposed on those of alcohol or that gsk1144814 slightly modifies the effects 
of alcohol. However, the additional cns effects were very limited in extent and 
are therefore not very likely to produce clinically relevant impairments on top of 
those of alcohol alone.
For exploratory purposes, we included an adapted version of the Epworth 
sleepiness scale in this study. The Epworth sleepiness scale35,36 was designed to 
measure only those components of daytime sleepiness that persist from week 
to week and longer in a given subject, independent of changes with the time of 
day and from day to day. However, by rating the subjective sleepiness in recent 
hours, instead of recent days to weeks, we used this scale to assess sleepiness over 
the course of a few hours following administration of gsk1144814. This adapted 
version of the Epworth sleepiness scale clearly demonstrated an increased 
chance of sleepiness and was one of the most sensitive parameters for the effects 
of gsk1144814. These results indicate that the Epworth sleepiness scale may be a 
sensitive tool not only for long-term assessment of drug-induced sleepiness, but 
also short-term effects after a single dose.
In a recent alcohol interaction study49, the cns effects of the nk1 receptor an-
tagonist aprepitant were studied, with or without co-administration of alcohol, 
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using pharmacodynamic tests similar to our present study. A therapeutic dose of 
160 mg aprepitant did not significantly impair performance on the digit-sym-
bol substitution test (dsst), vvlt, binary choice reaction time, visual analogue 
scales, critical flicker fusion, body sway, finger tapping and adaptive tracking, 
nor were there any signs of a significant interaction with alcohol. In another re-
cent study, the cns effects of the nk3 receptor antagonist talnetant were inves-
tigated, at a dose of 200 mg, which is at the low end of the range that is inves-
tigated in clinical trials34. Talnetant improved adaptive tracking performance, 
decreased a power electroencephalography (eeg), and reduced calmness, while 
vvlt performance, body sway, finger tapping, saccadic and smooth pursuit eye 
movements were not affected34. These studies suggest that single dose admin-
istration of nk1 and nk3 receptor antagonists affect cns performance of healthy 
volunteers to a rather limited extent. The present study was not designed to 
examine the cns effects of gsk1144814 alone. Therefore, it cannot be excluded 
that gsk1144814 by itself can cause limited cns effects. It is theoretically conceiv-
able that alcohol, which is an allosteric modulator of different transmembrane 
receptors, can change the properties of the ligand-receptor complex formed by 
gsk1144814 with its target receptors. However, the effects of gsk1144814 alone 
are unlikely to be large considering the limited extent of cns effects observed 
with talnetant and aprepitant alone and the lack of significant interactions be-
tween alcohol and aprepitant. Moreover, in the present study, the addition of 
gsk1144814 to alcohol caused only a limited increase of a few cns parameters, 
which also argues against large cns effects of gsk1144814 by itself.
The relative lack of effects of nk1 and nk3 receptor antagonists in healthy 
volunteers seems to contrast with the rather widespread expression of nk1 re-
ceptors50-55 and nk3 receptors55
,56 in the human central nervous system, and 
with the many interactions of these targets with dopamine, serotonin, nor-
adrenalin, acetylcholine and gaba1,3,23. It has been suggested that antagonism 
of neuropeptide receptors may show less dramatic effects than antagonism of 
classic neurotransmitter receptors, because the neuromodulatory nature of 
neuropeptides seems to result in milder effects than monoamines and amino 
acid transmitters and their direct agonists and antagonists57. In addition, much 
evidence indicates that neuropeptides are released after stressful and noxious 
stimuli52,57,58. Accordingly, it has been suggested that neuropeptides exert their 
main action after various types of challenges or pathological conditions57,58. 
Neuropeptide receptor antagonists might therefore have significant effects in 
pathological conditions with increased peptide release, while effects in normal 
healthy volunteers are limited57,58. However, it cannot be excluded that effects 
could have been detected more clearly after multiple dosing with gsk1144814, af-
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ter testing of other functional cns domains, or after challenge tests of relevant 
functional or pharmacological systems.
In conclusion, our study demonstrated that administration of the novel dual 
nk1/nk3 receptor antagonist gsk1144814 in the presence of alcohol was generally 
well tolerated. Administration of gsk1144814 did not notably affect alcohol 
pharmacokinetics, but did affect alcohol-induced impairments in several cns 
parameters. However, differences between the treatment groups were quite 
small and not very likely to produce clinically relevant additional impairments 
after alcohol consumption.
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abstract
objective: The effect of gaba and gabaergic drugs on prolactin secretion has 
been evaluated in many studies, often with inconsistent or opposing results. 
Moreover, little is known about the gabaa receptor subtypes that could be in-
volved with prolactin release. The present study aimed to provide additional 
data by evaluating the effects of the nonselective benzodiazepine lorazepam, as 
well as two novel a2/a3 subunit-selective gabaa receptor modulators azd7325 
and azd6280, on prolactin levels.
methods: Plasma prolactin concentrations were measured in 32 healthy male 
volunteers after administration of single oral doses of 2 mg lorazepam, 2 mg or 
10 mg azd7325, 10 mg or 40 mg azd6280 or placebo.
results: Following administration of lorazepam at 2 mg doses and azd6280 at 
10 mg and 40 mg doses, prolactin levels increased significantly compared with 
placebo (difference 42.0%, 19.8% and 32.8% respectively). The increases in prolac-
tin levels after administration of azd7325 at 2 mg and 10 mg doses (difference 
7.6% and 10.5% respectively) did not reach statistical significance.
conclusions: The nonselective benzodiazepine lorazepam and the novel a2/
a3 subunit-selective gabaa receptor modulator azd6280 increase prolactin lev-
els in healthy subjects, suggesting that the a2 and/or a3 receptor subtypes are in-
volved in gabaergic modulation of prolactin secretion, although possible roles 
of the a1 and a5 receptor subtypes are not excluded. Prolactin release following 
azd7325 was smaller and did not reach statistical significance, suggesting that 
doses of azd7325 or intrinsic efficacy at the a2 and a3 receptor subtypes may 
have been too low.
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introduction
Prolactin secretion by the lactotroph cells of the pituitary gland is primarily con-
trolled by the inhibitory influence of dopamine, released predominantly from 
the hypothalamic tuberoinfundibular dopaminergic neurons1,2. A variety of 
other neurotransmitters, amino acids and neuropeptides have also been dem-
onstrated to influence prolactin secretion. Many of these agents have multiple 
levels of action, often with opposing effects2. The effect of γ-aminobutyric acid 
(gaba) on prolactin secretion has been evaluated in a large number of in vitro 
studies, as well as in vivo studies in animals, which have reported both stimula-
tory and inhibitory effects3-7. In contrast, only a few studies have evaluated the 
direct effects of gabaergic drugs on circulating basal prolactin levels in healthy 
subjects. Diazepam8,9 and bromazepam10 did not significantly affect prolactin 
levels, while temazepam was found to increase prolactin levels only to a small 
extent11. Alprazolam at high doses increased prolactin levels12, while lower 
doses had no significant effect13. Zolpidem and bretazenil stimulated nocturnal 
secretion of prolactin14,15, while sodium valproate decreased prolactin levels16. 
The effect sizes in these studies, if any, were very small, especially compared with 
the potent prolactin-elevating effects of dopamine d2 receptor antagonists. 
However, all these studies used small group sizes (6-10 subjects in most studies) 
and it cannot be excluded that effects might have reached statistical significance 
if larger study groups had been used.
It has been proposed that gaba exerts a dual control of prolactin secretion, 
one inhibitory and the other stimulatory17. The inhibitory control of prolactin 
secretion by gaba is thought to occur peripherally at the level of the anterior pi-
tuitary. gaba is released from the median eminence into the hypophyseal portal 
vessels to act at gaba receptors in the anterior pituitary gland2,18. Through in-
teraction with gaba receptors on the lactotrophs, gaba inhibits prolactin secre-
tion and also prolactin gene expression19-21. However, while there is little doubt 
that gaba has an inhibitory effect on prolactin release in vitro, a direct in vivo 
inhibitory effect is less clear2,22. The stimulatory control of prolactin secretion 
by gaba is thought to occur at the level of the central nervous system. gabaergic 
neurons are present throughout the hypothalamus, including the arcuate nucle-
us and periventricular area, which constitute the origin of the tuberoinfundibu-
lar dopaminergic pathway23-26. Within the arcuate nucleus, gaba may directly 
inhibit the activity of the tuberoinfundibular dopaminergic pathway, with a re-
sulting decrease of pituitary dopamine levels and a concomitant increase in pro-
lactin secretion2,18,23,27,28.
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The counteracting peripheral and central effects of gaba could explain the lim-
ited net effect of benzodiazepines on prolactin secretion in healthy volunteers. 
In addition, although gaba generally causes a reduction of dopaminergic neu-
ronal activity29, benzodiazepines have also been shown to increase dopamine 
levels in the mesolimbic pathway30. This increase probably results from se-
rial inhibition of coupled gabaergic interneurons in the mesolimbic pathway, 
which leads to disinhibition of dopaminergic neurons, which outweighs the 
direct inhibitory influence of benzodiazepines on those dopaminergic neu-
rons31-33. Benzodiazepines are allosteric modulators of a1, a2, a3 and a5 sub-
unit-containing gabaa receptors34. Studies in animal models have provided 
indications that certain effects of benzodiazepines can be attributed to specific 
receptor subtypes, such as sedation (a1 receptor subtype35
,36), anxiolysis (a2 and 
a3 receptor subtypes37
-40) and learning and memory (a5 receptor subtype41
,42). 
The disinhibition of mesolimbic dopaminergic neurons and the resulting in-
crease in dopamine levels appear to be mediated by the a1 receptor subtype32
,33. 
It has been suggested that selective agonists at a3 receptor subtypes without ef-
ficacy at a1 receptor subtypes, may attenuate dopamine neurotransmission in 
the mesolimbic pathway, without counteractive disinhibition from gabaergic 
interneurons31. Accordingly, gabaa receptor subunit-selective agonists may 
differ significantly from nonselective benzodiazepines in their effects on dopa-
minergic pathways31.
Little is known about the gabaa receptor subtypes that could be involved 
with prolactin secretion. The a1, a2, a3, a4 and a5 receptor subtypes are all ex-
pressed to some extent in the nucleus accumbens and hypothalamus43. To 
explore the exact role of the various receptor subtypes in the regulation of 
prolactin secretion, the present study evaluated the effects of two novel a2/a3 
subunit-selective gabaa receptor modulators, azd7325 and azd628044, and 
a therapeutic dose of lorazepam on prolactin levels in an adequately powered 
group of 32 healthy volunteers. In vitro receptor binding studies demonstrated 
that azd7325 and azd6280 have high affinity for the a1 receptor subtype (mean 
ki = 0.5 nM for both compounds), a2 receptor subtype (mean ki = 0.3 and 21 nM, 
respectively) and a3 receptor subtype (mean ki = 1.3 and 31 nM, respectively), 
and lower affinity for the a5 receptor subtype (mean ki = 230 and 1680 nM, re-
spectively) (AstraZeneca data on file). Electrophysiological assays to evaluate 
the potentiation of gaba-induced current relative to the maximal response of 
diazepam (set at 100%) demonstrated potentiation by azd7325 and azd6280 at 
the a2 receptor subtype (18% and 32%, respectively) and a3 receptor subtype (15% 
and 34%, respectively), but neutral antagonism at the a1 receptor subtype (6% 
and 8%, respectively) and a5 receptor subtype (8% and 7%, respectively) (Astra-
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Zeneca data on file). These preclinical data suggest that azd7325 and azd6280 
are selective modulators of a2 and a3 subunit-containing gabaa receptors. 
Based on positron emission tomography (pet) using [11C]flumazenil in healthy 
volunteers, azd7325 at 2 and 10 mg doses and azd6280 at 10 and 40 mg doses 
are expected to result in substantial occupancy of gabaa receptors in the brain 
(e.g., ›50% occupancy of the maximal displaceable [11C]flumazenil binding in 
occipital cortex) (AstraZeneca data on file). Previous studies have demonstrated 
that sleep-inducing doses of classical benzodiazepines such as clonazepam45, 
diazepam46, midazolam47 and lorazepam48-50, as well as the nonbenzodiaz-
epine gaba receptor agonist zolpidem51 are associated with relatively low re-
ceptor occupancy levels (up to approximately 30%), whereas pharmacologically 
active doses of the a2/a3 subunit-selective gabaa partial agonists tpa02348 and 
tpa023b52 are associated with higher occupancy levels (i.e. approximately 50%). 
Also, doses of 2 and 10 mg of azd7325 and 10 and 40 mg of azd6280 are predict-
ed to lead to peak plasma concentrations above minimally efficacious concentra-
tions in animal models of anxiety (AstraZeneca data on file). These data demon-
strate that azd7325 and azd6280 cross the blood-brain barrier, interact with the 
target receptor, and have the potential to produce anxiolytic activity in humans.
methods
Study design
In total, 32 healthy male volunteers were planned to participate in two parallel 
double-blind, placebo-controlled, randomized, cross-over studies. To be eligible 
for inclusion in both studies, subjects were required to be aged between 18 and 
55 years, with a body mass index (bmi) of 18 to 30 kg/m2 and refrain from alco-
holic beverages, smoking and caffeine-containing products during study days. 
Both studies were approved by the medical ethics review board of the Leiden 
University Medical Center. Prior to medical screening, all subjects gave written 
informed consent. Both studies had an identical design, except the administered 
drugs. In the first study, 16 subjects were administered single oral doses of 2 mg 
lorazepam, 2 mg azd7325, 10 mg azd7325 or placebo, during four separate study 
periods. In the second study, 16 subjects were administered single oral doses of 
2 mg lorazepam, 10 mg azd6280, 40 mg azd6280 or placebo, during four sepa-
rate study periods. Study periods were scheduled in randomized order using a 
Williams Latin square design and were separated by a washout time of at least 7 
days. On study days, subjects fasted for minimally 2.5 hours after a light standard 
breakfast until dose administration (which generally occured between 11h00m 
and 12h00m am) and continued fasting until 4 hours after dose administration.
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Power calculation
A power calculation using data from a previous study53 indicated that the pres-
ent study (n = 32 subjects receiving lorazepam, power 80% and alpha 0.05) was 
powered to detect an increase of 12.5% or a decrease of 11% in prolactin concentra-
tion after administration of lorazepam, compared with placebo.
Plasma concentration of lorazepam and prolactin
Venous blood samples for analysis of lorazepam and prolactin concentration 
were collected prior to study drug administration and at 1⁄™, 1, 11⁄¢, 11⁄™, 2, 21⁄™, 31⁄¢, 
4, 41⁄™, 6, 8, 12 and 21 hours after study drug administration. Plasma concentra-
tions of lorazepam were determined using lc-ms/ms with a lower limit of quan-
tification of 0.3 ng/mL. Plasma concentrations of azd7325 were determined 
using lc-ms/ms with a lower limit of quantification of 0.05 ng/mL. Plasma con-
centrations of azd6280 were determined using lc-ms/ms with a lower limit of 
quantification of 0.15 ng/mL. Plasma concentrations of prolactin were deter-
mined using an electrochemiluminescence immunoassay (eclia) with a lower 
detection limit of 0.047 ng/mL.
Statistical analysis
Prolactin measurements up to 8 hours after administration of lorazepam or pla-
cebo were compared with a mixed model analysis of variance with treatment, 
period, time and treatment by time as fixed factors, and subject, subject by treat-
ment and subject by time as random factors, and the pre-value (measurement 
prior to study drug administration) as covariate. Prolactin measurements were 
log-transformed prior to analysis to correct for the log-normal distribution of 
the data. Estimates of treatment differences and back-transformed estimates of 
the difference in percentage with corresponding 95% confidence intervals (95% 
ci) and p-values were calculated. All calculations were performed using sas for 
Windows version 9.1.3 (sas Institute Inc., Cary, North Carolina, usa).
results
Subjects
Subjects had a mean age of 28.1 years (range 18-54), weight of 76.1 kg (range 62.0-
89.5) and body mass index (bmi) of 23.0 kg/m2 (range 19.1-26.7). Two subjects 
withdrew informed consent after completion of study period 1 for reasons un-
related to study drug administration. Another subject tested positive for thc 
in study period 2 and was excluded from participation. Pharmacodynamic data 
from these subjects were not used for further analysis. All three subjects were re-
placed. Therefore, in total, 32 subjects completed the study. 
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Plasma concentration of lorazepam, azd7325 and azd6280
Plasma concentrations of lorazepam, azd7325 and azd6280 are shown in 
Figures 1, 2 and 3, respectively. The pharmacokinetics of lorazepam were similar 
to those reported in literature54.
figure 1 Time course of plasma concentration of lorazepam after administration of single oral 
doses of 2 mg lorazepam (at t = 0 hours). Means are presented with standard deviations as error bars. 
figure 2 Time course of plasma concentration of azd7325 after administration of single oral 
doses of 2 mg and 10 mg azd7325 (at t = 0 hours). Means are presented with standard deviations as error 
bars.
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figure 3 Time course of plasma concentration of azd6280 after administration of single oral 
doses of 10 mg and 40 mg azd6280 (at t = 0 hours). Means are presented with standard deviations as 
error bars.
figure 4 Time course of plasma concentration of prolactin after administration of single oral 
doses of 2 mg lorazepam, 2 mg azd7325, 10 mg azd7325, 10 mg azd6280 and 40 mg azd6280 (at t = 0 
hours). Means are presented with standard deviations as error bars.
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table 1 Comparison of prolactin levels after administration of lorazepam, azd7325 and 
azd6280 compared with placebo. Treatment differences are expressed as percentages with 95% 
confidence intervals and p-values. 
 
Treatment comparisons Percentage difference (95% CI) p-value
Lorazepam versus placebo 42.0 (31.4/53.5) ‹ 0.0001
azd7325 2 mg versus placebo 7.6 (-2.8/19.1) 0.1566
azd7325 10 mg versus placebo 10.5 (-0.2/22.3) 0.0536
azd6280 10 mg versus placebo 19.8 (8.2/32.6) 0.0007
azd6280 40 mg versus placebo 32.8 (20.0/47.0) ‹ 0.0001
azd7325 2 mg versus lorazepam -24.2 (-31.6/-16.1) ‹ 0.0001
azd7325 10 mg versus lorazepam -22.2 (-29.7/-13.9) ‹ 0.0001
azd6280 10 mg versus lorazepam -15.7 (-23.8/-6.7) 0.0012
azd6280 40 mg versus lorazepam -6.4 (-15.5/3.6) 0.1957
 
 
Plasma concentration of prolactin
Plasma concentrations of prolactin after administration of lorazepam, azd7325 
and azd6280 are shown in Figure 4 and Table 1. Following administration of 2 
mg lorazepam, prolactin levels increased with 42.0% compared with placebo 
(95% ci 31.4/53.5%, p ‹ 0.001), which remained elevated until at least 8 hours af-
ter dose administration. Following administration of 2 mg and 10 mg azd7325, 
prolactin levels increased with 7.6% and 10.5%, respectively, compared with pla-
cebo. Both increases did not reach statistical significance, although the 10.5% in-
crease after the 10 mg dose has a p-value of 0.0536. Following administration of 
10 mg azd6280, prolactin levels increased significantly compared with placebo 
(difference 19.8% versus placebo, 95% ci 8.2/32.6%, p = 0.0007). A larger increase 
was observed after administration of 40 mg of azd6280 (difference 32.8% versus 
placebo, 95% ci 20.0/47.0%, p ‹ 0.0001). Prolactin levels after administration of lo-
razepam were significantly higher than those after azd7325 at 2 and 10 mg doses 
and azd6280 at 10 mg doses, but were not significantly different from those af-
ter azd6280 at 40 mg doses.
discussion
The present study was performed to evaluate the effects of the gabaergic drugs 
on circulating prolactin levels in healthy subjects, compared with placebo. After 
administration of placebo, prolactin levels showed an initial decrease with a re-
turn to baseline values at the end of the study day, which is consistent with a nor-
mal circadian rhythm2,55. Also, a peak in prolactin levels was observed 6 hours 
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after dose administration, which probably reflects normal prolactin release fol-
lowing food consumption56,57. After administration of a single oral dose of 2 mg 
lorazepam, an increase of 42.0% in prolactin levels was observed. The magnitude 
of the effects of lorazepam on prolactin levels was rather small, especially in 
comparison to the much more potent prolactin-elevating effects of dopamine d2 
receptor antagonists. Haloperidol at 3 mg doses increases prolactin levels with 
130.9%58. Thus, the effects of lorazepam administration on prolactin secretion 
are not likely to produce clinically relevant hyperprolactinaemia. However, our 
studies showed clear results in comparison with other studies that evaluated 
the effects of gabaergic drugs on basal prolactin levels in healthy subjects. The 
benzodiazepines diazepam and bromazepam showed no significant effects 
on prolactin levels under resting conditions8-10, whereas temazepam caused 
a small increase in prolactin levels of roughly 21.4 mU/L (which would corre-
spond to roughly 1 ng/mL), but only at a single time point 1 hour after dose ad-
ministration11. In contrast, our study demonstrates that lorazepam increases 
prolactin levels with roughly 5-6 ng/ml, which remain elevated until at least 8 
hours after dose administration. The dose of lorazepam (2 mg) used in our study 
is roughly equipotent with the doses of diazepam (10 mg), bromazepam (3 mg) 
and temazepam (20 mg) used in these earlies studies, although estimates of ben-
zodiazepine dose equivalencies differ somewhat between various authors59-61. 
Dose dependency of the effects on prolactin secretion has been demonstrated 
with the benzodiazepine alprazolam, which causes an increase of prolactin lev-
els with roughly 9-10 ng/mL at relatively high doses (3 mg)12, while doses in the 
lower therapeutic range (0.5 mg) demonstrated no effects13. The different find-
ings might be explained by the small sample sizes used in the earlier studies (6-
10 subjects in most studies) and statistical power may thus have been too small.
The increase in prolactin levels following administration of the gaba 
agonist lorazepam in our study suggests that the postulated stimulatory effect 
of gaba transmission (by suppressing the tuberoinfundibular dopaminergic 
neurons in the hypothalamus) exceeds the postulated inhibitory effect of gaba 
transmission (either directly at the anterior pituitary gland or by stimulating 
gaba release from the median eminence into the hypophyseal portal vessels). 
The preferential effect of lorazepam on the tuberoinfundibular dopaminergic 
neurons might result from differences in affinity for the pituitary and 
hypothalamic gaba binding sites, as has been shown for the gaba agonist 
muscimol and antagonist bicuculline62, both of which have higher affinity for 
the binding sites in the mediobasal hypothalamus than for the binding sites in 
the anterior pituitary. However, effects of benzodiazepines on the activity of the 
tuberoinfundibular dopaminergic neurons have not been confirmed in vivo in 
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man. A recent positron emission tomography (pet) study using the dopamine 
d2 receptor ligand [11C]flb457 in healthy subjects has demonstrated that 
single oral doses of 2.5 mg lorazepam induce a statistically significant decrease 
in dopamine d2 receptor binding potential (bpnd) in the medial temporal and 
dorsolateral prefrontal cortex63, but effects on the hypothalamus were not 
reported. Although a decrease in bpnd (i.e. suggesting dopamine release) in the 
cerebral cortex does not imply that lorazepam inhibits the tuberoinfundibular 
dopaminergic pathway in the hypothalamus, it does confirm that lorazepam can 
alter dopamine levels in extrastriatal areas in humans in vivo.
The present study also evaluated the effects of two novel a2/a3 subunit-selec-
tive gabaa receptor modulators, azd7325 and azd6280, on prolactin levels. Ad-
ministration of 2 mg and 10 mg azd7325 produced small increases in prolactin 
levels, which did not reach statistical significance, although the 10.5% increase 
after the 10 mg dose has a p-value of 0.0536. Administration of 10 mg and 40 mg 
azd6280 produced statistically significant increases in prolactin levels of 19.8% 
and 32.8%, respectively. These findings suggest that the a2 and/or a3 receptor 
subtypes are involved in gabaergic modulation of the tuberoinfundibular do-
paminergic pathway. Indeed, a2 and a3 subunit-containing gabaa recepors 
have been shown to be expressed in the arcuate nucleus and hypothalamus43. 
However, it is not excluded that a1 or a5 receptor subtypes, which are also ex-
pressed in the arcuate nucleus and hypothalamus43, are also involved in the con-
trol of prolactin secretion. The nonbenzodiazepine gaba agonist zolpidem (10 
mg), which has modest selectivity for a1 receptor subtypes64, increased noctur-
nal prolactin levels by two-fold15. Furthermore, despite functional selectivity 
for a2 and a3 receptor subtypes, azd7325 and azd6280 also have limited efficacy 
at a1 receptor subtypes (AstraZeneca data on file).
The effects of azd7325 on prolactin secretion were less clear than those of 
azd6280. Similarly, in other studies (Chen et al 2013, submitted; Chen et al 
2013, in preparation), azd7325 also caused fewer effects than azd6280 on peak 
velocity of saccadic eye movements, which is one of the most consistent and 
sensitive biomarkers for the effects of nonselective benzodiazepines65 and a2/
a3 subtype-selective compounds66 in healthy volunteers. These differences may 
be related to the lower dosages of azd7325 used. Although the dosages of both 
compounds were expected to result in relatively high levels of gabaa receptor 
occupancy, azd7325 is less effective in potentiation of gaba-induced current 
than azd6280 at the a2 receptor subtype (18% and 32%, respectively, compared 
to the maximal response of diazepam) and a3 receptor subtype (15% and 34%, 
respectively), whereas efficacy is very low and roughly similar at the a1 and a5 
receptor subtypes (AstraZeneca data on file).
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In conclusion, our study demonstrates that single oral doses of 2 mg lorazepam 
increase plasma prolactin levels in healthy male subjects. Our findings contrast 
with the inconsistent results obtained in earlier studies with other gabaergic 
drugs. The sample sizes or the administered doses used in these earlier studies 
may have been too small to adequately demonstrate statistically significant dif-
ferences, whereas our present results were obtained in an adequately powered 
group of 32 healthy volunteers, although it is not excluded that the different 
outcomes are caused by pharmacological differences between the various drugs. 
Our study also evaluated the effects of two novel a2/a3 subunit-selective gabaa 
receptor modulators, azd7325 and azd6280, on prolactin levels. azd6280 pro-
duced significant increases in prolactin levels, which may indicate that the a2 
and/or a3 receptor subtypes are involved in gabaergic modulation of prolactin 
secretion, although contributions of the a1 and a5 receptor subtypes are not 
excluded. The increases in prolactin levels after administration of azd7325 did 
not reach statistical significance, which may be related to the lower dosages of 
azd7325 used.
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This thesis describes early phase drug development studies that are part of larg-
er drug development programs which explore various stategies for improve-
ment of dopaminergic pharmacotherapy. These strategies include improve-
ment of receptor kinetics (chapter 2 and 3) and receptor selectivity (chapter 
4), as well as targeting tachykinergic (chapter 5 and 6) and gabaergic (chap-
ter 7) control mechanisms as a means to modulate dopamine neurotransmis-
sion. This thesis aims to evaluate pharmacokinetics and dose-effect relation-
ships of several drug candidates on various neurophysiological parameters in 
healthy volunteers in order to show penetration through the blood-brain bar-
rier, target engagement in vivo and differentiation of pharmacodynamic effects 
on several functional cns domains. This chapter reviews the use of these differ-
ent pharmacological approaches in the preceding chapters of this thesis and cor-
relates the findings to currently available clinical data obtained with these drug 
candidates in patients.
Improvement of receptor kinetics
It has been proposed that competitive dopamine receptor antagonists that dis-
sociate quickly from the receptor (i.e. a fast koff constant) are more accommodat-
ing to physiological fluctuations of dopamine concentrations than drugs with a 
slow koff1. Fast dissociation of an antipsychotic drug from the dopamine d2 re-
ceptor might therefore allow for a drug effect to occur with a lower risk for d2 
receptor-mediated side effects1. Using the rate of dissociation from the d2 recep-
tor as a means to screen novel compounds for antipsychotic drug candidates, the 
novel fast dissociating selective dopamine d2 receptor antagonist jnj-37822681 
was developed2. chapter 2 describes the pharmacokinetics and central ner-
vous system (cns) effects of jnj-37822681 in healthy volunteers. jnj-37822681 
was rapidly absorbed with a tmax of approximately 1–3 hours followed by a mean 
terminal half-life of 24–38 hours. The main cns effect of jnj-37822681 was dose-
related elevation of serum prolactin, which increased with approximately 750% 
after 20 mg doses. Other subjective, neuropsychological and neurophysiological 
effects were generally small. This effect profile is likely the result of the selectiv-
ity of jnj-37822681 for the d2 receptor, leading to strong d2 receptor-mediated 
elevations in serum prolactin, but fewer effects on more complex cns functions, 
which are likely to involve multiple neurotransmitters. However, serum prolac-
tin largely returned to baseline levels within 8 hours after administration of jnj-
37822681, which may prevent accumulation during chronic treatment. chap-
ter 3 evaluated the dopamine d2 receptor occupancy by jnj-37822681, which 
increased from 9-19% at 2 mg doses to 60-74% at 20 mg doses, with an estimated 
ec50 of 14.5 ng/mL. It has been suggested that 65–80% receptor occupancy is 
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optimal for most registered antipsychotic agents in terms of antipsychotic effect 
and adverse (i.e. extrapyramidal) events in clinical practice3-5. The present data 
indicate that 65–80% receptor occupancy is associated with plasma concentra-
tions of 27–58 ng/mL of jnj-37822681.
Based on chapter 2 and chapter 3 and the results of another [11C]raclo-
pride pet study6, which evaluated d2 receptor occupancy levels after multiple 
doses of 10 mg jnj-37822681 twice daily, the dosing regimens of 10, 20, and 30 
mg twice daily were selected for further study. A phase ii multicentre, double 
blind, placebo- and olanzapine-controlled trial with jnj-37822681 in patients 
with acute exacerbation of schizophrenia was performed, which indicated anti-
psychotic efficacy of all three dosing regimens superior to placebo to a roughly 
comparable extent7. Incidences of extrapyramidal symptoms were similar after 
administration of placebo, 15 mg olanzapine once daily, and 10 mg jnj-37822681 
bid, whereas incidence was higher after 20 or 30 mg jnj-37822681 bid7. Aver-
age prolactin levels were similar after administration of placebo and 10 mg jnj-
37822681 bid, but were numerically higher after administration of 20 and 30 
mg jnj-37822681 bid and 15 mg olanzapine once daily7. Regarding metabolic 
effects, which are of particular concern with the use of atypical antipsychotic 
drugs8, none of the jnj-37822681 dosing regimens showed a significant change 
in triglycerides, cholesterol, free fatty acids, glucose, HbA1c or insulin, whereas 
the lipid profile deteriorated significantly with olanzapine7. In addition, all jnj-
37822681 dosing regimens showed lesser weight gain compared with olanzap-
ine7. Although the lowest effective dose for jnj-37822681 has not yet been estab-
lished, the safety profile in the clinical studies suggests that the 10 mg bid dose 
may have the most positive benefit to risk ratio (i.e. efficacy with minimal to no 
weight gain, minimal metabolic effects or liability for extrapyramidal symp-
toms and no prolactin-elevating effects)7.
Many studies have attempted to correlate serum prolactin concentrations 
with clinical response to dopamine d2 antagonists in schizophrenia patients, 
which yielded inconsistent results9-17. Reasons for failure to establish this 
correlation include the use of high dosages (higher than required for maximal 
release of prolactin), failure to examine male and female patients separately 
(despite clear evidence that females develop higher prolactin levels), the 
use of clinician-adjusted dosages, varying time intervals between onset of 
antipsychotic therapy and assessment of clinical response, and differences in 
blood-brain barrier kinetics of the various drugs used12,13,18. Alternatively, 
several pet and spect studies have reported correlations between striatal 
d2 receptor occupancy and prolactin levels3
,13,19-21 and demonstrated that 
increases in prolactin levels were associated with striatal d2 receptor occupancy 
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higher than 50%13 or higher than 72-73%3,20. However, other studies found no 
clear correlation between d2 receptor occupancy and hyperprolactinemia22
-24, 
which may be attributable to sample sizes and differences in binding affinities 
and blood-brain barrier kinetics. The correlation between prolactin levels 
and striatal d2 receptor occupancy by jnj-37822681 can be inferred from 
chapter 2 and chapter 3. The relationship between plasma concentration 
of jnj-37822681 and striatal dopamine d2 receptor occupancy was described in 
chapter 3, as the following hyperbola:
 
Receptor occupancy (%) =            
100 ·  Cp
               Cp + 14,5
where Cp stands for the plasma concentration of jnj-37822681. This relation-
ship was determined using pet between 2 and 3 hours after dose administration. 
Application of this relationship to the plasma concentrations of jnj-37822681 
obtained within the same time interval in chapter 2, which were measured 
together with prolactin concentrations, allows evaluation of the correlation 
between striatal d2 receptor occupancy estimates and the associated serum pro-
lactin concentrations. This yields a curvilinear relationship (see Figure 1), which 
demonstrates that prolactin values can be used to estimate striatal dopamine d2 
receptor occupancy by jnj-37822681.
A review of cns effects of antipsychotic drugs in healthy volunteers demon-
strated that hyperprolactinaemia-inducing dose equivalencies of a wide range 
of registered antipsychotic drugs are correlated with affinity for the dopamine 
d2 receptor and also with the lowest therapeutic daily maintenance dose25. 
Accordingly, it has been suggested that the effects of novel antipsychotic com-
pounds may be compared with registered antipsychotic agents by using the pro-
lactin response to estimate dose equivalencies and to estimate a likely therapeu-
tic starting dose, provided that penetration through the blood-brain barrier is 
sufficient25. Using this strategy, an estimated dose of 5–10 mg of jnj-37822681 
was predicted as the lowest therapeutic maintenance dose, as described in 
chapter 2. Although the phase ii study was not able to identify the lowest ef-
fective dose for jnj-37822681, it has confirmed antipsychotic efficacy for the 10 
mg bid dose7. However, as demonstrated in chapter 3, single oral doses of 10 
mg produced d2 receptor occupancy levels of merely 50-53%, which is well below 
the occupancy levels associated with clinical response for most registered anti-
psychotic drugs (i.e. 65-80%)3-5. In addition, the multiple dose pet study6 dem-
onstrated that d2 receptor occupancy levels did not exceed 62% after multiple 
doses of 10 mg jnj-37833681 bid. Therefore, significant antipsychotic efficacy of 
the 10 mg dose jnj-37822681 bid was not immediately expected from these pet 
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data6,7. However, previous pet studies have also demonstrated relatively low oc-
cupancy levels with clozapine26-28 and quetiapine29 at clinically effective doses, 
which has been attributed to fast dissociation from the d2 receptor30. Further 
studies with shorter time intervals between dosing of quetiapine and pet scan-
ning showed higher occupancy levels, reflecting a rapid reduction in occupancy 
after transiently high levels31,32. If fast dissociation is the reason why clozapine 
and quetiapine are therapeutically active at relatively low striatal occupancy lev-
els, this could also be the case for jnj-37822681.
The phase ii study demonstrated that jnj-37822681 at 10 mg bid doses has 
antipsychotic efficacy with low incidence of extrapyramidal side effects, meta-
bolic side effects and hyperprolactinemia, although the incidence of extrapyra-
midal side effects as well as circulating prolactin levels seem to increase some-
what with higher dosing regimens7. However, the lowest effective dose of jnj-
37822681 has not yet been established. Therefore, the full therapeutic window 
of clinical antipsychotic efficacy of jnj-37822681 remains to be defined. Confir-
mation of the effect profile of jnj-37822681 in large phase iii trials may further 
support the ‘fast dissociation’ hypothesis as a means to achieve signifcant an-
tipsychotic effect with lower potential for side effects and also corroborate the 




figure 1 Correlation between serum concentration of prolactin and striatal dopamine d2 recep-
tor occupancy by jnj-37822681, limited to a time interval between 2 and 3 hours after administration of 
doses between 0.5 and 20 mg.
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Improvement of receptor selectivity
Despite the major role of dopamine neurotransmission in the acute rewarding 
effects of addictive drugs, no dopaminergic agents have been demonstrated to 
be uniformly effective for drug addiction33, which may be (at least partly) due to 
lack of pharmacological and functional selectivity for the mesolimbic pathway, 
as well as poor tolerability. Given the primarily mesolimbic expression pattern 
of dopamine d3 receptors, it has been suggested that selective dopamine d3 re-
ceptor antagonism may be an effective strategy in pharmacotherapy of addic-
tion by decreasing craving and preventing relapse34. gsk598809 is a novel selec-
tive dopamine d3 receptor antagonist35. chapter 4 describes the pharmacoki-
netics and cns effects of single oral doses of 175 mg gsk598809 in healthy vol-
unteers. In addition, possible interactions between gsk598809 and alcohol were 
evaluated, because the target population of patients will have alcohol depen-
dence as primary disorder or may abuse alcohol as comorbidity next to another 
substance abuse disorder. Plasma concentration of gsk598809 was maximal 2-3 
hours postdose and decreased with a half life of roughly 20 hours. cns effects of 
gsk598809 were limited to prolactin elevation and a decrease in adaptive track-
ing performance. The cause of prolactin elevation by gsk598809 is not known 
and could reflect antagonist effects at dopamine d3 receptors in the tuberoin-
fundibular dopaminergic pathway, but could also be due to off-target antago-
nist effects at dopamine d2 receptors, despite a greater than 100-fold selectivity 
of gsk599809 for d3 receptors over d2 receptors. The increases in serum prolac-
tin following gsk598809 administration were much larger in female volunteers 
(approximately 900%) than in male volunteers (approximately 350%), probably 
due to the effects of estrogens. Co-administration of gsk598809 and alcohol did 
not affect alcohol pharmacokinetics, but caused a 9% decrease of Cmax and a 15% 
increase of auc of gsk598809, which was not considered to be of any clinical sig-
nificance. cns effects of co-administration were mainly additive, except a small 
supra-additive increase in saccadic reaction time and decrease in delayed word 
recall. gsk598809 did not significantly affect the subjective feelings of drunken-
ness after alcohol administration. Thus, dopamine d3 receptor antagonism does 
not appear to inhibit the neurophysiological effects of alcohol. These findings 
are in line with preclinical models which have shown that selective dopamine 
d3 receptor antagonists do not affect the primary reinforcing effects of drugs of 
abuse, but rather regulate the motivation to self-administer drugs under certain 
schedules of reinforcement34. No validated biomarkers for drug addiction or 
(challenge) models in healthy volunteers exist, which precludes any means for 
prediction of pharmacodynamic effects in patients.
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In a study in healthy male and female smokers36, a single dose of 75 mg 
gsk598809, giving submaximal levels of dopamine d3 receptor occupancy (72–
89%), transiently alleviated craving after overnight abstinence. Although the 
findings also suggested that gsk598809 does not affect the rewarding proper-
ties of nicotine per se (in line with preclinical findings showing that selective d3 
receptor antagonists do not interfere with the primary reinforcing properties of 
drugs of abuse), there was a slightly increase in cigarette consumption and puffs/
cigarette when subjects were allowed to smoke freely in the natural environment 
after the experimental session, which the authors attributed to a compensatory 
mechanism36. These data provide the first clinical evidence of potential efficacy 
of a selective d3 receptor antagonist for the treatment of substance abuse disor-
ders36. However, further studies with long term abstinent smokers motivated 
to quit, with repeated dose treatment designed to achieve higher and more sus-
tained levels of d3 receptor occupancy, are needed to further investigate the role 
of gsk598809 or other dopamine d3 receptor antagonists in human craving36.
Modulation of the tachykinergic control of dopamine neurotransmission
An alternative to direct pharmacological modulation of dopamine neurotrans-
mission is modulation of the control mechanisms of dopamine neurotrans-
mission. Among the many control mechanisms, the peptide neuromodulators 
have been proposed as suitable targets for novel drug candidates, perhaps even 
advantageous compared with antagonists to classic monamine neurotransmit-
ters37. Tachykinins (also known as neurokinins) are a group of related peptide 
neurotransmitters that control and activate dopaminergic neurons in all major 
dopaminergic pathways38. Accordingly, it has been suggested that antagonists 
at tachykinin (nk1) receptors may modulate stress- and reward-related pro-
cesses and may contribute in altering drug reward39. In chapter 5, the phar-
macokinetics and cns effects of the nk1 receptor antagonist aprepitant, and 
possible interactions with alcohol, were investigated in healthy volunteers. 
Aprepitant did not significantly affect cns performance and there were no in-
dications for clinically relevant interactions between aprepitant and alcohol. In 
chapter 6, the pharmacokinetics and cns effects of the dual nk1/nk3 recep-
tor antagonist gsk1144814 were investigated in alcohol-intoxicated volunteers. 
Co-administration of gsk1144814 and alcohol caused only small additional cns 
effects, compared with administration of alcohol alone, which are not likely to 
cause clinically relevant impairments. gsk1144814 did not significantly affect 
the subjective feelings of drunkenness after alcohol administration. The doses 
of aprepitant and gsk1144814 used in chapter 5 and 6 can produce high levels 
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of receptor occupancy, as demonstrated with positron emission tomography 
using [18F]spa-rq40 and [11C]gr205171 (GlaxoSmithKline data on file), respec-
tively. Thus, effects of antagonists at central nk1 and nk3 receptors on cns per-
formance in healthy volunteers appear to be very limited or absent.
It has been previously argued that the poor results obtained with tachykinin 
antagonists in clincial trials might be attributable to redundancy in expression 
of tachykinins and nk receptor subtypes41. Substance P and neurokinin A are 
both encoded by the preprotachykinin A (ppt-a or tac1) gene, whereas neuroki-
nin B is encoded by the preprotachykinin B (ppt-b or tac3) gene38,41. These two 
ppt genes exhibit marked structural similarity and therefore possibly evolved 
from a common ancestor gene by duplication38. Also, the three known nk recep-
tor genes originate from duplication of a common ancestral gene41. Duplicated 
genes are common in genomes and the products may have different functions 
but in many occasions they share the same function41. A main consequence of 
redundancy could be that the loss of function of a particular gene product (e.g. 
tachykinins or nk receptors) might not have noticeable effects due to functional 
substitution by the duplicate gene product41. Indeed, considerable overlap ex-
ists between the expression patterns of nk1 and nk3 receptors in the brain38. 
Also, the neuropeptides substance P, neurokinin A and neurokinin B all have 
demonstrated affinity to all three nk receptors to some extent38,41. Functional 
substitution could theoretically explain the lack of effect of the selective nk1 
receptor aprepitant in healthy volunteers in chapter 5. However, as demon-
strated in chapter 6, simultaneous antagonism of both nk1 and nk3 receptors 
with gsk1144814 in alcohol-intoxicated volunteers caused only small additional 
cns effects, compared with administration of alcohol alone. Although the cns 
effects of gsk1144814 alone were not investigated, comparisons with reference 
data suggested that these are unlikely to be large. In addition, a recent study of 
the selective nk3 receptor antagonist talnetant in healthy volunteers demon-
strated improved adaptive tracking performance, decreased a power electro-
encephalography (eeg) and reduced feelings of calmness, all to a small extent, 
while vvlt performance, body sway, finger tapping, saccadic and smooth pur-
suit eye movements were not affected42. Taken together, these studies suggest 
that the effects of selective nk1 antagonists or nk3 antagonists are limited or ab-
sent, and a dual nk1/nk3 receptor antagonist probably also has limited cns ef-
fects in healthy volunteers. This argues against significant functional substitu-
tion of nk1 receptor-mediated events by nk3 receptors.
A more likely explanation for the relative lack of effect of tachykinin receptor 
antagonists in healthy volunteers may be the fact that much evidence indicates 
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that neuropeptides are released after stressful and noxious stimuli, challenges 
or pathological conditions37,43,44. Neuropeptide receptor antagonists might 
therefore have significant effects in pathological conditions with increased pep-
tide release, whereas effects in normal healthy volunteers are limited37,43. This 
would imply that measurements of neurophysiological parameters in healthy 
volunteers are not an adequate model for pharmacodynamic effects in patients. 
An alternative would be to increase peptide release by functional or pharmaco-
logical challenge tests, provided that this can be achieved in a safe manner. Cur-
rently, no readily applicable and validated pharmacological challenges or mod-
els exist in humans. To this end, pharmacological challenges such as amphet-
amine or other drugs of abuse, which are known to induce dopamine release, 
could be evaluated for possible induction of tachykinin release. Alcohol has also 
been shown to increase dopamine levels in the mesolimbic pathway45,46. Thus, 
intravenous alcohol infusion might constitute a mild dopaminergic challenge. 
No indications for clinically relevant interactions between aprepitant and al-
cohol were found, as demonstrated in chapter 5, whereas gsk1144814 caused 
only small additional cns effects on top of those of alcohol alone, as demonstrat-
ed in chapter 6. However, the target alcohol serum concentration of 0.6-0.65 
g/L may have been too small to detect any modifications by tachykinin antago-
nists.
The nk1 receptor antagonist aprepitant has been shown to be effective 
against postoperative and chemotherapy-induced nausea and vomiting47. At 
present, the effects on other dopaminergic disorders are unclear. A clinical trial 
with the nk1 receptor antagonist ly686017 in detoxified alcoholic inpatients (n 
= 25) demonstrated suppression of spontaneous alcohol cravings and improved 
overall well-being48. Preliminary findings from another small pilot study in 
patients maintained on methadone49 demonstrated that aprepitant slightly 
diminished the desire to use methadone, compared with placebo, but the effect 
did not reach statistical significance, possibly due to the study design and the 
small sample size (n = 15). However, aprepitant also appeared to increase the posi-
tive subjective effects of methadone49. Similarly, another recent study evaluated 
the effects of aprepitant on the response to oxycodone in opioid abusers (n = 8)50, 
which demonstrated that aprepitant significantly enhanced the subjective and 
observer-rated effects of euphoria and liking. Although these findings do not 
clearly confirm therapeutic utility of aprepitant in the treatment of substance 
abuse disorders, they do suggest a biologically meaningful interaction between 
nk1 receptors and drug reward-related processes, worthy of further explora-
tion50.
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Modulation of the gabaergic control of dopamine neurotransmission
gaba is one of the major inhibitors of dopamine neurotransmission. 
Accordingly, drugs that modulate gaba neurotransmission may indirectly 
influence dopamine neurotransmission. It has recently been suggested that 
subunit-selective gabaa receptor agonists, in contrast to the nonselective ben-
zodiazepines, may have therapeutic potential in schizophrenia by selectively 
inhibiting dopamine neurotransmission in the mesolimbic pathway51. Selective 
agonists at a3 receptor subtypes without efficacy at a1 receptor subtypes may at-
tenuate dopamine neurotransmission in the mesolimbic pathway which, unlike 
benzodiazepines, is not counteracted by disinhibition from gabaergic inter-
neurons51. Thus, gabaa receptor subunit-selective compounds may differ sig-
nificantly from nonselective benzodiazepines in their effects on dopaminergic 
pathways. To explore the exact role of the various receptor subtypes in the regu-
lation of different dopaminergic activities, chapter 7 describes the effects of 
two novel positive modulators of a2 and a3 subunit-containing gabaa recep-
tors, azd7325 and azd628052, and the nonselective benzodiazepine lorazepam 
on circulating prolactin levels as a marker for activity of the tuberoinfundibular 
pathway, which is the most readily accessible dopaminergic pathway for evalu-
ation in vivo. Prolactin levels increased significantly after administration of 
azd6280 and lorazepam, whereas increases in prolactin levels after administra-
tion of azd7325 did not reach statistical significance. This difference may be re-
lated to the lower dosages of azd7325 used, which was also suggested in another 
study that demonstrated a relative lack of pharmacodynamic effects of the same 
dose of azd7325 (Chen et al 2013, submitted). These findings suggest that the a2 
and/or a3 receptor subtypes are involved in gabaergic modulation of the tuber-
oinfundibular dopaminergic pathway, but do not exclude that a1 or a5 recep-
tor subtypes are also involved. These results clearly confirm modulating effects 
of gabaergic drugs on prolactin levels in human in vivo, which contrasts with 
the inconsistent results obtained in many earlier studies with other gabaergic 
drugs.
Recently, gabaergic drugs have been suggested as possible treatments for 
several diseases, such as (aspects of) Parkinson’s disease53, drug addiction54, 
schizophrenia and other neuropsychiatric disorders51,55,56. None of these strat-
egies have yet found general application in clinical practice, which may reflect 
the complex role of gabaergic mechanisms in the regulation of dopaminergic 
circuits and the lack of specific compounds. The modulatory effects of gabaa 
receptor subtype-selective compounds on the tuberoinfundibular pathway, as 
demonstrated in chapter 7, offers the possibility that these compounds are se-
lective enough for targeted modification of other dopaminergic pathways with 
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fewer off-target effects on other gabaa receptor subtypes. However, given the 
complex control mechanisms of prolactin secretion57,58 and gabaergic neuro-
circuitry59,60, effects of gabaergic drugs on the tuberoinfundibular pathway, as 
demonstrated in chapter 7, cannot readily be extrapolated to the mesocorti-
colimbic and striatonigral dopaminergic pathways. Future pet studies using 
[11C]raclopride and [18F]fallypride are needed to evaluate the indirect effects of 
subunit-selective gabaa receptor modulators on dopaminergic neurotransmis-
sion in striatal and extrastriatal areas.
Conclusion
The neurotransmitter dopamine is involved in the pathogenesis of several neu-
ropsychiatric disorders, but pharmacological methods to alter dopamine neu-
rotransmission currently have only limited efficacy in alleviating the symptoms 
of these disorders, while adverse side effects can be debilitating. The findings 
in this thesis and clinical follow-up studies demonstrate that modulation of 
kinetics at the level of the dopamine receptors, as well as improvement of selec-
tivity for dopamine receptor subtypes, are promising strategies to increase effi-
cacy and reduce side effects of dopaminergic pharmacotherapy. Modulation of 
tachykinergic and gabaergic control of dopamine neurotransmission as a strat-
egy to improve dopaminergic pharmacotherapy currently have not yet shown 
clear indications of therapeutic utility, but the findings do suggest biologically 
meaningful effects of these indirect dopamine modulators that are worthy of 
further exploration. These lines of research demonstrate that, despite the large 
number of registered dopamine receptor agonists and antagonists, the thera-
peutic potential of dopaminergic agents is far from exhausted.
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The neurotransmitter dopamine is involved in various neurophysiological func-
tions as well as the pathogenesis of several neuropsychiatric disorders, including 
Parkinson’s disease, schizophrenia, drug addiction and hyperprolactinemia. A 
large number of registered dopamine agonists and antagonists is available for 
treatment of these disorders, but these have only limited efficacy in alleviating 
the symptoms of these disorders, while adverse side effects can be debilitating. 
Thus, improvement of dopaminergic pharmacotherapy remains a high prior-
ity. The introduction of this thesis (chapter 1) provides a detailed overview of 
the physiological role of dopamine, the involvement in the pathophysiology of 
several neuropsychiatric disorders, and the specific aims of this thesis. The fol-
lowing chapters describe several strategies for improvement of dopaminergic 
pharmacotherapy, including improvement of receptor kinetics (chapter 2 
and 3) and receptor selectivity (chapter 4), as well as targeting control mecha-
nisms as a means to modulate dopamine neurotransmission (chapter 5, 6 and 
7). This thesis aims to evaluate pharmacokinetics and dose-effect relationships 
of several drug candidates on various neurophysiological parameters in healthy 
volunteers in order to show penetration through the blood-brain barrier, target 
engagement in vivo and differentiation of pharmacodynamic effects on several 
functional cns domains. In the discussion chapter of this thesis (chapter 8) the 
findings in the preceding chapters of this thesis are correlated to currently avail-
able clinical data obtained with these drug candidates in patients, which have 
appeared in the literature.
Improvement of receptor kinetics
It has been proposed that competitive dopamine receptor antagonists that dis-
sociate quickly from the receptor (i.e. a fast koff constant) are more accommodat-
ing to physiological fluctuations of dopamine concentrations than drugs with 
a slow koff. This characteristic might lead to a significant pharmacotherapeutic 
effect, with an appropriate functioning of normal dopaminergic neurotrans-
mission and a substantially lower risk for side effects associated with persistent 
strong activity at the d2 receptor. Using this hypothesis, the novel selective do-
pamine d2 receptor antagonist jnj-37822681, which has a fast koff constant, 
was developed. chapter 2 describes the pharmacokinetics of jnj-37822681 in 
healthy volunteers. In addition, pharmacodynamic effects of jnj-37822681 on 
several neurophysiological functions were evaluated. The main effect of jnj-
37822681 was elevation of serum prolactin. Other neurophysiological effects 
were generally small, compared with the effects on prolactin secretion. This ef-
fect profile is likely the result of the selectivity of jnj-37822681 for the d2 recep-
tor, leading to strong d2 receptor-mediated elevations in serum prolactin, but 
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fewer effects on more complex cns functions, which are likely to involve mul-
tiple neurotransmitters. Using prolactin concentrations, dose equivalencies of 
new and registered antipsychotics can be estimated. Accordingly, 5-10 mg jnj-
37822681 was predicted as the lowest therapeutic maintenance dose.
chapter 3 evaluated if jnj-37822681, despite its fast rate of dissociation, is 
able to achieve significant levels of dopamine d2 receptor occupancy. Dopamine 
d2 receptor occupancy in the corpus striatum was evaluated with positron 
emission tomography (pet) using [11C]raclopride in healthy volunteers. 
Receptor occupancy increased from 9-19% at 2 mg doses to 60-74% at 20 mg 
doses of jnj-37822681. Receptor occupancy following therapeutic doses of most 
registered antipsychotic agents is roughly 65-80%. Thus, despite the fast koff, 
jnj-37822681 is able to occupy a significant percentage of receptors.
In the discussion chapter of the thesis, chapter 8, the results of the first clin-
ical trial evaluating the efficacy of jnj-37822681 in the treatment of schizophre-
nia patients are reviewed. Twice daily dosing with 10 mg, 20 mg and 30 mg all 
demonstrated antipsychotic efficacy to a roughly comparable extent. Although 
the lowest effective dose for jnj-37822681 has not yet been established, these 
results confirm therapeutic efficacy of the 10 mg bid dose, which is in line with 
the prediction in chapter 2 that 5-10 mg may be the lowest therapeutic mainte-
nance dose. Receptor occupancy of the 10 mg dose, as demonstrated in chapter 
3, is lower than the receptor occupancy of most other antipsychotic drugs, but 
is more comparable to the receptor occupancy of clozapine, which may be ex-
plained by the fast rate of dissociation of both jnj-37822681 and clozapine. Fur-
ther studies on the effects of jnj-37822681 are needed, but the present results in-
dicate that modulation of receptor kinetics may be a promising strategy for drug 
development.
Improvement of receptor selectivity
Improvement of selectivity of a drug for a receptor may reduce side effects asso-
ciated with interactions with receptors other than the primary target. Despite 
the major role of dopamine in the neurobiological effects of addictive drugs and 
the pathophysiology of drug addiction, no dopaminergic agents have been dem-
onstrated to be uniformly effective for drug addiction, which may be (at least 
partly) due to lack of functional selectivity. It has been suggested that selective 
dopamine d3 receptor antagonists, contrary to nonselective antagonists, may 
have therapeutic efficacy in the treatment of drug addiction. In theory, dopa-
mine d3 antagonists do not affect the primary reinforcing properties of drugs of 
abuse, but may decrease craving and prevent relapse. chapter 4 describes the 
pharmacokinetics of 175 mg doses of the novel selective dopamine d3 receptor 
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antagonist gsk598809, as well as the pharmacodynamic effects on several neu-
rophysiological functions in healthy volunteers. In addition, possible interac-
tions between gsk598809 and alcohol were evaluated, because the target popu-
lation of patients will have alcohol dependence as primary disorder or may abuse 
alcohol as comorbidity next to another substance abuse disorder. Also, alcohol 
has small stimulating effects on mesolimbic dopaminergic neurotransmission. 
Thus, interactions between gsk598809 and the dopaminergic reward system 
might also be evaluated. The main effect of gsk598809 was elevation of prolac-
tin concentration. The cause of prolactin elevation by gsk598809 is not known 
and could reflect antagonist effects at dopamine d3 receptors in the tuberoin-
fundibular dopaminergic pathway, but could also be due to off-target antago-
nist effects at dopamine d2 receptors, despite a greater than 100-fold selectivity 
of gsk599809 for d3 receptors over d2 receptors. The increases in serum prolac-
tin following gsk598809 administration were much larger in female volunteers 
than in male volunteers, probably due to the effects of estrogens. gsk598809 had 
no other neurophysiological effects except for a small impairment of eye-hand 
coordination. Co-administration of gsk598809 and alcohol did not affect alco-
hol pharmacokinetics and caused only small effects on the pharmacokinetics of 
gsk598809. cns effects of co-administration were mainly additive. Thus, dopa-
mine d3 receptor antagonism does not appear to inhibit the neurophysiological 
effects of alcohol. These findings are in line with preclinical models which have 
shown that selective dopamine d3 receptor antagonists do not affect the primary 
reinforcing effects of drugs of abuse, but rather regulate the motivation to self-
administer drugs.
In the discussion chapter of this thesis, chapter 8, the results of the first 
clinical trial evaluating the efficacy of gsk598809 in male and female smokers 
are reviewed. In that study, gsk598809 transiently alleviated craving, which 
constitutes the first clinical evidence of potential efficacy of a selective d3 
receptor antagonist for the treatment of substance abuse disorders, although 
further studies are needed to confirm these findings.
Modulation of the tachykinergic control of dopamine neurotransmission
An alternative to direct pharmacological modulation of dopamine neurotrans-
mission is modulation of the control mechanisms of dopamine neuro trans-
mission. Tachykinins are peptide neurotransmitters that control and activate 
dopaminergic neurons in all major dopaminergic pathways, and are thus suit-
able targets for novel drug development. Antagonists at tachykinin nk1 and nk3 
receptors may have therapeutic efficacy in the treatment of drug addiction and 
schizophrenia. In chapter 5, the pharmacodynamic effects of the nk1 receptor 
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antagonist aprepitant on several neurophysiological functions were evaluated 
in healthy volunteers, as well as possible interactions with alcohol. In addition, 
amitriptyline was included as a positive control to obtain a further impression 
of the profile of neurophysiological effects. Aprepitant did not cause any neuro-
physiological impairments and there were no indications for clinically relevant 
interactions between aprepitant and alcohol. In chapter 6, the effects of the 
novel dual nk1/nk3 receptor antagonist gsk1144814 onto the neurophysiologi-
cal effects of alcohol were investigated in healthy volunteers. gsk1144814 caused 
only small additional effects on the effects of alcohol, which are not likely to 
cause clinically relevant impairments. The lack of effects of tachykinin antago-
nists in healthy volunteers is likely the result of the fact that neuropeptides (in-
cluding tachykinins) are mainly released after stressful and noxious stimuli, 
challenges or pathological conditions. As a result, neuropeptide receptor an-
tagonists might therefore have significant effects in pathological conditions 
with increased peptide release, whereas effects in normal healthy volunteers are 
limited. Following mild dopaminergic stimulation by alcohol infusion, there 
were no indications of clinically relevant interactions between aprepitant or 
gsk1144814 and alcohol. However, the serum concentration of alcohol may have 
been too low to show effects of tachykinin receptor antagonists.
In the discussion chapter of this thesis, chapter 8, the effects of aprepitant 
in disorders characterized by dopaminergic stimulation are reviewed. Apre-
pitant is registered for clinical use to prevent nausea and vomiting induced by 
chemotherapy. Recently, the first preliminary results of studies evaluating the 
effects of aprepitant in the treatment of drug addicted patients have been pub-
lished. Although aprepitant caused a small, statistically non-significant de-
crease in the desire to use methadone, aprepitant also appeared to increase the 
positive subjective effects of methadone and oxycodon. Although these findings 
do not clearly confirm therapeutic utility of aprepitant in the treatment of sub-
stance abuse disorders, they do suggest a biologically meaningful interaction 
between nk1 receptors and drug reward-related processes, worthy of further ex-
ploration.
Modulation of the gabaergic control of dopamine neurotransmission
gaba is one of the major inhibitors of dopamine neurotransmission. 
Accordingly, drugs that modulate gaba neurotransmission may indirectly in-
fluence dopamine neurotransmission. Compounds with functional selectivity 
for gabaa receptor subtypes may have selective modulatory effects on dopami-
nergic systems. The exact role of the gabaa receptor subtypes in the regulation 
of different dopaminergic activities is not fully known. chapter 7 evaluates the 
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gabaergic control of the tuberoinfundibular dopamine system. The effects of 
two novel positive modulators of a2 and a3 subunit-containing gabaa recep-
tors, azd7325 and azd6280, and the nonselective benzodiazepine lorazepam on 
circulating prolactin levels were evaluated in healthy male volunteers. Prolactin 
levels increased significantly after administration of azd6280 and lorazepam, 
whereas increases in prolactin levels after administration of azd7325 did not 
reach statistical significance, probably because the dosages were too low. These 
findings suggest that the a2 and/or a3 receptor subtypes are involved in gabaer-
gic modulation of the tuberoinfundibular dopaminergic pathway, but do not 
exclude that a1 or a5 receptor subtypes are also involved. Thus, gabaa subtype-
selective compounds are able to modulate dopaminergic systems. Absence of ef-
fects on other gabaa receptors might prevent other gabaergic side effects, such 
as sedation or instability. However, the effects of these compounds on other do-
paminergic systems cannot be extrapolated from these data and need to be ex-
amined separately.
Conclusion
The neurotransmitter dopamine is involved in various neurophysiological func-
tions and is involved in the pathogenesis of several neuropsychiatric disorders, 
including Parkinson’s disease, schizophrenia, drug addiction and hyperprolac-
tinemia. Current pharmacological methods to alter dopamine neurotransmis-
sion have only limited efficacy in alleviating the symptoms of these disorders, 
while adverse side effects can be debilitating. Thus, improvement of dopami-
nergic pharmacotherapy remains a high priority. The findings in this thesis and 
clinical follow-up studies demonstrate that modulation of kinetics at the level 
of the dopamine receptors, as well as improvement of selectivity for dopamine 
receptor subtypes, are promising strategies to increase efficacy and reduce side 
effects of dopaminergic pharmacotherapy. Modulation of tachykinergic and ga-
baergic control mechanisms currently have not yet shown clear indications of 
therapeutic utility, but the findings do suggest biologically meaningful effects 
of these indirect dopamine modulators that are worthy of further exploration. 
These lines of research demonstrate that, despite the large number of registered 
dopamine receptor agonists and antagonists, the therapeutic potential of dopa-
minergic agents is far from exhausted.
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De neurotransmitter dopamine speelt een essentiële rol in diverse neurofysiolo-
gische functies en is betrokken bij de pathofysiologie van diverse neuropsychia-
trische aandoeningen, waaronder de ziekte van Parkinson, schizofrenie, drugs-
verslaving en hyperprolactinemie. Er is een groot aantal geregistreerde dopa-
mine receptor agonisten of antagonisten beschikbaar voor de behandeling van 
deze ziekten, maar deze hebben slechts beperkt effect in vermindering van de 
symptomen, terwijl hinderlijke bijwerkingen kunnen optreden. Derhalve heeft 
verbetering van de farmacotherapie van deze ziekten een hoge prioriteit. De 
inleiding van dit proefschrift (hoofdstuk 1) geeft een gedetailleerd overzicht 
van de fysiologische rol van dopamine, de betrokkenheid bij de pathofysiolo-
gie van diverse neuropsychiatrische aandoeningen, en de doelstellingen van dit 
proefschrift. De verdere hoofdstukken beschrijven een aantal strategieën die 
momenteel worden toegepast in diverse onderzoekslijnen ter verbetering van 
dopaminerge farmacotherapie, namelijk verbetering van de kinetiek van het 
geneesmiddel ter plaatse van de receptor (hoofdstuk 2 en 3), verbetering van 
de selectiviteit van het geneesmiddel (hoofdstuk 4), en beïnvloeding van de 
controle mechanismen van dopamine (hoofdstuk 5, 6 en 7). Dit proefschrift 
onderzoekt de farmacokinetiek en dosis-effect relaties van een aantal experi-
mentele geneesmiddelen op verschillende neurofysiologische functies in ge-
zonde vrijwilligers. Aldus wordt gepoogd passage door de bloed-hersenbar-
rière aan te tonen, binding aan de receptoren in de hersenen te bevestigen en 
farmacodynamische effecten op diverse functionele domeinen van het centrale 
zenuwstelsel te beschrijven. In de discussie van dit proefschrift (hoofdstuk 
8) worden de uitkomsten van deze studies gecorreleerd aan de resultaten van 
onderzoeken naar de therapeutische effecten van behandeling van patiënten 
met deze experimentele geneesmiddelen, die inmiddels in de literatuur zijn 
verschenen.
Verbetering van de receptor kinetiek
Enkele jaren geleden werd de hypothese geformuleerd dat competitieve recep-
tor antagonisten met een snelle dissociatie na binding aan de receptor (d.w.z. 
een snelle koff constante) een flexibeler effect hebben met betrekking tot fysio-
logische fluctuaties in concentraties van dopamine dan geneesmiddelen met een 
langzame koff. Deze eigenschap zou zodoende kunnen leiden tot een significant 
farmacotherapeutisch effect, terwijl de normale dopaminerge neurotransmis-
sie zo weinig mogelijk wordt verstoord, met aanzienlijk minder bijwerkingen 
(door langdurig sterk receptor antagonisme) tot gevolg. Op basis van deze hy-
pothese werd de selectieve dopamine d2 receptor antagonist jnj-37822681, 
welke een snelle koff constante heeft, ontwikkeld. hoofdstuk 2 beschrijft de 
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farmacokinetiek van jnj-37822681 in gezonde vrijwilligers. Tevens werden de 
farmacodynamische effecten van jnj-37822681 op diverse neurofysiologische 
functies onderzocht. Het belangrijkste effect van jnj-37822681 was stijging 
van de plasma concentratie van prolactine. De overige neurofysiologische effec-
ten van jnj-37822681 waren slechts bescheiden in vergelijking met de effecten 
op prolactine secretie. Dit profiel van effecten is waarschijnlijk het gevolg van 
hoge selectiviteit van jnj-37822681 voor de dopamine d2 receptor. Dit leidt tot 
sterke effecten op prolactine secretie, wat normaliter voornamelijk gereguleerd 
wordt door dopamine en dopamine d2 receptoren, maar kleinere effecten op 
complexere neurofysiologische functies, die veelal door meerdere neurotrans-
mitters gereguleerd worden. Met behulp van prolactine concentraties kunnen 
schattingen van de equivalente doseringen van nieuwe en geregistreerde anti-
psychotica gemaakt worden. Zodoende werd een voorspelling gemaakt dat 5-10 
mg jnj-37822681 de laagste therapeutische onderhoudsdosering is.
In hoofdstuk 3 werd onderzocht of jnj-37822681, ondanks de hoge snel-
heid van dissociatie, in staat is om een significant percentage van de dopamine 
d2 receptoren te bezetten. De dopamine d2 receptor bezetting in het corpus 
striatum werd onderzocht door middel van positron emissie tomografie (pet) 
en [11C]raclopride in gezonde vrijwilligers. De receptor bezetting nam toe van 
9-19% bij 2 mg doseringen tot 60-74% bij 20 mg doseringen van jnj-37822681. 
De receptor bezetting van therapeutische doseringen van de meeste geregis-
teerde antipsychotica bedraagt ongeveer 65-80%. Derhalve is jnj-37822681, on-
danks de snelle koff, in staat een relevant percentage van receptoren te bezetten.
In het discussie hoofdstuk van dit proefschrift, hoofdstuk 8, werden de 
resultaten van het eerste klinische onderzoek naar behandeling van schizofrenie 
patiënten met jnj-37822681 besproken. Tweemaal daags behandeling met 10 
mg, 20 mg of 30 mg bleken allemaal een vergelijkbaar antipsychotisch effect in 
schizofrenie patiënten teweeg te brengen. Alhoewel de laagste therapeutische 
onderhoudsdosering vooralsnog niet bekend is, bevestigen deze resultaten 
therapeutisch effect van de 10 mg bid dosering, hetgeen in overeenstemming 
is met de voorspelling in hoofdstuk 2 dat 5-10 mg jnj-37822681 de laagste 
therapeutische onderhoudsdosering is. De receptor bezetting van de 10 mg 
dosering, zoals vastgesteld in hoofdstuk 3, is lager dan de receptor bezetting 
van de meeste andere antipsychotica, maar is meer vergelijkbaar met de 
receptor bezetting van clozapine, hetgeen mogelijk verklaard kan worden 
door de snelle dissociatie van jnj-37822681 en clozapine. Verdere onderzoek 
naar de effecten van jnj-37822681 is nodig, maar de huidige uitkomsten geven 
aan dat modulatie van receptor kinetiek een veelbelovende strategie is voor 
geneesmiddelontwikkeling.
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Verbetering van de receptor selectiviteit
Verbetering van de selectiviteit van een geneesmiddel voor een receptor, kan lei-
den tot afname van bijwerkingen die veroorzaakt worden door interactie met 
andere receptoren. Ondanks de centrale rol die dopamine speelt in de neurobio-
logische effecten van drugs en de pathofysiologie van drugsverslaving, zijn er 
vooralsnog geen dopaminerge stoffen ontwikkeld die bewezen effectief zijn bij 
farmacotherapie van verslaving, waarschijnlijk ten gevolge van gebrek aan func-
tionele selectiviteit. Op basis van eerdere onderzoeken werd de hypothese gefor-
muleerd dat selectieve antagonisten van dopamine d3 receptoren, in tegenstel-
ling tot niet-selectieve antagonisten, therapeutisch effect tegen drugsverslaving 
zouden kunnen hebben. In theorie zouden dopamine d3 antagonisten niet zo-
zeer de euforische effecten van drugs tegengaan, maar vooral de motivatie om 
drugs in te nemen remmen. hoofdstuk 4 beschrijft de farmacokinetiek van 
175 mg doseringen van de nieuwe selectieve dopamine d3 receptor antagonist 
gsk598809 in gezonde vrijwilligers, alsmede de farmacodynamische effecten 
op diverse neurofysiologische functies. Tevens werden mogelijke interacties 
met alcohol onderzocht, aangezien de populatie van patiënten waarvoor deze 
behandeling bedoeld is, veelal een alcoholverslaving heeft of alcohol misbruikt 
naast een andere drugsverslaving. Alcohol heeft bovendien een licht stimule-
rend effect op het dopaminerge mesolimbische systeem, zodat ook een indruk 
kon worden verkregen van de interacties van gsk598809 met dit dopaminerge 
beloningssysteem. Het belangrijkste effect van gsk599809 was stijging van de 
plasma concentratie van prolactine. De oorzaak van de stijging van prolactine is 
niet geheel duidelijk en kan mogelijk het gevolg zijn van antagonisme van do-
pamine d3 receptoren in de tuberoinfundibulaire dopaminerge neuronen, maar 
kan ook het gevolg van antagonisme van dopamine d2 receptoren. Ondanks dat 
gsk598809 een honderdvoudige selectiviteit heeft voor d3 receptoren in verge-
lijking met d2 receptoren, kan er bij 175 mg doseringen mogelijk toch voldoende 
d2 antagonisme optreden om een stijging van plasma prolactine teweeg te bren-
gen. De stijging van plasma prolactine was veel sterker in vrouwelijke vrijwil-
ligers dan in mannelijke vrijwilligers, hetgeen waarschijnlijk het gevolg is van 
modulerende effecten van oestrogenen. gsk598809 had geen andere neurofy-
siologische effecten, behoudens een kleine verslechtering van oog-handcoordi-
natie. Gelijktijdige toediening van gsk598809 en alcohol had geen effect op de 
farmacokinetiek van alcohol en slechts geringe effecten op de farmacokinetiek 
van gsk598809. Na gelijktijdige toediening van gsk598809 en alcohol waren 
de farmacodynamische effecten voornamelijk additief. Antagonisme van dopa-
mine d3 receptoren lijken dus geen duidelijke vermindering van de neurofysio-
logische effecten van alcohol teweeg te brengen, hetgeen in overeenstemming is 
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met eerdere onderzoeken die suggereerden dat dopamine d3 receptor antago-
nisten niet zozeer de euforische effecten van drugs tegengaan, maar de motiva-
tie om drugs in te nemen tegengaan.
In het discussie hoofdstuk van dit proefschrift, hoofdstuk 8, werden de 
resultaten van het eerste klinische onderzoek naar de effecten van gsk598809 
in mannelijke en vrouwelijke rokers besproken. In dat onderzoek verminderde 
gsk598809 het verlangen om te roken, hetgeen de eerste klinische aanwijzing 
vormt voor therapeutische waarde van dopamine d3 antagonisten, alhoewel 
verder onderzoek nodig is om deze effecten te bevestigen.
Beïnvloeding van de dopaminerge controle door tachykinines
Als alternatief voor direct antagonisme van dopamine receptoren, werd beïn-
vloeding van de controle mechanismen onderzocht als methode om dopamine 
neurotransmissie te moduleren. Tachykinines zijn neuropeptides die active-
rende controle uitoefenen op alle belangrijke dopaminerge neuronen en zijn 
derhalve een geschikt doelwit voor nieuwe geneesmiddelen. Antagonisten van 
tachykinine receptoren, zoals de neurokinine nk1 en nk3 receptoren, zouden 
een rol kunnen spelen binnen de behandeling van drugsverslaving en schizo-
frenie. hoofdstuk 5 beschrijft de farmacodynamische effecten van de nk1 re-
ceptor antagonist aprepitant op diverse neurofysiologische functies in gezonde 
vrijwilligers, alsmede mogelijke interacties met alcohol. Tevens werd amitripty-
line onderzocht als positieve controle om een indruk te krijgen van het profiel 
van neurofysiologische effecten. Aprepitant veroorzaakte geen enkele relevante 
verslechtering van neurofysiologische functies en er waren geen aanwijzingen 
voor klinisch relevante interacties tussen aprepitant en alcohol. hoofdstuk 6 
beschrijft de effecten van de nieuwe nk1/nk3 receptor antagonist gsk1144814 op 
de farmacodynamische effecten van alcohol in gezonde vrijwilligers. gsk1144814 
had slechts geringe effecten of de neurofysiologische effecten van alcohol en er 
waren derhalve geen aanwijzingen voor klinisch relevante interacties tussen 
gsk1144814 en alcohol. Het gebrek aan effecten van tachykinine receptor antago-
nisten in gezonde vrijwilligers is waarschijnlijk het gevolg van het feit dat neu-
ropeptides (waaronder tachykinines) vooral tot expressie komen tijdens stress-
volle momenten, schadelijke omstandigheden of pathologische processen. Dit 
betekent dat tachykinine receptor antagonisten mogelijk significante effecten 
hebben bij pathologische processen, terwijl de effecten in gezonde vrijwilli-
gers minimaal is. Na milde dopaminerge stimulatie door alcohol infusie, waren 
er geen aanwijzingen voor klinisch relevante interacties tussen aprepitant of 
gsk1144814 en alcohol. De serum concentratie van alcohol was echter misschien 
te laag om effecten van tachykinine receptor antagonisten aan te tonen.
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In het discussie hoofdstuk van dit proefschrift, hoofdstuk 8, werden de effec-
ten van aprepitant beschreven bij klinische aandoeningen die gekenmerkt wor-
den door dopaminerge stimulatie. Aprepitant is geregistreerd ter voorkoming 
van misselijkheid en braken ten gevolg van hoog-emetogene chemotherapie. 
Recent zijn de eerste (voorlopige) resultaten van onderzoeken naar de effecten 
van aprepitant in drugsverslaafde patiënten geopenbaard. Alhoewel er een klei-
ne, statistisch niet-significante, afname van het verlangen om methadon te ge-
bruiken werd veroorzaakt door aprepitant, leken de subjectieve eufore effecten 
van methadon en oxycodon toe te nemen. Deze resultaten lijken geen therapeu-
tisch nut van aprepitant aan te bevestigen, maar suggereren wel degelijk een ef-
fect van nk1 antagonisme op de effecten van drugs. Verder onderzoek naar de rol 
van tachykinines binnen de neurobiologische effecten van drugs lijkt derhalve 
aangewezen.
Beïnvloeding van de dopaminerge controle door gaba
gaba is één van de belangrijkste dopamine-modulerende neurotransmitters. 
Geneesmiddelen met een effect op gaba transmissie kunnen indirect ook dopa-
mine neurotransmissie beïnvloeden. Stoffen met functionele selectiviteit voor 
bepaalde gabaa receptor subtypes hebben mogelijk een selectief modulerend 
effect op dopaminerge systemen. De exacte rol van gabaa receptor subtypes in 
de regulering van dopaminerge systemen is echter niet volledig duidelijk. In 
hoofdstuk 7 werd de gabaerge controle van het tuberoinfundibulaire dopa-
mine systeem onderzocht. De effecten van twee nieuwe a2/a3 receptor subtype-
selectieve agonisten, azd7325 en azd6280, en de niet-selectieve benzodiaze-
pine lorazepam op de plasma concentratie van prolactine werd onderzocht in 
gezonde mannelijke vrijwilligers. Zowel lorazepam als azd6280 veroorzaakten 
een significante stijging van plasma prolactine. De stijging van prolactine con-
centraties door azd7325 was niet statistisch significant, vermoedelijk omdat 
de dosering te laag was. De resultaten suggereren dat a2 en/of a3 receptoren 
betrokken zijn bij gabaerge modulatie van prolactine secretie, alhoewel een rol 
van a1 en/of a5 niet uitgesloten is. gabaa receptor subtype-selectieve stoffen 
zijn dus in staat tot modulatie van dopaminerge systemen, waarbij de afwezig-
heid van effecten op andere gabaa receptoren ongewenste gabaerge nevenef-
fecten, zoals sedatie of instabiliteit, zou kunnen voorkomen. De effecten van dit 
soort stoffen op andere dopaminerge systemen kunnen echter niet uit deze data 




De neurotransmitter dopamine speelt een essentiële rol in diverse neurofy-
siologische functies en is betrokken bij de pathofysiologie van diverse neuro-
psychiatrische aandoeningen, waaronder de ziekte van Parkinson, schizofrenie, 
drugsverslaving en hyperprolactinemie. De huidige farmacotherapeutische 
methoden om dopaminerge neurotransmissie te beïnvloeden, hebben slechts 
een beperkt effect op de symptomen, terwijl hinderlijke bijwerkingen kunnen 
optreden. Derhalve heeft verbetering van de farmacotherapie van deze ziekten 
een hoge prioriteit. De bevindingen van studies in dit proefschrift en follow-
up studies tonen aan dat verbetering van de kinetiek van het geneesmiddel ter 
plaatse van de receptor en verbetering van de selectiviteit van het geneesmiddel 
veelbelovende strategieën zijn. De resultaten van beïnvloeding van de controle 
mechanismen door tachykinines en gaba lijken vooralsnog minder therapeu-
tisch nut op te leveren, maar geven wel indicaties voor biologische effecten die 
verder onderzoek verdienen. Deze onderzoekslijnen geven aan dat, ondanks de 
grote verscheidenheid aan beschikbare dopamine agonisten en antagonisten, de 
therapeutische mogelijkheden om dopamine neurotransmissie te beïnvloeden 
nog lang niet verzadigd zijn.
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